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Patients vary widely in their response to medications. This is reflected in differences in 
treatment efficacy and toxicity and results in significant morbidity and mortality. The etiology of 
this observed variation is multifactorial, and can be explained in part by genetic factors. Gaining a 
better understanding of the relationship between human genetics and drug response is essential 
in cancer chemotherapy, as most chemotherapeutics have a narrow therapeutic window, and 
could lead to the development and adoption of personalized treatments. In this thesis we focused 
on the identification of germline genetic variants associated with treatment outcome in children 
diagnosed with Ewing sarcoma and risk of development of specific toxicities induced by the 
cytotoxic drug capecitabine (hand-foot syndrome) and by anthracyclines (chronic cardiotoxicity).  
Despite the effectiveness of current treatment protocols for Ewing sarcoma, the prognosis for 
patients with metastatic or refractory disease is dismal. The identification of genomic biomarkers 
of response and survival is therefore of major importance in order to optimize treatment for 
these patients. We studied the genetic variation across the genes involved in the transport and 
metabolism of drugs used in Ewing sarcoma. We identified and replicated associations with 
overall survival for three common variants located in the ABCC6, ABCB1 and CYP2C8 genes. 
Hand-foot syndrome is one of the most relevant dose-limiting adverse effects of capecitabine, 
experienced by more than 30% of patients and commonly leading to early discontinuation of 
capecitabine-based therapy. The few proven genetic markers of toxicity risk are variants involved 
in capecitabine biotransformation, but their predictive utility is uncertain. By combining 
genotyping-based genome-wide analysis and functional studies we identified a risk locus near the 
CDH4 gene, encoding R-cadherin, strongly associated with severe capecitabine-induced hand-foot 
syndrome occurrence and prompting changes in CDH4 gene expression, possibly through changes 
in chromatin topology. We also found that skin from patients who develop severe toxicity 
exhibited low levels of R-cadherin (highly expressed in the suprabasal granular layer of the 
epidermis) and involucrin (a component of the cornified envelope of the epidermis and essential 
for the skin barrier function) before capecitabine treatment. 
Anthracyclines, which are widely used chemotherapeutic drugs, can cause progressive and 
irreversible cardiac damage and fatal heart failure in children and in adult cancer patients; 
established risk factors have been proven insufficient to accurately stratify patients. We found 
novel associations for low-frequency coding variants in the GPR35 gene in pediatric oncology 
patients and in the ETFB and WISP1 genes in anthracycline-treated patients, independently of age 
at diagnosis. 
The studies performed as part of this thesis provide clear evidence that genetic variants could 
be used as predictors of drug efficacy and adverse drug reactions and could therefore be 
informative in the design of personalized cancer therapy. 
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Es bien conocida la existencia de importantes diferencias interindividuales en la respuesta a la 
mayoría de los medicamentos, pero dicha variabilidad es de especial relevancia en oncología, ya 
que el cáncer es una de las principales causas de morbilidad y mortalidad y puesto que los 
antineoplásicos presentan un índice terapéutico muy estrecho. Aunque dicha variabilidad puede 
ser atribuida a diferentes factores, la variación genética se postula como uno de los factores más 
importantes. En esta tesis doctoral nos hemos centrado en la identificación de variantes genéticas 
asociadas a respuesta tumoral, supervivencia y efectos adversos en pacientes oncológicos.  
A pesar de la eficacia de los tratamientos actuales para el sarcoma de Ewing, el pronóstico 
para aquellos pacientes con enfermedad metastásica y refractaria es desfavorable. Por tanto, la 
identificación de variantes genéticas predictivas y pronósticas resulta esencial para optimizar el 
tratamiento en dichos pacientes. Con este objetivo estudiamos variantes genéticas en aquellos 
genes implicados en el transporte y metabolismo de los fármacos más comúnmente utilizados en 
el tratamiento del sarcoma de Ewing e identificamos tres variantes comunes en los genes ABCC6, 
ABCB1 y CYP2C8 asociadas con la supervivencia de estos pacientes. 
El síndrome mano-pie es el más común de los afectos adversos producidos por la capecitabina, 
afectando a más de un 30% de los pacientes. Su aparición conlleva graves consecuencias clínicas 
ya que obliga a reducir la dosis o incluso a la suspensión del tratamiento. Los marcadores 
genéticos identificados hasta la fecha se encuentran involucrados en su totalidad en el proceso de 
biotransformación de la capecitabina y su utilidad predictiva es incierta. La combinación de un 
estudio de asociación del genoma completo junto con estudios funcionales nos ha permitido la 
identificación de un locus de susceptibilidad a este efecto adverso. Este locus regula la expresión 
del gen CDH4, probablemente mediante alteraciones en la topología de la cromatina. Además 
encontramos que aquellos pacientes que sufren una toxicidad más severa presentan en su piel 
reducidos niveles de la proteína que codifica CDH4, R-cadherina (altamente expresada en el 
estrato granuloso de la epidermis) y de involucrina (proteína del estrato cornificado esencial para 
la función de barrera de la epidermis).  
El tratamiento con antraciclinas produce efectos cardiotóxicos irreversibles e incluso fatales 
tanto en niños como en adultos y los factores de riesgo identificados hasta la fecha se han 
mostrado insuficientes para la estratificación de los pacientes. En esta tesis hemos encontrado 
nuevas variantes poco frecuentes asociadas a cardiotoxicidad en los genes GPR35 en pacientes 
oncológicos infantiles, y ETFB y WISP1 independientemente de la edad de diagnóstico. 
Todos los resultados obtenidos en esta tesis doctoral suponen una clara evidencia del 
importante papel que juega la variación genética en las diferencias interindividuales observadas 
tanto en la eficacia como en la toxicidad de los quimioterapéuticos y por tanto, podrían ser 
utilizados en el futuro en el diseño de una medicina individualizada en estos pacientes.
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1. Identification of genomic biomarkers  
There is great heterogeneity in the way individuals respond to clinical drugs in terms of both, 
treatment efficacy and host toxicity. A drug that is effective in one person may have no 
discernible therapeutic effect in another, and in some may result in undesirable or fatal side-
effects, even though the medication is administered at a normal recommended dose1. Both drug 
inefficacy and adverse drug reactions (ADRs) remain a major clinical problem. It has been 
estimated that the non-response rate to a major drug among patients diagnosed with several 
important diseases ranges from 20% to 75%, with the lowest rate for cancer chemotherapy2. On 
the other hand, ADRs are one of most common causes of drug withdrawal, accounting for 7% of 
all hospital admissions and responsible for >100,000 deaths per year, making ADRs between the 
fourth and sixth leading cause of death in developed countries3,4. This is particularly important in 
oncology because cancer is one of the leading causes of morbidity and mortality worldwide; and 
chemotherapeutic agents, which in general affect tumor and non-tumor cells, have a narrow 
therapeutic index, with the potential for life-threatening toxicity and where treatment 
discontinuation is often fatal5. Thus, there is an urgent need for novel treatment strategies that 
can improve cure rates and decrease adverse events in oncology. 
 
Although there are multiple contributory factors influencing the effect of drugs, such as 
physiopatological factors (e.g., age, gender, body mass index, organ function, concomitant 
diseases ) and environmental variables (e.g., nutritional factors, alcohol consumption), genetic 
factors can account for 20% to 40% of interindividual heterogeneity in drug efficacy and play a 
significant role in the incidence and severity of ADRs6. In fact, for certain drugs or drug classes, 
genetic factors have been shown to be the most important influence on drug treatment 
outcome7. Over the last decades rapid advances in research have greatly increased our 
understanding of the molecular basis and genetics of tumor progression and drug response, and 
these advances have also led to the identification of numerous genomic biomarkers in oncology. 
In general, a biomarker is defined as a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention8. According to U.S Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) a genomic biomarker is defined as a measurable DNA 
and/or RNA characteristic that is an indicator of normal biologic or pathogenic processes and/or 
response to therapeutic or other interventions9,10. Potential genomic biomarkers could, for 
example, be in genes involved in the pharmacokinetics (drug absorption, distribution, 
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metabolism and elimination) or pharmacodynamics (effects on drug receptors and other drug 
targets) of medications. DNA characteristics include, but are not limited to: single nucleotide 
variants (SNVs), variability of short sequence repeats, DNA modifications (e.g., methylation), 
deletions or insertions, copy number variations (CNVs) and cytogenetic rearrangements (e.g., 
translocations, duplications, deletions or inversions). RNA characteristics include, but are not 
limited to: RNA sequences, expression levels or processing (e.g., splicing and editing) and 
microRNA levels.  
 
In general, biomarkers can be divided into two types: prognostic and predictive. Prognostic 
markers aim to objectively predict the patient’s clinical outcome, such as the probability of 
cancer recurrence after standard treatment. Predictive biomarkers aim to objectively predict the 
response of a patient to a specific clinical intervention and are associated with tumor sensitivity 
or resistance to that therapy, including toxicities11,12. Cancer treatment is especially complex 
because a combination of inherited variations within the individual (germline) and acquired 
variations within the tumor (somatic) influence disease outcome and the response/ toxicity to 
the drug therapy13,14. Germline variation may alter drug pharmacokinetics and 
pharmacodynamics leading to toxicity and/or lack of efficacy. On the other hand, somatic 
alterations, but also germline changes can be relevant to predict tumor response 15,16 
 
In this thesis we focused on the identification of predictive and prognostic germline SNVs for 
cancer treatment. SNVs are single-nucleotide substitutions of one nucleotide for another and 
are by far the most common genetic alteration. SNVs can occur in both coding and non-coding 
regions of the genome, and when located in a coding region, they can alter the amino acid 
sequence (non-synonymous or missense variants) or be silent (synonymous variants). SNVs may 
influence, for example, gene expression, messenger RNA (mRNA) stability, gene splicing, 
transcription factor binding, subcellular localization of mRNAs and/or proteins, or the sequence 
of non-coding RNA17. 
 
The ability to identify genomic biomarkers corresponding to a therapeutic effect is the basis 
for the concept of the so-called personalized medicine. The National Cancer Institute (NCI) has 
defined personalized medicine …“as a form of medicine that uses information about a person’s 
genes, proteins and environment to prevent, diagnose, and treat disease”18. Rather than having 
a unique treatment for each individual person, the ultimate goal of personalized medicine is to 
identify patients who are drug responders and patients who are prone to develop drug toxicity; 
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that is, effective and safe medication to targeted patients with appropriate genotypes19,20. 
Achieving individualized medicine requires a deep understanding of the genomic and molecular 
basis underlying variability in drug response, especially in complex diseases, such as cancer. 
Large international projects such as the 1000 Genomes Project21, the Cancer Genome Atlas22, or 
the International Cancer Genome Project23, are producing increasingly comprehensive maps 
outlining the regions of the human and cancer genomes containing variants. These international 
initiatives along with the high-throughput “omics” technologies´ evolution will help us move 
from population-based prescribing toward individualized cancer treatment; with the ultimate 
goal of improving treatment efficacy, reduce toxicity and minimize cost. 
 
2. Strategies to identify genomic biomarkers  
In general there are two approaches used to evaluate how genetic variation contributes to 
interindividual variability in drug response (drug efficacy and related-toxicity): candidate gene 
and genome-wide.  
2.1. Candidate gene analysis 
Candidate gene approaches focus on one or more candidate genes or pathways and are 
hypothesis-driven. Selection of putative genes in the candidate gene approach is based in the 
current knowledge of human pathophysiology, pharmacology, and cancer biology. In general, 
genetic variants are selected for having a functional consequence in our candidate gene, either 
by affecting gene regulation or its protein product is selected. The hypothesis is that the genetic 
variants, mostly within a gene with a relevant role in the drug pharmacokinetics and 
pharmacodynamics, would affect the drug´s efficacy and/or toxicity and these studies are 
therefore also termed hypothesis-driven association studies. Typical candidate genes encode, 
for example, drug transporters, biotransformation enzymes, or drug receptors; and clinically 
relevant samples (e.g., blood, tissues or tumor specimens), which represent either drug toxicity 
or functional sites, are used. A classical example of a clinically relevant candidate gene is TPMT 
(thiopurine S-methyltransferase) in which three non-synonymous common variants, TPMT*2, 
TPMT*3A, and TMPT*3C, account for 80%–95% of the lower TPMT enzyme activity24. The 
positive finding of a candidate gene approach is easy to interpret and can yield clinically relevant 
information, but the candidate gene strategy carries the risk of not finding an association, likely 
due to small simple size of cohorts used to detect an effect; and the exclusion of important or 
causal variants or genes25–27. 
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However, in most of the cases, one single gene/genetic variant is not sufficient to explain the 
wide interindividual differences observed in drug efficacy or toxicity; which are often polygenic, 
with several genes within and across many pathways involved. For this reason, it seems obvious 
the advantage of conducting a candidate pathway approach; combining information on several 
genes that are common to a pathway; although there is still a risk of excluding other relevant 
genes. The pharmacological pathways of methotrexate and mercaptopurine illustrate the 
potential of this kind of approach28.  
 
Besides genotyping-based candidate gene approaches, next-generation sequencing is 
currently being used to perform candidate-gene strategies by targeted enrichment of a set of 
genes and exclusively performing sequencing on them (gene panels). Gene panels represent a 
cost-effective alternative to whole-genome and whole-exome sequencing (WES) and entail 
considerably lower sequencing costs, but will only succeed if the trait-causing gene is included in 
the panel. Furthermore, targeted-gene sequencing is at the forefront of the current efforts given 
in the application of routine diagnostics into the clinic29–31.  
 
In this thesis we adopted a genotyping-based candidate pathway strategy to identify genetic 
variants that predict treatment outcome in children diagnosed with Ewing sarcoma (Study I). 
 
2.2. Genome-wide association analysis  
In contrast to candidate gene strategies, a genome-wide approach gives equal weight to all 
genes in the genome, is hypothesis-generating, and can be used when little is known regarding 
gene-drug effect; helping to prioritize genes or genomic regions for further investigation27. 
 
Genome-wide association studies (GWAS) using genotyping arrays have evolved over the last 
ten years into a powerful tool for investigating the genetic architecture of complex diseases, 
including drug response to chemotherapeutics. These studies analyze hundreds of thousands of 
common SNVs across the entire human genome. Therefore, these studies do not make use of 
the current knowledge about gene function or a drug´s mechanism of action and they are 
hypothesis-generating32,33.  
 
Genotyping arrays used in GWAS studies include mostly tagSNVs, which are representative 
SNVs sufficient to capture most of the haplotype structure of a particular region in high linkage 
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disequilibrium with them. Due to the very large number of SNVs interrogated in a GWAS, they 
require much larger sample sizes to achieve an adequate statistical power34 and positive findings 
always need to be replicated in independent series of patients35 in order to avoid false positive 
findings. Given that most of GWAS tagSNVs (approximately 88%)36 are located in intergenic or 
intronic regions a major challenge lies in the recognition of the causal variant responsible for the 
observed association; as well as the interpretation of study results, requiring fine mapping and 
mechanistic studies to understand the biological plausibility of certain findings32. Biological 
interpretation of GWAS findings is even more difficult in cancer pharmacogenetics (the study of 
the genetic factors that influence drug efficacy and toxicity37), since drug response represent a 
polygenic phenotype and in most cases they are measured in the form of a subjective, ordinal 
scale (grade); and the complexity and the multifactorial nature of cancer with many intrinsic and 
extrinsic factors involved. A useful approach to overcome this problem is to select patients with 
extremely differentiated phenotypes at both ends of the phenotype, which have a greater 
chance of carrying the causal genetic variant/s contributing to the trait, rather than to include 
large series of patients that might dilute gene-phenotype associations38–40. 
 
GWAS have been extensively applied in pharmacogenetics studies and they have helped in 
the identification of novel associations that would be unlikely to have been detected by 
candidate gene studies. The primary area in which this methodology was used in 
pharmacogenetics was in drug efficacy (approximately 70% of published GWAS in 
pharmacogenetics), whereas the remaining studies focused on ADRs32,36. As an example, using a 
genome-wide interrogation of germline variation, Treviño et al41. uncovered genetic variants 
that affected the disposition and effects of methotrexate in children with acute lymphoblastic 
leukemia in SLCO1B1, a gene not previously investigated as a candidate gene in clinical 
pharmacogenetic studies of methotrexate.  
 
In the current thesis we performed a genotyping-based genome-wide study applying extreme 
phenotype sampling to identify capecitabine-induced hand-foot syndrome (CiHFS) susceptibility 
variants (Study II).  
 
Genotyping-based GWAS have greatly improved our understanding of the genetic basis of 
multitude of complex traits and diseases and they have identified more than 29,000 disease-
associated variants36. However, most of these associated SNVs are common variants having a 
population frequency of 5% or greater, and they usually explain only a small proportion of the 
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genetic variance of the trait42,43; leading to the possibility that low-frequency and rare variants 
could explain additional risk or trait variability and play an important role in uncovering the so-
called “missing heritability”. Low-frequency and rare genetic variants are likely to have arisen 
from mutation events and, a priori, they are expected to have larger effects on complex traits 
than common variants because they will not have been subject to negative selection44. The most 
comprehensive approach to characterize low-frequency and rare genetic variation is through 
whole-genome sequencing in large number of individuals. However, the combination of large 
scale whole-genome sequencing and classical association studies is impractical for many 
research groups because of the high cost. Until whole-genome sequencing is inexpensive 
enough to be generally used in large samples, various approaches have arisen as principal 
alternatives for sequencing-based genome-wide studies, such as WES, and whole-exome 
genotyping arrays45. Both, WES and whole-exome genotyping arrays focused on the protein-
coding regions of the genome, which represent a very small portion of the whole genome 
(around 1%) but are more likely to affect protein function and thereby have an impact on human 
traits and disease46. In the current thesis we performed an exome-array genome-wide analysis 
to identify genetic variants predictive of susceptibility to chronic anthracycline-induced 
cardiotoxicity (AIC) in pediatric and breast cancer patients (Study III and Study IV) 
 
The exome content of whole-exome genotyping arrays, such as the Illumina Infinium 
HumanExome BeadChip used in this thesis, have been selected from over >12,000 individual 
exome and whole-genome sequences representing diverse ethnicities and a range of common 
traits (cancer, type 2 diabetes, metabolic and psychiatric disorders). Apart from non-
synonymous and splicing and stop-altering variants, exonic genotyping arrays contain additional 
variants, including variants associated with complex traits in previous GWAS, ancestry-
informative markers, human leukocyte antigen (HLA) tagSNVs and mitochondrial SNVs47. 
Although exome arrays constitute a cost-effective alternative to genome-wide sequencing in 
large number of individuals, substantially increasing statistical power for variants that are on the 
chip; the limitation of these chips compared with whole-exome sequencing is that they does not 
provide complete coverage of all coding variants at each locus and of ethnic-specific variants, 
since individuals with European ancestry are the predominant source of variation in these 
arrays. However, the utility of these arrays has been clearly demonstrated and during the last 
three years the first results of exome chip-based studies have been published, and novel 
associations for low-frequency and rare coding variants with complex traits such as insulin 
processing48, asthma49, liver disease50, type 2 diabetes51, or schizophrenia52 have been found.  
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2.3. Novel statistical association analyses 
Associations between genetic variants and a particular trait are typically evaluated by linear 
regression for continuous traits and by logistic regression for binary traits; however, single-
variants test is adequate for common variants but is often underpowered to detect rare variant 
associations. The development of appropriate statistical methods to analyze rare variant 
associations to achieve an adequate statistical power has become a very active research 
area45,53. Methods for rare variant association testing have mainly focused on the analyses of 
rare variants within the same functional region (e.g., gene or pathway) and then consider their 
joint effects on complex traits. Because rare variants are traditionally grouped by genes, these 
tests are referred to as gene-based tests. Gene-based tests can be divided into two broad 
categories: burden and variance-component tests. Burden tests collapse or summarize the rare 
variants within a region into a single genetic variable, which can then be tested for association 
with the trait. The main limitation of burden tests is they assume that all variants within the 
collapsed regions are causal and influence the trait in the same direction and magnitude of 
effect45. However, in practice variants with protective and deleterious effects exist and the 
magnitude of each variant´s effect is likely to vary. To address these limitations, variance-
component tests such as SKAT54, were developed. Variance component tests avoid the 
directionality of effect and consequently are more powerful than burden tests if a region has 
many noncausal variants or if the variants have different directions of association53,54. However, 
if a large proportion of the rare variants in a region are truly causal with the same direction of 
association, then burden tests are more powerful. Because both scenarios can arise and the true 
underlying genetic model is in most cases unknown, combined tests unifying burden and 
variance-component tests, such as the SKAT-O55, are desirable. 
 
In the current thesis we used gene-based tests (SKAT-O) to identify new genes and novel low-
frequency and rare genetic variants influencing the susceptibility to chronic anthracycline-
induced cardiotoxicity (AIC) (Study III and Study IV).  
 
3. Identification of predictive and prognostic genomic biomarkers for Ewing sarcoma (Study I) 
In Study I we focused on the identification of predictive and prognostic germline genetic 
variants for Ewing sarcoma. 
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Ewing sarcoma is a rare, highly cellular malignant round-cell tumor of bone and soft tissue 
primarily affecting children and adolescents, with a peak incidence at age 15. It is also called the 
Ewing sarcoma family of tumors and includes Ewing sarcoma of bone, extraosseous Ewing 
sarcoma, peripheral primitive neuroectodermal and Askin’s tumors56. Despite being the second 
most frequent primary malignant bone tumor after osteosarcoma, Ewing sarcoma accounts for 
only 2.9% of all childhood cancers, with an annual incidence of 2.5-3 cases per million57.  
 
The majority of Ewing sarcoma tumors develop in the diaphyseal regions of long bones, such 
as the femur; followed by the pelvis, chest wall and the spine; although, approximately 20% arise 
in soft tissues. Ewing sarcoma is an aggressive tumor with a high incidence of metastasis at 
presentation ranging from 20%-25% (10 % lung, 10 % bones/bone marrow, 5 % combinations or 
others)58. This pediatric tumor occurs predominantly in Caucasians, with very few cases in 
African and Asian populations59 and is slightly more common in males than in females (ratio 
55:45). Interestingly, it has been found significant racial and ethnic differences in the age, 
primary tumor site (bone v soft tissue), and tumor size in Ewing sarcoma patients suggesting the 
presence of genetic factors for Ewing sarcoma susceptibility59,60.  
 
Current therapy for Ewing sarcoma consists of initial chemotherapy after biopsy (neoadjuvant 
chemotherapy) to eradicate systemic disease; then local control with surgery and/or radiation, 
followed by chemotherapy (adjuvant or consolidation chemotherapy) to treat, not only the 
primary tumor, but also presumed microscopic metastases and, to prevent recurrence. 
Chemotherapy for Ewing sarcoma consists of a 6-drug backbone of vincristine, doxorubicin and 
cyclophosphamide alternating with ifosfamide, etoposide and actinomycin-D58. With the use of 
these modern multimodal regimens, cure rates of around 70% can be achieved in patients with 
localized disease, however, they are ranging between 20%-40% for those with metastatic Ewing 
sarcoma. Furthermore, 30%-40% of patients with a localized primary tumor and 60%-80% of 
patients with disseminated disease experience relapse (either locally or distantly, or both) after 
treatment and have a dismal prognosis, with a likelihood of long-term survival after recurrence 
lower than 15%61,62. Thus, the main challenge for Ewing sarcoma remains in preventing 
recurrence and drug resistance and improving outcome, especially in those patients with 
metastatic and relapsed/recurrent disease.  
 
The majority of biomarkers studied in Ewing sarcoma are prognostic and nearly all are 
somatic biomarkers63. The outcome of Ewing sarcoma tumors is influenced by many clinical-
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pathologic and treatment-related factors. Central primary tumor location (axial v appendicular), 
increasing tumor size and patient age at diagnosis and decreased tumor necrosis after 
neoadjuvant chemotherapy have all been implicated as negative prognostic features; however 
the presence of metastatic disease at diagnosis is currently the strongest prognostic biomarker 
in Ewing sarcoma and has been proven in all clinical studies and routine clinical practices58,61,64. 
Outside of above mentioned prognostic factors, many efforts have been made to identify 
potential biomarkers in Ewing sarcoma. Ewing sarcoma is specifically characterized by a 
translocation that fuses the EWSR1 (EWS RNA binding protein 1) gene to one of the several 
different genes belonging to the ETS family, being the EWSR1-FLI1 translocation (also known 
type 1 fusion) the most common fusion type observed (~85% of Ewing sarcoma cases)65. Early 
retrospective studies reported better outcome for tumors harboring a type 1 fusion, compared 
with those with other fusion types66,67; however, prospective studies evaluating EWSR1 fusion 
status and patient outcome failed to confirm the original findings68.  
 
On the other hand, genetic alterations affecting cell-cycle proteins, including CDKN2A (cyclin 
dependent kinase inhibitor 2A) (INK4A/ARF locus) deletion and TP53 (tumor protein p53) 
overexpression or mutations [especially when STAG2 (stromal antigen 2) and TP53 co-ocurred] 
have been associated with poor prognosis in Ewing sarcoma patients69,70. On the other hand, 
several of the most frequent copy number alterations (CNAs) observed in Ewing sarcoma 
tumors, such as the gain of the whole chromosome 8 and chromosome 12, the gain of the long 
arm of chromosome 1 and deletion of the long arm of chromosome 1669 have been also 
correlated with poor prognosis58,64, but a prospective analysis of CNAs and clinical outcome has 
not yet been undertaken.  
 
Recent studies have used flow cytometry to identify circulating tumor cells in peripheral 
blood and bone marrow samples from Ewing sarcoma patients and these studies provide 
preliminary support for the potential prognostic significance of circulating tumor cells, especially 
for subclinical disease71,72. Many other prognostic markers in Ewing sarcoma have been studied 
and associated with significant differences in outcome, including biomarkers related with 
angiogenes, such as VEGF (vascular endothelial growth factor)73; or tumor microenvironment, 
such as the chemokine receptor CXCR474; however most of these studies were retrospective 
and/or have been conducted in small cohorts of patients58,64.  
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Regarding predictive biomarkers, the expression of the cell surface protein CD133 has been 
associated with chemoresistant Ewing sarcoma disease75 and the expression and nuclear 
localization of the insulin receptor IGF1R has been identified as a putative marker of treatment 
response76. 
 
Given the lack of candidate gene studies in Ewing sarcoma exploring the role of germline 
variants on treatment outcome (on both, tumor response and overall survival), in this thesis we 
focused on the identification of genetic variants in genes involved in the pharmacokinetics of the 
chemotherapeutic drugs most commonly used to treat Ewing sarcoma. 
 
4. Predictive genomic biomarkers for ADRs 
4.1. Identification of genetic variants predictive of susceptibility to capecitabine-induced 
hand-foot syndrome (CiHFS) (Study II) 
 
Capecitabine is and oral prodrug of 5-fluorouracil (5-FU), which is currently approved for its 
use as a single agent for patients with metastatic breast cancer that is resistant to both paclitaxel 
and anthracyclines, and for those with breast cancer resistant to paclitaxel and for whom further 
anthracycline therapy is contraindicated. Capecitabine is also approved for combination therapy 
with docetaxel for the treatment of patients with metastatic or locally advanced breast cancer in 
whom prior anthracycline-based therapy has failed. It is also approved as monotherapy in the 
adjuvant setting when treating Dukes’ stage C colon cancer and patients with metastatic 
colorectal cancer, as well as in the adjuvant setting in combination with platinum-based therapy 
for patients with advanced or metastatic colorectal tumors77. 
 
Capecitabine has a number of advantages over traditional 5-FU: i) it is orally administered, 
enabling dosing that approximates to continuous infusion 5-FU but in a more convenient 
outpatient setting, avoiding the inconvenience and complications associated with central venous 
catheters or infusion pumps78,79; ii) it has increased tumor selectivity and thus, reduced toxicity; 
and iii) improved efficacy80. 
 
After absorption across the digestive tract, capecitabine is metabolized and activated to 5-FU 
through three sequential enzymatic reactions (Figure I1). In the first step, capecitabine is 
hydrolysed to 5′-deoxy-5-fluorocytidine (5′-DFCR) by carboxylesterase (CES) in the liver, which is 
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further converted to 5′-deoxy-5-fluorouridine (5′-DFUR) via cytidine deaminase (CDA) a 
ubiquitous enzyme which is found in high concentrations in liver, intestine, plasma and tumor 
tissue. As part of the capecitabine´s rationally designed activation, 5′-DFUR conversion to 5-FU 
preferentially occurs in tumor tissue via thymidine phosphorylase (TYMP)81. It has been shown 
that TYMP is present in higher concentrations in tumor tissue (2.5-fold more) compared with 
normal adjacent tissues, and 14-fold more than in the plasma82, thus theoretically providing 
tumor specificity and limiting systemic toxicity. 5-FU is further activated in the tumor to 
cytotoxic active metabolites that inhibit DNA and protein synthesis through the binding to 
thymidylate synthetase (TYMS) and the incorporation of metabolites as false nucleotides into 
DNA and RNA, leading to cell proliferation inhibition. 5-FU can be converted to its active 
metabolites 5-fluoro-2′-deoxyuridine 5′-monophosphate (FDUMP) and 5-fluorouridine-5′-
triphosphate (FUTP) in both normal and tumor cells but it occurs at higher rates in rapid 
proliferating cells, such as malignant cells82,83. Finally, 5-FU is catabolised in the liver into 
dihydro-5-fluorouracil by the dihydropyrimidine deshydrogenase (DPYD) enzyme82. 
 
 
 
 
 
 
 
Capecitabine is a generally well-tolerated cytotoxic and has an improved tolerability profile 
compared with bolus 5-FU/leucovorin80, however its clinical use is limited by the appearance of 
adverse events, being the most common dose-limiting toxicities diarrhea and hand–foot 
syndrome. Other frequent adverse events include hyperbilirubinaemia, fatigue/weakness, and 
other gastrointestinal effects such as nausea/vomiting, abdominal pain and stomatitis/mucositis. 
Figure I1. Enzymatic activation of capecitabine. Following oral administration, capecitabine is metabolized and 
activated to 5-FU via a three-step enzymatic process. Capecitabine was rationally designed so that concentrations 
of the cytotoxic metabolites FDUMP (5-fluoro-2′-deoxyuridine 5′-monophosphate) and FUTP (5-fluorouridine-5′-
triphosphate) are higher within malignant cells than within normal cells. Abbreviations: 5-FU, 5-fluorouracil; CES2, 
carboxylesterase 2; 5′-DFCR, 5'-deoxy-5-fluorocytidine; CDA, cytidine deaminase; 5′-DFUR, 5'-deoxy-5-fluorouridine; 
UPP1, uridine phosphorylase 1; TYMP, thymidine phosphorylase; FUDR, 2′-deoxy-5-fluorouridine; TK1, thymidine 
kinase 1; TYMS, thymidylate synthetase; MTHFR, methylenetetrahydrofolate reductase; DPYD, dihydropyrimidine 
deshydrogenase.  
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The incidence of adverse events in breast and colorectal cancer patients treated with 
capecitabine is very similar as well as the safety profile for capecitabine administered as  
monotherapy or in combination80,84,85.  
Capecitabine-induced hand–foot syndrome (CiHFS), also called palmar-plantar 
erythrodysaesthesia, is a cutaneous adverse event and the most frequent cause for dose 
reduction or therapy discontinuation. CiHFS is characterized by tenderness, redness and swelling 
and, in more severe cases, blistering, ulceration, desquamation or severe pain on the palms of 
the hands and/or the soles of the feet. CiHFS can appear in three different grades of severity 
Table I1. Capecitabine-induced hand–foot syndrome (CiHFS) grading scale 
Grade Signs and symptoms Presentation 
Grade 1 
Numbness, dysaesthesia, 
paresthesia, tingling, painless 
swelling, erythema or 
discomfort of the hands and/or 
the feet that does  
not interrupt normal activity 
 
Grade 2 
Painful erythema 
and swelling of the hands or 
the feet, resulting in 
interruption to daily routine 
 
Grade 3 
Desquamation, severe 
blistering 
and ulceration causing severe 
pain and discomfort of the 
hands and/or the feet, 
resulting 
in the inability to perform 
activities of day living 
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according to the NCI Common Terminology Criteria for Adverse Events (CTAE)86 (Table I1), and 
hands are usually more affected than the feet. Grade 1 toxicity requires  
close monitoring, but no therapy interruption. For grade 2 and grade 3 toxicities capecitabine 
administration should be stopped until resolution of symptoms or diminution to grade 1. For 
prolonged appearance of CiHFS and grade 3 toxicity dose reductions for subsequent cycles are 
recommended and even treatment withdrawal. 
 
Treatment interruption and dose reduction usually lead to rapid reversal of symptoms 
without long-term consequences and CiHFS is never life-threating80,84,85,87. The overall incidence 
of CiHFS is around 30%, although it has been reported as high as 50% on clinical trials; with 17% 
of patients reporting a severe grade 3 form80,85. The severity of CiHFS is dependent on age, 
gender, local clinical practice and, possibly diet88–90; but also is influenced by genetic factors. 
Over the last decade a number of publications have identified common polymorphisms, but also 
rare variants contributing to the susceptibility to CiHFS91–99. However, all of these studies have 
focused on genes involved in the biochemical pathway of capecitabine activation and 
subsequent 5-FU action and catabolism, and the majority throughout a candidate gene 
approach. Although these studies provided important biological and clinical information, they do 
not fully explain the whole spectrum of the interindividual variabilities observed in CiHFS97. In 
addition, the biological mechanisms underlying CiHFS remain poorly understood. Thus, in this 
thesis we focused on the identification of additional genetic susceptibility variants by using a 
genotyping-based genome-wide approach coupled with a selection of extreme phenotype breast 
and colorectal capecitabine-treated patients, in order to ensure accurate patient phenotyping 
and to avoid the subjectivity associated to grading scales of CiHFS. 
 
4.2. Identification of genetic variants predictive of susceptibility to chronic anthracycline-
induced cardiotoxicity (AIC) (Study III and Study IV) 
Daunorubicin was the first anthracycline antibiotic to be characterized and was isolated from 
Streptomyces peucetius in 1963100. Daunorubicin was found to be quite effective in treating 
leukemias and lymphomas101. Doxorubicin (also known as adriamycin) was identified a few years 
later, and shown to be a more effective anticancer drug102. After that, many other anthracyclines 
have subsequently become available, such as epirubicin or idarubicin. Anthracyclines are 
currently among the most widely used chemotherapeutics agents in children and adults and 
they are used in a broad variety of hematological malignancies, solid tumors (e.g., breast, lung, 
ovarian cancers), soft-tissue and bone sarcomas103. Despite their efficacy and widespread use, 
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anthracyclines are among the most notorious anti-neoplastic agents that cause cardiotoxicity104. 
Along with cancer recurrence and secondary malignancies, cardiovascular disease is the leading 
cause of morbidity and mortality among long-term cancer survivors105,106. Children cancer 
survivors are at higher risk than adults for anthracycline-induced cardiotoxicity (AIC), given that 
anthracyclines are more extensively used in children and young adolescents (more than half of 
the children with cancer receive an anthracycline as part of their treatment therapy107) and their 
developing cardiovascular system is particularly vulnerable to cardiotoxic effects of 
anthracyclines108. 
 
The mechanisms underlying AIC remain controversial and poorly understood, although they 
are probably multifactorial. Oxidative stress is the most study and widely accepted cause of AIC, 
although mitochondrial damage, impairment of mitochondrial calcium homeostasis and 
inhibition of sarcoplasmic reticulum function have all been also implicated in AIC109–111. The heart 
may be particularly vulnerable to anthracycline-induced damage for several reasons. 
Cardiomyocytes have an abundance of mitochondria and high concentrations of cardiolipin, a 
phospholipid found in abundance on the inner mitochondrial membrane and with high affinity 
for anthracyclines; allowing anthracyclines to enter mitochondria112. In addition, cardiomyocytes 
have low levels of key antioxidant enzymes, such as catalase and glutathione peroxidase, and 
therefore are especially vulnerable to oxidative stress. Anthracyclines have also been found to 
inhibit some of these enzymes, such as cardiac glutathione peroxidase, making cardiomyocytes 
even more susceptible to anthracycline damage113. 
 
AIC can be categorized as acute or chronic cardiotoxicity based on the time that symptoms 
manifest (Table I2)103,104. Acute cardiotoxicity usually occurs within 1 week of therapy and it is 
characterized by depression of contractile function. With current anthracycline protocols, acute 
cardiotoxicity is a rare event, occurring in less than 1%114 of patients, and symptoms usually 
resolve with anthracycline therapy discontinuation. Chronic toxicity can be divided in two forms 
depending on the time of onset: early- (occurring the first year after anthracycline 
administration) and late-onset cardiotoxicity (occurring more than 1 year after anthracycline 
treatment). Both chronic forms are characterized by an irreversible left ventricle (LV) 
dysfunction that can be progressive and, which, in some cases leads to heart failure. Although 
chronic AIC takes the form of dilated cardiomyopathy in adults, children tend to present initially 
a dilated cardiomyopathy y that progressively becomes a restrictive cardiomyopathy115 (Figure 
I2).  
Introduction 
 
53 
 
 
 
 
 
Early-onset AIC occurs in 1.6-2.1% of anthracycline-treated patients116. Remarkably, late-
onset AIC may not become apparent until to 10 to 20 years after the first anthracycline dose and 
risk of cardiac events can persist up to 45 years after therapy completion105,117. In fact, the 30-
year incidence of severe cardiac events for childhood cancer survivors treated with anthracycline 
is 7.3%111. The Childhood Cancer Survivor Study, a study enrolling 14,358 5-year survivors of 
childhood malignancies, revealed that the use of <250 mg/m2 of anthracycline was associated 
with a 2.4-fold higher risk of developing congestive heart failure compared to those non 
anthracycline-treated patients 30 years after cancer diagnosis. When patients were treated with 
≥250 mg/m2, this risk increased to 5.2-fold, and 1.8-fold and 2.3-fold for pericardial disease and 
valvular abnormalities, respectively110. Long-term cardiotoxicity has not been extensively studied 
in long-term survivors of adult malignancies, but the French Adjuvant Study Group reported that 
among 3,577 early breast cancer survivors, the 7-year risk of LV dysfunction was 1.36% in 
epirubicin-treated patients compared to 0.21% in non-epirubicin-treated patients118. 
Independently if they are children or adults, survivors with late-onset AIC can be asymptomatic 
for several years before experiencing a symptomatic cardiac dysfunction, with subclinical 
changes in LV structure and function only detectable through echocardiography (up to 57% of 
Table I2. Characteristics and course of the different types of AIC 
Characteristic 
Acute 
cardiotoxicity 
Early-onset, chronic 
progressive 
cardiotoxicity 
Late-onset, chronic 
progressive cardiotoxicity 
Onset 
Within the first 
week of 
anthracycline 
treatment 
<1 year after the 
completion of 
anthracycline treatment 
≥1 year after the completion 
of 
anthracycline treatment 
Clinical features 
in adults 
Transient 
depression of 
myocardial 
contractility 
Dilated cardiomyopathy Dilated cardiomyopathy 
Clinical features 
in children 
Transient 
depression of 
myocardial 
contractility 
Restrictive 
cardiomyopathy, dilated 
cardiomyopathy, or both 
Restrictive cardiomyopathy, 
dilated 
cardiomyopathy, or both 
Course 
Usually reversible 
when 
anthracycline 
treatment is 
discontinued 
Can be progressive. 
Irreversible 
Can be progressive. 
Irreversible 
Introduction 
 
54 
 
patients)119. Thus, the main challenge for anthracycline therapy remains in preventing subclinical 
damage and chronic symptomatic cardiotoxicity. 
 
 
 
 
 
On the other hand, echocardiography is the most commonly used technique to monitor 
cardiac structure and function after anthracycline administration, and LV ejection fraction (LVEF) 
and shortening fraction (SF) are the most common echocardiographic indices measured120; 
however, in most cases echocardiography lacks the sensitivity and specificity to detect 
symptomatic cardiotoxicity and especially subclinical cardiac dysfunction108,120,121. As an 
alternative, serum biomarkers such as B-type natriuretic peptide and cardiac troponins (T and I) 
are increasingly being used to evaluate AIC during and after treatment120,121. Regarding primary 
prevention, there are two main strategies for prevention of AIC: i) reduce cardiotoxic potency by 
administering via continuous infusion, liposome encapsulation, or using a less cardiotoxic drug 
(e.g., epirubicin or idarubicin) and ii) use a cardioprotective agent (e.g., dexrazoxane)104,122. 
 
A high cumulative dose of anthracycline is the greatest risk factor for AIC; however there is 
no absolutely safe dose for these chemotherapeutics, and even low doses < 200 mg/m2 can 
cause cardiac damage123. In addition to the cumulative dose, other risk factors increase the risk 
of cardiotoxicity, including female gender, younger (in children) and advanced (in adults) age at 
diagnosis, radiation therapy (especially in the mediastinal region), concomitant therapy (e.g., 
trastuzumab, cyclophosphamide, bleomycin and vincristine), and the presence of cardiac disease 
and comorbidities, such as diabetes or obesity104. However, some patients appear to be more 
vulnerable than others, independent of these risk factors, and some others are not going to 
Figure I2. Characteristics of dilated and restrictive cardiomyopathies. In dilated cardiomyopathy, the left ventricle 
is enlarged (in some cases the right ventricle will also be larger) and has thin walls. Thus, the heart does not 
contract well; causing systolic dysfunction. In restrictive cardiomyopathy, the left ventricle is slightly smaller in 
chamber size and has rigid walls. As a result, the LV relaxes abnormally and does not properly fill with blood, 
leading to diastolic dysfunction. Figure adapted from Blausen gallery 2014 (DOI:10.15347/wjm/2014.010).  
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experience cardiotoxicity; suggesting a genetic predisposition to AIC. Several studies124–139 have 
identified genetic variants associated with AIC; including common variants in genes involved in 
anthracycline transport and metabolism (e.g., CBR1 and CBR3125,127, SLC28A3133,134, ABCB1133, 
ABCC1129,133) or pharmacodynamic genes (e.g., NCF4124,125,131, NQO1125). Only Aminkeng et al.139 
used a genome-wide approach to identify susceptibility genetic variants to AIC. All the remaining 
studies are hypothesis-driven candidate-gene studies and all have focused on common genetic 
variants [minor allele frequency (MAF)≥5%]; thus, it is plausible that analyses of low-frequency 
(MAF=1-5%) and rare (MAF<1%) potentially functional variants could explain additional 
interpatient variability in susceptibility to AIC. Moreover, genetic studies may help to identify 
genomic biomarkers predictive of AIC and could help to elucidate the precise molecular 
mechanisms. In this thesis we focused on the identification of additional genes and susceptibility 
variants to chronic AIC, with particular attention to rare variation, by using exome array analysis 
in both, anthracycline-treated pediatric and adult oncology patients.  
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Table I3. Summary of the studies 
Trait Clinical problem Aim Study 
Ewing sarcoma  
 
 Rare (2.5-3 cases per million) and aggressive pediatric bone tumor  
 
 High incidence of recurrence (>40%)  
 
 Dismal outcome for patients with metastatic disease (cure 
rates=20-40%) and for those with recurrent/refractory disease 
(long-term survival <15%)  
 
Identification of predictive and 
prognostic genetic variants 
Study I 
Capecitabine-
induced hand-foot 
syndrome (CiHFS) 
 
 Frequently used for the treatment of breast and colorectal 
carcinomas, especially for metastatic tumors 
 
 CiHFS is a common (>30%) cutaneous adverse event  
 
 ~17% of patients experience severe CiHFS (grade 3) resulting in 
dose reduction or therapy discontinuation and the inability to 
perform daily routines 
 
Identification of additional 
genetic variants predictive of 
susceptibility to CiHFS apart 
from those involved in the 
enzymatic metabolic pathway 
of capecitabine 
biotransformation 
Study II 
Anthracycline-
induced 
cardiotoxicity (AIC) 
 
 Widely used chemotherapeutic agents in children and adults 
 
 Their clinical use is compromised by cardiotoxicity.  
 
 Children cancer survivors are particularly vulnerable to AIC 
 
 Symptomatic chronic AIC is rare (7.3% of patients), but subclinical 
alterations are quite frequent (up to 57% of patients) 
 
 Risk of cardiac events can persist several decades after therapy 
completion and can progress to fatal heart failure 
 
Identification of novel genes 
and variants predictive of 
susceptibility to AIC with 
special attention to low 
frequency and rare coding 
variants 
Study III and IV 
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The principal purpose of this thesis was to identify predictive and prognostic germline 
genetic variants for chemotherapeutics efficacy and toxicity, to provide essential data that will 
help to understand the molecular mechanisms underlying drug response and with the ultimate 
goal of improving anticancer treatment and establish the basis for an individualized therapy 
management in cancer patients. To achieve this, we developed the following specific aims: 
 
 
1. To discover genomic biomarkers that predict treatment outcome in children diagnosed 
with Ewing sarcoma. 
 
2. To identify novel genomic biomarkers associated with increased susceptibility to 
capecitabine-induced hand-foot syndrome (CiHFS) in adult breast and colorectal 
cancer patients.  
 
3. To establish the contribution of low-frequency and rare genetic variants to 
susceptibility to chronic anthracycline-induced cardiotoxicity (AIC) in pediatric 
oncology patients and in adult breast cancer patients. 
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In order to facilitate the understanding of this section, detailed information about the 
materials and methods used in Study I and Study II is given separately. Studies III and IV used 
the same methodology, and so the materials and methods used are presented together. In 
addition, a table is provided summarizing the main materials and methods for each study. 
1. Materials & Methods, Study I: identification of predictive and prognostic genetic variants for 
Ewing sarcoma  
1.1. Patients 
Eligible patients had histologically confirmed Ewing sarcoma diagnosed before age 30 years. 
The discovery cohort consisted of 106 Spanish Ewing sarcoma pediatric patients recruited 
between 1993 and 2012 at the La Paz University Hospital and the Niño Jesús University Hospital 
in Madrid and at the University Clinic of Navarra in Pamplona. The replication cohort consisted 
of 389 Ewing sarcoma pediatric patients from Austria (153), France (110), Italy (97) and Germany 
(29), recruited in 1991-2010, 1999-2007, 1987-2010 and 1994-2008, respectively. In both 
cohorts, patients were treated according to a multimodal protocol consisting of multiagent 
chemotherapy mostly involving combinations of vincristine (V), ifosfamide (I), doxorubicin (D), 
cyclophosphamide (C), etoposide (E) and/or actinomycin-D (A), combined with surgery and/or 
radiation therapy. In the induction chemotherapy, three main protocols were used: VIDE (62% of 
patients), VDC (17%) and VDC+VAI+VDC+IE (14%). Information about the neoadjuvant protocols 
is shown in Table MM1.  
Table MM1. Neoadjuvant treatment given to Ewing sarcoma patients 
Neoadjuvant 
chemotherapy 
Discovery 
(N=106) 
Replication (N=389) 
Spain  
(106) 
Germany 
(29) 
Italy 
(97) 
Austria 
(153) 
France  
(110) 
N (%) N (%) N (%) N (%) N (%) 
VIDE 27 (25%) 15 (52%) - 153 (100%) 110 (100%) 
VDC 79 (75%) - 3 (3%) - - 
VDC+VAI+VDC+IE - - 70 (72%) - - 
VDI+C*E*+VDI+C*E 
- - 15 (15%) - - 
VDCA+I - - 5 (5%) - - 
VDIA - 4 (14%) -  - - 
EVDIA - 4 (14%) - - - 
VDIA+EVDIA  1 (3%) - - - 
VIDE+VAI - 3 (10%) - - - 
VIDE+VAI+VAC - 1 (3%) - - - 
Other - 1 (3%) - - - 
Missing - - 4 (4%) - - 
Abbreviations: A, actinomycin-D; C, cyclophosphamide; C*, high-dose cyclophosphamide; D, doxorubicin; E, 
etoposide; E*, high-dose etoposide; I, ifosfamide; V, vincristine. Other: chemotherapy regimen involving 
vincristine, doxorubicin, etoposide and cisplatin. 
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Postoperative chemotherapy typically consisted of the administration of the VAC or the VAI 
regimen. Of patients in the replication cohort with metastasis at diagnosis and/or non-resectable 
primary tumor, 18% were treated with high-dose chemotherapy. None of the patients in the 
discovery cohort received high-dose chemotherapy. 
 
Information on age at diagnosis, sex, primary tumor site, therapy, existence of metastasis at 
diagnosis and development of recurrence was abstracted from medical records. Where possible, 
tumor response to treatment, defined as the percentage of necrosis induced in the tumor after 
neoadjuvant chemotherapy, was determined histologically. Recurrence was defined as any 
evidence of new disease during/after the completion of therapy, including both locoregional and 
distant disease relapses. Overall survival was calculated as the time from tumor diagnosis until 
death from any cause or date last known to be alive. 
 
Written informed consent was obtained from adult patients and from the parents or legal 
guardians of children. The study was approved by the ethics committees of all participating 
universities and hospitals.  
1.2. Selection of genes and polymorphisms 
Since often transporters and metabolizing enzymes are shared between different drugs and 
the existence of a functional interplay between them in drug absorption and disposition, it 
seems essential the integration of multiple drug pathways to allow a comprehensive analysis of 
genetic factors influencing pharmacokinetics and drug efficacy, especially when 
polychemotheraphy is administered. Therefore, we decided to adopt a genotyping-based 
candidate pathway strategy and selected 24 genes reported to be involved in the 
pharmacokinetics of the 6 agents (vincristine, ifosfamide, doxorubicin, cyclophosphamide, 
etoposide and actinomycin-D) commonly used in chemotherapy regimens for Ewing sarcoma, 
based on the literature and on the information available in the Pharmacogenomics Knowledge 
PharmaGKB database140 (Table MM2).  
 
Table MM2. Candidates genes studied 
Category Genes 
Transporters 
ABCA3, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC6, 
ABCG2, SLC31A1, SLCO6A1, SLC19A1 
Phase I metabolism enzymes 
MPO, SOD1, ALDH1A1, CYP3A4, CYP3A5, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19 
Phase II metabolism enzymes GSTM1, GSTP1, GSTT1 
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A total of 384 common variants were selected across these candidate genes, as previously 
described141. Briefly, both SNVs with potentially functional effects (causing amino acid changes, 
potentially causing alternative splicing, located in the promoter region, in putative transcription 
factor binding sites, or disrupting miRNAs and their targets) identified using the bioinformatics 
tool PupaSuite142, and other functional variants already described in the literature were selected. 
In addition, across these genes we selected tagSNVs to ensure a more extensive evaluation of 
the contribution of common variation within each gene using Haploview software (v.4.0)143. 
MAF>5% and r2 threshold of 0.8 were employed for tagging procedure. The preliminary list of 
variants was filtered using as criteria suitability for the Illumina genotyping platform (selecting 
only those with an assay score >0.6, associated with a high success rate) and MAFs of at least 
5%. A final number of 384 variants relevant to this study were included in an oligonucleotide 
pool assay for analysis using the Illumina Veracode technology (Illumina, San Diego, USA).  
1.3. Isolation and quantification of DNA  
Five to ten ml of peripheral blood samples were collected in tubes containing anticoagulant. 
Whole blood was fractionated by centrifuging during 10 min at 3000 rpm; the plasma upper 
layer was aspirated off, while the buffy coat containing the white blood cells was extracted by a 
Pasteur pipette. Germline DNA was extracted using standard phenol-chloroform extraction 
protocols and an automatic DNA extraction instrument (Magnapure, Roche, Mannheim, 
Germany). DNA was quantified using the Quant-iT™ PicoGreen dsDNA kit (Invitrogen, Carlsbad, 
USA). For the standard curve, a series of dilutions of genomic DNA (Clontech, Mountain View, 
USA), giving a final DNA concentration from 20 to 200 ng/µl, were prepared in TE buffer (10 mM 
Tris, 1 mM EDTA, pH 7.5). The standards and 2 µl of each sample were pipetted into a 96 well 
microplate (Falcon, BD Biosciences, San Jose, USA). PicoGreen reagent was diluted in TE buffer 
according to the kit instructions and 198 µl of the mix was pipetted in the wells. The 
fluorescence was read at 520 nm after 480 nm excitation using the DTX 800 Multimode Detector 
(Beckman Coulter, Fullerton, USA). 
 
250 ng of genomic DNA from each sample were genotyped using the GoldenGate assay with 
VeraCode technology (Illumina, San Diego, USA) on the BeadXpress platform according to the 
published protocol. Illumina GoldenGate technology is based on allele-specific primer extension 
assays (Figure MM1). Briefly, in the first step DNA is activated through a chemical reaction with 
biotin to enable binding to streptavidin-conjugated paramagnetic particles and then hybridized 
with the assay oligonucleotides. Three oligonucleotides are designed to query the allele at each 
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SNV locus. Two oligos are specific to each allele of the SNV site, called the Allele-Specific Oligos 
(ASOs). Each ASO contains a region of genomic complementarity but has a different nucleotide 
on the 3' end, which corresponds to the complement of each possible allele in the genomic DNA; 
and also contains a unique universal PCR primer sequence. A third  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
oligo, the Locus Specific Oligo (LSO), hybridizes several bases downstream from the SNV site and 
contains an additional unique address sequence that targets a particular VeraCode bead type 
and also contains a region of genomic complementarity and a universal PCR primer site. After 
the oligo hybridization, allele-specific extension of the appropriate ASO and ligation of the 
extended product to the LSO were performed. These joined full-length products provide a 
Figure MM1. Illumina VeraCode GoldenGate protocol (from Illumina website
144
) 
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template for PCR using universal PCR primers P1, P2, and P3. Universal primers P1 and P2 are 
Cy3 and Cy5 labeled to allow allele discrimination. PCR products were hybridized to their 
VeraCode bead type through their unique address sequence and each VeraCode microtitre bead 
plate was imaged on the Illumina BeadXpress Reader System (Illumina, San Diego, USA). After 
scanning, SNV genotype clustering and individual sample genotype calls were interrogated using 
the Illumina GenomeStudio software (v.3.2)144. 
 
We excluded variants with a call rate <0.95 with MAF<0.05, whose genotype distribution 
deviated from Hardy-Weinberg equilibrium (P<10-6), with Mendelian allele-transmission errors, 
or with discordant genotypes between duplicate samples. Samples with a call rate <0.90 were 
excluded.  
1.4. Statistical analysis 
We studied the association of SNVs with tumor response and overall survival. Patients were 
divided into two categories: good responders, with tumor necrosis ≥90%; and poor responders, 
with tumor necrosis <90%145. Odds ratios (ORs) and 95% confidence intervals (CIs) for good 
tumor response by genotype were estimated using logistic regression analysis. Variants for 
which associations with P<0.05 were observed were assessed in the European replication 
cohort.  
 
We also tested associations between SNV genotypes and overall survival using Cox-regression 
analysis. Variants with P<0.05 in the discovery set were assessed in the replication cohort.  
Table MM3. Clinical information recorded from Ewing sarcoma patients and associations in 
univariable analyses with tumor response and overall survival 
 
Tumor response Overall survival 
 Discovery Replication Discovery Replication 
Clinical information P P P P 
Age at diagnosis 0.039 0.002 0.048 0.038 
Sex 0.52 0.38 0.55 0.79 
Primary tumor site 0.29 0.99 0.33 0.69 
Metastasis at diagnosis  0.001 0.042 1.67x10
-6
 6.8x10
-12
 
Neoadjuvant therapy 0.55 0.54 0.15 0.15 
Response to treatment NA NA 0.029 6.0x10
-5
 
Recurrence 0.093 0.082 1.67x10
-6
 8.7x10
-22
 
Vital status NA NA NA NA 
Overall survival NA NA NA NA 
Country of origin NA 0.90 NA 0.81 
Country of origin was included as covariate in analyses with overall survival in the replication cohort due to 
incomplete information regarding adjuvant therapy protocols. Abbreviations: NA, not applicable. 
Materials & Methods Study I 
 
68 
 
Survival curves were plotted using the Kaplan-Meier product-limit method, and the significance 
of differences between these curves was determined using the log-rank test. 
 
Clinical factors with associated P<0.05 in univariable analyses (Table MM3) with tumor 
response or overall survival were included as covariates in corresponding multivariable analyses.  
 
In addition to the additive genetic model, we considered dominant and recessive models. 
 
Analysis were carried out using PLINK (v.1.07)146,147 or SPSS software (v.18.0; SPSS, Chicago, 
USA). 
1.5. Functional annotations 
We used information from the Encyclopedia of DNA Elements (ENCODE)148 using custom 
tracks on the UCSC Genome browser149 and HaploReg150 to investigate whether the risk-
associated SNVs or their correlated SNVs [r2≥0.8] had potential regulatory functions. ENCODE 
describes genes, transcripts, and transcriptional regulatory regions, as well as DNA binding 
proteins, that interact with regulatory regions in the genome, including transcription factors, 
histones and other markers, and DNA methylation patterns that define states of the genome in 
various cell types148. HaploReg is a web tool that provides information about predicted 
chromatin states in nine cell types, conservation across mammals and effects on regulatory 
motifs151. 
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Table MM4. Summary of the main materials and methods of Study I 
Patients  
 
Discovery cohort: 106 Spanish pediatric Ewing sarcoma patients 
 
Replication cohort: 389 pediatric Ewing sarcoma patients from across Europe 
 
Genotyping 
 
Candidate pathway approach: analysis of 24 pharmacokinetic genes 
involved in the transport or metabolism of the 6 agents commonly used for 
Ewing sarcoma treatment (Illumina VeraCode GoldenGate). 384 SNVs were 
selected across these 24 candidate genes. 
 
Statistical analysis 
Single-variant associations:  
 
 Tumor response: logistic regression analysis 
 Overall survival: Cox-regression analysis 
 Significance level: P<0.05 
 
 
Functional 
annotations 
ENCODE (UCSC Genome browser) and Haploreg 
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2. Materials & Methods, Study II: identification of genetic variants predictive of susceptibility 
of capecitabine-induced hand-foot syndrome (CiHFS)  
 
2.1. Patients 
Capecitabine-treated adult breast and colorectal cancer patients were recruited 
retrospectively through several Hospital Oncology Units across Spain. The discovery cohort 
consisted of 166 patients recruited at the San Carlos University Hospital (Madrid, Spain) (N=87) 
and the Virgen de la Victoria University Hospital (Málaga, Spain) (N=79). The validation cohort 
consisted of 85 patients recruited at the Gregorio Marañón University Hospital (Madrid, Spain) 
(N=58) and 27 patients enrolled in a clinical trial comparing standard versus continuous 
administration of capecitabine in metastatic breast cancer (www.clinicaltrials.gov, identifier 
code: NCT00418028). To ensure accurate patient phenotyping and maximize genotyping 
efficiency we applied an extreme phenotype sampling152: case patients selected for both 
discovery and replication studies were required to have grade 3 toxicity experienced across any 
treatment cycle before completing eighteen cycles of treatment (over one year) and control 
patients were those not developing CiHFS during treatment (grade 0). Patients who did not fulfill 
these criteria were excluded. CiHFS grade was determined according to the NCI Common 
Terminology Criteria for Adverse Events v 4.0 (CTCAE v4.0)86. Cumulative dose was calculated as 
the amount in mg/m2 of capecitabine taken prior to the development of toxicity or the end of 
follow-up, whichever was lower. Capecitabine was administered according to different 
schedules. Colorectal cancer patients were treated with a standard regimen (1250 mg/m2 orally 
every 12 h on days 1-14, every 3 weeks), while breast cancer patients were treated either with 
the same standard regimen or with a continuous regimen (800 mg/m2 orally every 12 h daily 
during 21 days). All protocols were approved by the institutional review boards at each 
institution, and all subjects provided written informed consent. 
 
Information on age at diagnosis, sex, primary tumor, treatment regimen, capecitabine 
cumulative dose and CiHFS grade was recorded from medical records 
2.2. Isolation and quantification of DNA  
Genomic DNA was isolated from peripheral blood lymphocytes and quantified using the same 
procedures above described (section 1.3). 
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2.3. Genotyping  
250 ng of genomic DNA from each sample in the discovery cohort were genotyped using 
Illumina Human610-Quad BeadChips containing 616,795 variants according to the 
manufacturer's protocols (Illumina, San Diego, USA). The Illumina Human610-Quad array is 
based on the Infinium assay (Illumina, San Diego, USA) (Figure MM2).  
 
 
 
In this system a whole-genome amplification step is used to increase the amount of DNA up 
to 1000-fold. The DNA is fragmented and captured on BeadChips by hybridization to immobilised 
SNV-specific primers, followed by single-base primer extension. Single-base extension of the 
oligos on the BeadChip, using the captured DNA as a template, incorporates detectable labels on 
the BeadChip and determines the genotype call for the sample. If there is a perfect match, 
extension occurs and signal is generated. If there is a mismatch, extension does not occur and no 
signal is generated. BeadChips are imaged using the Illumina iScan System, a two-channel high-
resolution laser imagers that scan BeadChips at two wavelengths simultaneously and create an 
image file for each channel (e.g., two per array). The GenomeScan software determines intensity 
values for each bead type and creates data files for each channel. The GenomeStudio software 
Figure MM2. The Illumina Infinium protocol (from Illumina website, www.illumina.com) 
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package extracts whole-genome DNA analysis data from image data files created by the Illumina 
BeadArray Reader153.  
DNA samples from the replication cohort were genotyped by KASpar Assays (Kbioscience, UK) 
and fluorescence was determined by the sequencer Detection System 7900HT (Applied 
Biosystems, Foster City, USA) (Figure MM3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The KASpar genotyping system is based on:  
 two allele-specific primers (one for each SNV allele). Each primer has an unlabelled tail 
sequence at the 5' end and the two primers have different tail sequences. 
 a common reverse primer. 
Figure MM3. KASPar SNV genotyping system (adapted from http://www.lgcgroup.com/services/KASP_genotyping). 
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 two fluor-labelled oligos complementary to the sequences of the tails of the allele-
specific primers. This oligos are labelled with a fluorochrome (FAM or VIC) and with a 
quencher; so that there is no fluorescence emission. 
 
In the beginning of the PCR, the appropriate allele-specific primer and the common primer 
binds to the DNA at the SNV locus and PCR occurs. As PCR proceeds further, the fluor-labelled 
oligo becomes incorporated into the template as well, and is hence no longer bound to its 
quencher-labelled complementary oligo. As the fluorescence is no longer quenched, the 
appropriate fluorescent signal is generated and detected by the usual means (Figure MM3). If 
the genotype of a diploid individual for a particular SNV is homozygous, only a FAM or VIC signal 
will be generated. If the individual is heterozygous, a FAM and VIC signal will be generated. The 
Sequence Detection System (SDS) Software (v.2.2.2) uses the fluorescence measurements made 
during the plate read to plot fluorescence values based on the signals from each well. The 
plotted fluorescence signals indicate which alleles are in each sample (Figure MM4). Coriell 
sample/s in duplicate (Coriell Cell Repository, Camden, USA) as positive controls (e.g., DNAs with 
known genotypes) and NTC (no template control) were included in all assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure MM4. KASPar allelic discrimination. Each data point represents the fluorescence signal of an individual 
DNA sample. Samples of the same genotype will have generated similar levels of fluorescence and will therefore 
cluster together on the plot. Abbreviations: NTC, no template controls. 
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Fine-mapping genotyping was performed by using the MassARRAY genotyping system 
(Sequenom, San Diego, USA) and Infinium assay (Illumina, San Diego, USA) following the 
manufacturer's instructions. The MassARRAY genotyping system consists of an initial locus-
specific PCR reaction, followed by a locus-specific primer extension reaction (iPLEX assay) in 
which an oligonucleotide primer anneals immediately upstream of the polymorphic site being 
genotyped. In the iPLEX assay, the primer and amplified target DNA are incubated with mass-
modified dideoxynucleotide terminators. The primer extension is made according to the 
sequence of the variant site, and is a single complementary mass-modified base. Through the 
use of MALDI-TOF mass spectrometry, the mass of the extended primer is determined. The 
primer’s mass indicates the sequence and, therefore, the alleles present at the polymorphic site 
of interest154 (Figure MM5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure MM5. Genotyping using the Sequenom MassARRAY iPLEX platform154. Abbreviations: SAP, Shrimp Alkaline 
Phosphatase; MS, mass spectrometry.  
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2.4. Quality control (QC) 
Samples from the discovery cohort were excluded from further analyses if they had more 
than 5% missing genotype. Variants excluded were non-diploid variants, CNVs and SNVs deemed 
unreliable by Illumina (Tech Note: Infinium Genotyping Data Analysis, 2007), variants with 
missing genotypes in more than 5% of samples, with MAF <0.05 as well as SNVs whose genotype 
frequencies departed from Hardy-Weinberg equilibrium at P<10-6. To control for potential 
population stratification, we performed a principal component analysis (PCA)155 using the 
snpStats package in R (v.3.0.1) considering only variants that passed QC (520,052). 
2.5. Statistical analysis 
Genotypes were assessed in relation to the cumulative dose of capecitabine using Cox 
regression analysis; modeling the cumulative dose of capecitabine (mg/m2) up to the 
development of at least grade 3 CiHFS for cases. Patients not experiencing CiHFS of any grade 
during capecitabine treatment (controls) were censored at the total cumulative dose received. 
Estimated hazard ratios (HRs) were interpreted as relative risks of developing severe CiHFS at a 
given cumulative dose. Cox regression analysis was performed in the global data set [discovery 
cohort (166) + validation cohort (85), N=251] to identify clinical factors associated with CiHFS 
development. Associations were assessed under an additive genetic model by multivariable 
analysis, adjusting for sex, tumor type and treatment regimen. Cox regression analyses were 
performed using the R statistical environment (v.3.0.1) and PLINK (v.1.07)146,147. Kaplan-Meier 
comparisons of cumulative dose of capecitabine taken up to the development of grade 3 CiHFS 
according to SNV genotype were performed using the SPSS software (v.18.0; SPSS, Chicago, USA) 
and the log-rank test was applied.  
 
A quantile-quantile (Q-Q) plot comparing the distribution of P-values observed (from Cox 
regression analysis adjusted for sex, tumor type and treatment regimen for 520,052 variants 
that passed QC in the discovery cohort) to those expected to account for population 
stratification was generated using the qqman package in R (v.3.0.1). The genomic inflation factor 
(λ) based on Q-Q plot was calculated using R (v.3.0.1).  
 
Variants with associated P-values below a predefined threshold of 10-5 in the discovery 
cohort were assessed using the same statistical methods. 
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Haplotype estimation for the four most strongly associated SNVs (P<5x10-7 and MAF>5%) was 
performed using PHASE156 (v2.1.1) and haplotype-specific HR, P-values and confidence limits 
were estimated using SPSS software (v.18.0; SPSS,Chicago, USA).  
2.6. Block definition, variants selection and imputation 
The boundaries for the linkage disequilibrium (LD) block containing the replicated SNV 
rs6093063 in 20q13.33 locus were defined by the furthest upstream and downstream correlated 
SNVs with rs6093063 (r2>0.10). Based on data from the June 2012 release of the 1000 Genomes 
Project21, we selected for genotyping all SNVs with r2>0.10 with the marker plus a minimum set 
of SNVs tagging all other SNVs in the block at r2>0.8, the latter identified using Haploview 
software (v.4.2)143. We catalogued 605 variants at the region and we successfully genotyped 34. 
Prediction of the untyped SNVs within the LD block was carried out using IMPUTE (v.2.0)157 
based on phased haplotypes from 1000 Genomes Project data21. Genotypes for 80 SNVs were 
reliably imputed (imputation information score>0.3). 
2.7. Cell lines and tissue samples 
Cell lines: HaCaT cells (spontaneously immortalized human keratinocytes) were provided by 
Manuel Serrano (Spanish National Cancer Research Centre, CNIO, Madrid, Spain) and cultured in 
MEME-based (M8167, Sigma) low calcium medium (Nowak and Fuchs, 2009) containing 0.05 
mM Ca2+. Normal Human Epidermal Keratinocytes (NHEK) were purchased from Lonza (Cat Nº: 
00192627; Lot Nº: 0000246915) and grown in Lonza's KGM-Gold media (basal medium 
supplemented with bovine pituitary extract, human epidermal growth factor, bovine insulin, 
hydrocortisone, Gentamicin, Amphotericin-B, Epinephrine and Transferrin; Cat Nº 00192060). 
Proliferative keratinocytes are normally found in the basal layer of the epidermis and move to 
suprabasal layers upon differentiation. In culture, keratinocytes proliferate and grow in a 
monolayer in low calcium medium, but the addition of calcium promotes cell-cell contact 
formation and differentiation into post-mitotic keratinocytes158. So, to induce keratinocyte 
differentiation, 2 mM Ca2+ was added to the medium. Cell lines were maintained under standard 
conditions and routinely tested for Mycoplasma.  
 
Tissue samples: fifty healthy liver tissue samples were obtained from the Spanish National 
Cancer Research Center (CNIO, Madrid, Spain) Tumor Bank. The study was approved by the 
ethics committee of the Spanish National Cancer Research Center (CNIO, Madrid, Spain).  
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2.8. Circular chromosome conformation capture (4C)-sequencing 
Human epidermal keratinocytes, NHEK and HaCaT, homozygous for the reference or the risk 
haplotypes, respectively, were treated with 2 mM Ca2+ for 72 h before collection. Preparation of 
4C samples was performed as previously described159 with some modifications (Figure MM6). 
Briefly, 2x107 cells of each haplotype were trypsinized, PBS (phosphate buffered saline) washed 
and resuspended in 10 ml of fixing solution containing 1% formaldehyde in PBS. After 10 min, 
0.125 M glycine was added to stop fixation and the mixture was incubated for 5 min at room 
temperature. Cells were pelleted and nuclei isolated after 40 min of incubation in cold lysis 
buffer (50 mM Tris pH 7.5, 50 mM NaCl, 5 mM EDTA, 1% NP40, 2% TX-100 + protease inhibitors 
cocktail). Proper lysis was determined by methyl green-pyronin staining. HindIII and DpnII (NEB) 
were used as first and second cutters, respectively. 4C libraries were amplified using long 
primers with 18-20 bp homology to the bait sequence and Illumina paired-end adapter flanks. 
Primer sequences were chosen to viewpoint sites, which were within the CDH4 promoter region 
as follows:  
P5_Vp1:AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTCTACAGATGT
TTGCTAAGCTT  
P7_Vp1: CAAGCAGAAGACGGCATACGAAGAATCAATGTAGCAGGTCT  
P5_Vp2:AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCCCCTCCC
AGAAGCTT  
P7_Vp2: AAGCAGAAGACGGCATACGAATTTCCGAGGTTACAACAGCGC  
 
4C-seq data analysis and normalization was performed with 4Cseqpipe159 on the Genome 
Reference Consortium Human Build 37 (GRCh37/hg19). 
2.9. Functional annotations 
We used information from ENCODE148 using custom tracks on the UCSC Genome browser149 
to investigate whether the risk-variant containing locus might have potential regulatory 
functions.  
2.10. mRNA expression analysis in nontumoral human liver tissues 
Total RNA was extracted from cryopreserved liver tissues using 1ml TriZol (Invitrogen, CA, 
USA) and treated with DNase I (Ambion, Austin, USA) according to the instructions of the 
manufacturer. 1 µl of RNA was used to measure the concentration by Nanodrop ND-1000 
(Wilmington, DE, USA) and the RNA quality was tested through 1% agarose gel electrophoresis. 
Materials & Methods Study II 
 
78 
 
Reverse transcription was performed in a single tube using 1 µg of the total RNA, Superscript II 
Reverse Transcriptase (Invitrogen, CA, USA) and oligo random hexamers primers following the 
manufacturer’s instructions.  
 
 
 
 
 
 
 
CDH4 mRNA was quantified by real-time quantitative PCR (qRT-PCR) with the ABI PRISM® 
7900HT Sequence Detection System (Applied Biosystems, Foster City, USA), using human CDH4-
specific primers (Table MM5) and fluorescent probes from the Human Universal ProbeLibrary 
Set (Roche, Mannheim, Germany). The expression levels of PCR products were normalized 
according to ACTB gene expression (Table MM5). The final concentrations of the primers and 
the probes were 500 nM and 1000 nM, respectively, with a final volume of 12 ul, using 2.4 ul of a 
1:10 cDNA dilution for each reaction. Negative controls were present in all series of qRT-PCR 
reactions and all assays were carried out in triplicate. For the amplification reaction, the 
Universal PCR Master Mix (PE Applied Biosystems, Foster City, USA) was used and the conditions 
consisted in an initial step of 95 ºC for 10 min, followed by 55 cycles of 15 s at 95 ºC and 1 min at 
60 ºC. The delta–delta Ct method160 was used for the calculation of the different amounts of 
mRNA.  
 
Figure MM6. Outline of the 4C technology
159
. After cross-linking by formaldehyde and digestion with the first 
restriction enzyme (RE), “hairballs” of cross-linked DNA are created (1). Chromatin is diluted and religated to fuse the 
ends of DNA fragments present in the same “hairball” (2). The ultimate outcome of this ligation event is large DNA 
circles encompassing multiple restriction fragments. Cross-links are removed by heating (3); DNA is digested by a 
second RE (usually a four cutter) (4) and religated under diluted conditions to create small DNA circles, most of which 
carry a primary ligation junction. Inverse PCR primers specific for the fragment of interest (“viewpoint”) and carrying 
5´adapter overhangs for next-generation sequencing allow amplification of all its captured sequences followed by 
high-throughput sequencing. Abbreviations: Next-gen, next generation. 
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Association between the risk locus haplotypes and expression levels of CDH4 gene was 
assessed using the Student’s t test, after natural log transformation to obtain normally 
distributed expression data. Differences were considered significant when P<0.05. These 
analyses were carried out using SPSS (v.18.0; SPSS, Chicago, USA). 
 
2.11. R-cadherin and involucrin protein expression in skin samples 
Normal paraffin-embedded skin samples derived from mastectomy of 16 breast cancer 
patients before capecitabine treatment (12 CiHFS grade 3 samples and 4 CiHFS grade 0 samples) 
were available for tissue microarray (TMA) construction. Duplicate 2-mm tissue cores using the 
MTA1-Manual Tissue Arrayer (Beecher Instruments) were selected from each skin sample. 3 μm 
thick tissue sections were cut from TMAs for R-cadherin and involucrin expression analysis by 
immunohistochemistry (IHC). Further IHC analyses of additional cadherins (E-cadherin, P-
cadherin and N-cadherin) were performed to confirm the R-cadherin antibody specificity and to 
compare the location of the different cadherins in the skin layers. IHC was done using the 
following protocol: after overnight incubation at 55°C and deparaffinization, antigen retrieval 
was performed using EnVision FLEX TRS High pH (Dako, Glostrup) for 20 min. Blocking of 
endogenous peroxidase activity, incubation with primary antibody, signal enhancement of R-
cadherin and involucrin staining with EnVision FLEX HRP (Dako, Glostrup) and E, P and N-
cadherins staining with EnvisionFlex+Mouse (Linker) (Dako, Glostrup) and revealing 
immunoreactivity were performed in an Autostainer Link 48 (Dako, Glostrup). The following 
primary antibodies were applied: R-cadherin: dilution 1:300, (HPA015613, Sigma, St. Louis); E-
cadherin: ready to use (1R059, Dako, Glostrup); P-cadherin: dilution 1:75, (610228, BD 
Biosciences, New Jersey, USA); N-cadherin: dilution 1:100, (M3613, Dako, Glostrup); involucrin: 
ready to use (Thermo Fisher Scientific, CA, USA). Incubation times for the primary antibodies 
were 20 min (E-cadherin and P-cadherin) and 40 min (R-cadherin, N-cadherin and involucrin). 
Slides were counterstained with hematoxylin using an automatic slide stainer Varistain Gemini 
ES (Thermo Fisher Scientific, CA). Immunostained slides were digitized using a Zeiss Mirax 
automated slide scanner (Zeiss, Germany) with an objective of 40x magnification (0.12μm/pixel). 
Digital image analysis was performed by importing the Mirax file into the image analysis 
Table MM5. CDH4 and ACTB specific primers 
Gene Forward Primer Reverse Primer Probe (5´-3´) 
CDH4 AGCACGCCTCTTACCACCT ACGTAGATGTACAGGTCGATGG UPL #39a 
ACTB CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG UPL #64a 
a. Human Universal ProbeLibrary Reference Gene Assay 
Materials & Methods Study II 
 
80 
 
software HistoQuant (3DHistech Ltd, Budapest, Hungary). For R-cadherin and involucrin 
expression quantification, the epidermis was selected according to morphological differences 
and IHC staining (Figure MM7). HistoQuant algorithm was used to quantify the intensity of R-
cadherin and involucrin positive staining. Each positive area was analyzed at pixel level with each 
pixel containing staining intensity information corresponding to the red-green-blue (RGB) 
channels. In digital image analysis, the pixel intensity values for any color range from 0 to 255, 
wherein, 0 represents the darkest shade of the color and 255 represent the lightest shade of the 
color as standard. Since the optical density is proportional to the concentration of the stain, R-
cadherin and involucrin positive staining was measured as the average of RGB channels and 
subtracted from 255 to associate large intensity values with a high R-cadherin or involucrin 
staining161,162. Differences in R-cadherin and involucrin expression were assessed using Student’s 
t test and the SPSS software (v.18.0; SPSS, Chicago, USA). A P-value of <0.05 was considered to 
be statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
2.12. R-cadherin expression knock-down (KD) 
For knock-down experiments HaCaT cells were transfected with the short hairpin RNA 
(shRNA)expressing pGFP-V-RS plasmid (TR30007, OriGene) 12 h after plating using X-tremeGENE 
9 DNA transfection reagent (Roche, Mannheim, Germany) according to the manufacturer’s 
instructions. 24 h after transfection 2 mM Ca2+ was added to the medium for 48 h. Control cells 
Figure MM7. Quantification of R-cadherin an involucrin expression in the skin from breast cancer patients 
sampled prior capecitabine treatment. For automated image acquisition, the TMA areas of interest were selected 
according to the epidermal morphological differences and brown marker (DAB) intensity. These image areas were 
used as training samples for the HistoQuant pattern recognition software to set quantification thresholds for the 
analysis. For that purpose the HistoQuant Wizard was used to set the algorithm, establishing different values for 
contiguous nucleus separation, cytoplasmic area definition, colour intensity separation for quantification and 
grading and size exclusion. For quantification of R-cadherin expression only the suprabasal layers of the epidermis 
were selected (in red). For quantification of involucrin, positive staining areas (corresponding to the cornified 
envelope of the epidermis) were selected. Each positive area was analyzed at pixel level with each pixel 
containing staining intensity information corresponding to the RGB channels. 
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were transfected with a scramble shRNA expressing plasmid. The following R-cadherin shRNA 
sequences were used:  
 Clon 1: AGGCGACATCGGTGACTTCATCAATGAGG 
 Clon 2: TATGTTCACCATCAACAGCGAGACTGGAG 
 
Antibodies: the following antibodies were used: β-actin mouse mAb (A5441, Clone AC-15, 
Sigma, St. Louis, USA), E-cadherin human mAb (Clone HECD-1, ab1416, Abcam), R-cadherin 
rabbit pAb (HPA015613, Sigma, St. Louis, USA), filaggrin rabbit pAb (PRB‐417P, Covance, New 
Jersey, USA), loricrin rabbit pAb (PRB-145P, Covance, New Jersey, USA), involucrin rabbit pAb 
(PRB-140C, Covance, New Jersey, USA). 
 
RNA isolation and qRT-PCR: total RNA was isolated from cells using TriZol reagent (Invitrogen, 
CA, USA) and treated with DNase I (Ambion, Austin, USA) according to the instructions of the 
manufacturer. 1 µl of RNA was used to measure the concentration by Nanodrop ND-1000 
(Wilmington, DE, USA) and the RNA quality was tested through 1% agarose gel electrophoresis. 
2 g were used for cDNA synthesis using the Ready to Go You Prime It First-Strand beads and 
random primers (GE Healthcare, Uppsala, Sweden). qRT-PCR reactions for CDH1 (E-cadherin), 
FLG (filaggrin), KRT1 (keratin 1), KRT10 (keratin 10)  and IVN (involucrin) were performed using 
the GoTaq qPCR Master Mix (Promega, Wisconsin, USA) in a MasterCycler Ep-Realplex thermal 
cycler (Eppendorf, Hamburg, Germany), with the following settings: 2 min at 95  C for initial 
denaturing and 35 cycles of 15 s at 95 C denaturing, 40 s at 57 C annealing, and 45 s at 72 C 
extension. The expression levels of PCR products were normalized according to GAPDH gene. 
Primers sequences for CDH1, FLG, KRT1, KRT10, IVN and GAPDH are shown in Table MM6.  
 
qRT-PCR reactions for CDH4 were carried out in an ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems, Foster City, USA), using the Hs00899698_m1 TaqMan Gene 
Expression probe and the Hs9999905_m1 TaqMan Gene Expression probe for the GAPDH gene, 
used as reference. 2.4 ul of a 1/10 CDH4 cDNA dilution were used for each reaction, and 
combined with 6 ul of 2X TaqMan Universal PCR Master Mix (No AmpErase UNG), 0.6 ul of 20X 
TaqMan Gene Expression assay, and water to a final reaction volume of 12 ul. The amplification 
conditions consisted of an initial step at 95ºC for 10 min, followed by 55 cycles of 15 s at 95ºC 
and 1 min at 60ºC.  
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Immunoblot: protein lysates were prepared in RIPA buffer containing: 50 mM Tris-HCl pH 7.4, 
1% NP-40, 0.2% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA and 0.2% SDS. Proteins were 
detected by immunoblot following standard procedures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table MM6. Primers sequences 
Primer pair Forward Primer Reverse Primer 
CDH1 CGAGAGCTACACGTTCACGG GGGTGTCGAGGGAAAAATAGG 
FLG TTTCGTGTTTGTCTGCTTGC CTGGACACTCAGGTTCCCAT 
KRT1 GTACCTGGTTCTGCTGCTCC TGACCCTGAGATCCAAAAGG 
KRT10 TGAGCCGCATTCTGAACGAG GATGACTGCGATCCAGAGGA 
IVN ACTGAGGGCAGGGGAGAG TCTGCCTCAGCCTTACTGTG 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
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Table MM7. Summary of the main materials and methods of Study II 
Patients  
 
Extreme phenotype sampling: grade 0 (controls) v grade 3 (cases) patients 
 
Discovery cohort: 166 capecitabine-treated patients (78 grade 0 v 88 grade 3) 
 
Replication cohort: 85 capecitabine-treated patients (61 grade 0 v 24 grade 3) 
 
Genotyping 
 
Genome-wide association study (GWAS): analysis of 616,795 SNVs across the 
human genome on the Illumina Human610 array  
 
Statistical 
analysis 
 
Single-variant associations: Cox proportional hazards regression, modeling the 
cumulative dose of capecitabine (mg/m
2
) up to the development of grade 3 CiHFS 
for cases, or the total cumulative dose received in the case of controls.  
 
Functional 
studies 
 
 
 4C-seq experiments in normal human epidermal keratinocytes 
 R-cadherin and involucrin protein expression in human keratinocytes and in 
skin samples from cancer patients before capecitabine treatment 
 R-cadherin expression knock-down 
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3. Materials & Methods, Study III and Study IV: identification of genetic variants predictive of 
susceptibility to chronic anthracycline-induced cardiotoxicity (AIC) in pediatric oncology and 
breast cancer patients 
3.1. Patients 
3.1.1. Pediatric oncology patients 
93 anthracycline-treated pediatric cancer patients aged less than 30 years and treated at the 
La Paz University Hospital and the Niño Jesús University Hospital in Madrid and at the University 
Clinic of Navarra in Pamplona were reviewed between 2010 and 2014. All patients were treated 
with doxorubicin, daunorubicin or epirubicin as part of their chemotherapy protocol.  
3.1.2. Breast cancer patients 
Spanish breast cancer patients: 71 locally advanced adult breast cancer patients treated at 
the San Carlos University Hospital, (Madrid, Spain) were included. These patients were enrolled 
in a neoadjuvant phase II randomized clinical trial (www.clinicaltrials.gov, identifier code: 
NCT00123929). The eligibility patient criteria included the following (i) women aged between 18 
and 79 years; (ii) clinical stage IIB, IIIA or IIIB breast cancer and palpable breast tumors not 
amenable to breast-preserving surgery. Patients were randomly assigned to receive four cycles 
of either neoadjuvant doxorubicin (75 mg/m2) (39 patients) or neoadjuvant docetaxel (100 
mg/m2) (32 patients) every 3 weeks. After surgery, patient treatment assignment was crossed-
over to receive four cycles of the opposite drug. 
 
Belgium breast cancer patients: 142 early adult breast cancer patients treated at the Leuven 
Multidisciplinary Breast Cancer Center (University Hospitals Leuven, Belgium) were included. 
These patients were treated with 3–6 cycles of (neo) adjuvant 5-fluorouracil (500 mg/m2), 
epirubicin (100 mg/m2) and cyclophosphamide (500 mg/m2).  
 
All patients (pediatric and adult breast cancer patients) received anthracyclines as part of 
their chemotherapy protocol, had normal cardiac function before anthracycline chemotherapy 
and had echocardiographic evaluations (pre-chemotherapy and post-chemotherapy). Patients 
were excluded if they had a personal history of cardiac disease or were treated with 
concomitant (neo) adjuvant use of trastuzumab, because of its well-known association with 
cardiotoxicity. Written informed consent was obtained from adult patients and from the parents 
or legal guardians of children. The study was approved by the ethics committees of each 
participating hospital and university. 
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Patient medical records were reviewed retrospectively by oncologists and cardiologists. 
Demographic, clinical and therapeutic information extracted from medical records included 
demographics, disease characteristics, chemotherapy, diagnostic echocardiograms to document 
baseline and follow-up cardiac function and any cardiac compromise and its severity, and any 
symptoms or signs consistent with chronic AIC. 
3.1.3. AIC definition 
AIC was defined as early-onset (occurring within 1 year after anthracycline treatment 
completion) or late-onset (occurring >1 year after anthracycline therapy completion) chronic LV 
dysfunction in both, pediatric and adult breast cancer patients. To rule out acute AIC, only 
echocardiograms obtained 30 days or more after an anthracycline dose were considered. 
 
AIC definition in pediatric oncology patients: AIC in pediatric patients was defined as chronic 
LV dysfunction assessed by echocardiogram measurements and evidenced by shortening 
fraction (SF) ≤27% at any time after anthracycline treatment completion (asymptomatic AIC) or 
symptoms/signs of cardiac complications, including severe mitral valve insufficiency, pericardial 
effusion, left ventricular hypertrophy or pulmonary hypertension (symptomatic AIC). The criteria 
for determining a symptomatic event were established by pediatric cardiologists. Controls were 
patients who had no symptoms or signs of cardiac complications and had normal 
echocardiograms (SF≥35%) during and after anthracycline therapy. 
 
AIC definition in adult breast cancer patients: AIC in breast cancer patients was defined as 
early or late-onset (i) cardiac failure grade 3–5 using the NCI CTCAE v4.0 scoring system (grade 3: 
severe symptoms at rest or with minimal activity or exertion, intervention indicated; grade 4: 
life-threatening consequences, urgent intervention indicated; 5: death)86 (ii) asymptomatic 
decrease of left ventricular ejection fraction (LVEF) ≥10%. Control patients were defined as those 
having no symptoms or signs of cardiac complications and normal echocardiograms (with a 
LVEF>60% at both baseline and follow-up and with a decline in LVEF≤5%) during and after 
anthracycline therapy.  
3.2. Isolation and quantification of DNA  
Genomic DNA was isolated from peripheral blood lymphocytes and quantified using the same 
procedures above described (section 1.3). 
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3.3. Genotyping  
DNA samples from the Spanish pediatric and the adult breast cancer cohorts were genotyped 
on the Illumina HumanExome-12v1_A Beadchip (Illumina, San Diego, USA) array according to the 
manufacturers´ recommended protocols. The HumanExome arrays are based on the Illumina 
Infinium technology detailed for the genome-wide genotyping in Study II (section 2.3 and Figure 
MM2). As it was mentioned in the introduction, the HumanExome array includes 247,870 
variants focused on protein-altering variants, selected from >12,000 exome and genome 
sequences representing multiple ethnicities and complex traits. Additional array content 
includes variants associated with complex traits in previous GWAS, HLA tags, ancestry 
informative markers, markers for identity-by-descent estimation, and random synonymous 
SNVs47. 
 
DNA samples from the Belgium adult breast cancer patients were genotyped for selected 
variants [rs79338777 (ETFB), rs149172980 (WISP1), rs72731540 (WISP1) and rs143089011 
(WISP1)] using the MassARRAY genotyping system (Sequenom Inc., San Diego, USA) following 
the manufacturer's instructions (section 2.3 and Figure MM5).  
3.4. Quality control (QC) 
Genotype clustering and calling was carried out using GenTrain (v. 2.0) in GenomeStudio (v. 
2011.1) (Illumina, San Diego, USA) in combination with zCall (v. 2.2)163. Anthracycline-treated 
pediatric and Spanish breast cancer samples were excluded from further analyses if they had 
more than 5% missing genotype data or showed a level of heterozygosity greater than 4.9 
standard deviations from the mean. The remaining samples were subsequently assessed for 
population outliers and stratification using a PCA-based approach155. We carried out two PCAs, 
the first considering the Spanish pediatric cohort or the Spanish breast cancer cohort samples, to 
identify population outliers and the second including HapMap samples genotyped using the 
same array164 using the snpStats package in R (v.3.0.1) (Figure R21 and Figure R24). Variants 
were excluded if had a call rate<0.99 or deviated from Hardy-Weinberg equilibrium (P<10-8). 
3.5. Statistical analyses 
We performed statistical analyses using PLINK (v. 1.07)147, R (v.3.0.1) and SPSS (v.18.0; SPSS, 
Chicago, USA) software. 
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Covariates identification: associations between clinical factors and chronic AIC were assessed 
using Fisher´s exact test for categorical variables and Wilcoxon-Mann-Whitney U test for 
continuous variables. A P-value of <0.05 was considered to be statistically significant.  
 
Single-variant associations: single-marker associations with risk of chronic AIC were 
performed assuming an additive genetic model and using logistic regression analysis. Covariates 
for the pediatric oncology cohort included age at diagnosis, cumulative anthracycline dose and 
bleomycin concomitant therapy. Covarites for the Spanish breast cancer cohort included age at 
diagnosis. Covariates for the overall series combined considering the pediatric oncology, the 
Spanish breast and the Belgium breast cancer cohorts together included age at diagnosis, 
cumulative anthracycline dose and whether patients had breast or childhood cancers. P-values 
were adjusted for multiple testing using Benjamini-Hochberg’s false discovery rate (FDR-BH) 
procedure165. A P-value <0.05 was considered to be statistically significant after multiple testing 
correction. 
 
Gene-based associations: for gene-based testing, we used the optimized sequence kernel 
association test (SKAT-O)55,166 in GenABEL167 with default weights55 to assess the joint effects of 
common and low-frequency variants within each gene. Only genes with at least 3 genotyped 
variants were considered. Covariates for gene-based testing in the Spanish pediatric oncology 
cohort included age at diagnosis, cumulative anthracycline dose and bleomycin concomitant 
therapy. Covarites for gene-based testing in the Spanish breast cancer cohort included age at 
diagnosis. To adjust for multiple comparisons, the FDR-BH was applied165. A P-value of <0.05 was 
considered to be statistically significant after multiple testing correction. While the SKAT-O does 
not provide any parameter estimates, sensitivity analyses were applied to genes found to be 
associated, whereby we removed one variant at a time and repeated this SKAT-O test. 
 
Likelihood ratio tests were used to select the best fitting model for the association with 
chronic AIC and to identify independent association signals across multiple variants, comparing 
the model considering both each genetic variant and clinical factors with the model with only 
clinical factors. 
3.6. Gene enrichment analysis 
To gain an in-depth understanding of the biological interpretation of large gene lists that are 
enriched in exome array analyses, we used the functional annotation clustering analysis module 
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of the bioinformatic tool DAVID168. This type of grouping of functional annotations gives a more 
insightful view of the relationships between annotation categories and terms than the 
traditional linear list of enriched terms169. Each annotation term group is assigned an enrichment 
score (ES) to rank overall importance. ES≥1.3 indicates biological significance. DAVID also 
provides a P-value to assess the significance of gene-term enrichment, which is corrected by 
applying the FDR-BH procedure165. 
3.7. Pathway enrichment analysis 
We also carried out an exploratory SKAT-O analysis on a combined pathway set consisting of 
1912 gene sets taken from the Gene Ontology170,171, Kyoto Encyclopedia of Genes and Genomes 
(KEGG)172,173, and Reactome174,175 repositories.  
3.8. GPR35 Sanger sequencing 
Primers spanning the two exons of the GPR35 transcript ENST00000430267 were used to 
amplify germline DNA from the 93 anthracycline-treated pediatric cancer patients. A 244 bp 
fragment containing the exon 1 of the GPR35 transcript ENST00000430267 was amplified 
starting from 100 ng of genomic DNA using the following primers 5’-
ACAAATACATTCTGGAGATGACC-3’ and 5’-TGACCCAATAACCCCACTTC-3’ (amplification 
product=244 bp). Exon 2 was amplified using 3 pairs of primers: i) first pair: 5’-
CAGAGGTGGGCAGAGTGG-3’ and 5’-CAGCCTGCCTGGGGGAC-3’ (amplification product=531 bp); 
ii) second pair: 5’-ACTCCCTGCGAGACACCTC-3’ and 5’-TTCAGGGAGCAGAAGACCAC-3’ 
(amplification product=346 bp); iii) third pair: 5’-ATTCTACCTGCCCCTGGCC-3’ and 5’-
TGCTACTGGTTCCAGCTTCC-3’ (amplification product=476 bp); starting from 100 ng of genomic 
DNA. The purified products were subsequently sequenced using the automatic sequencer ABI 
3730xl (Applied Biosystems).  
3.9. In silico prediction  
We used the SIFT algorithm176 and the programs PolyPhen-2177, MutPred178, SNPs&GO179 and 
PON-P2180 to predict the impact of selected variants on protein structure or function. SIFT is a 
sequence homology-based tool to predict tolerated and deleterious substitutions for every 
position of a given query sequence. PolyPhen-2 classifies variants as “benign,” “possibly 
damaging” or “probably damaging” based on a sequence-based characterization of the 
substitution site, profile analysis of homologous sequences, as well as their location in the three-
dimensional structure of the protein molecule. MutPred not only uses multiple alignment 
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information based upon SIFT but also includes information on the gain or loss of 14 different 
structural and functional properties to assign a pathogenicity score; we considered scores 
greater than 0.5 to define pathogenicity. SNPs&GO predicts whether a variant is disease-related 
or neutral by exploiting protein sequence, evolutionary information, and function. PON-P2 
utilizes information about evolutionary conservation of sequences, physical and biochemical 
properties of amino acids, GO annotations and if available, functional annotations of variation 
sites, to classify amino acid substitutions in human proteins. In addition, we used PredictSNP181 
to obtain a consensus prediction of pathogenicity based on MAPP, PhD-SNP, PolyPhen-1, 
Polyphen-2, SIFT, SNAP nsSNPAnalyzer, and PANTHER. We also used the F-SNP database182 
which extracts information from large number of resources, such as PolyPhen, SIFT, SNPeffect, 
SNPs3D, LS-SNP, Ensembl, ESEfinder, RescueESE, ESRSearch, PESX, TFSearch, Consite, 
GoldenPath, KinasePhos, OGPET, and Sulfinator, to predict functional effects at the splicing, 
transcriptional, translational, and post-translational level.  
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Table MM8. Summary of the main materials and methods of Study III 
Patients  
 
93 Spanish anthracycline-treated pediatric cancer patients (58 controls v 35 cases) 
 
Patient 
definition 
 
Symptomatic case: anthracycline-treated patients with symptoms/signs of cardiac 
complications, including severe mitral valve insufficiency, pericardial effusion, left 
ventricular hypertrophy or pulmonary hypertension 
 
Asymptomatic case: anthracycline-treated patients with LV dysfunction evidenced 
by shortening fraction (SF)≤27% at any time after anthracycline treatment 
completion 
 
Control: anthracycline-treated patients with no symptoms or signs of cardiac 
complications and with normal echocardiograms (SF≥35%) during and after 
anthracycline therapy 
 
Genotyping 
 
Exome array: analysis of 247,870 coding variants on the Illumina Human Exome 
Beadchip, which is enriched for low-frequency and rare coding variants (>80% 
variants with MAF ≤1%) 
 
Statistical 
analysis 
 
Single-variant associations: logistic regression analysis considering and additive 
genetic model. Significance level: P-value of <0.05 after multiple testing correction. 
 
Gene-based associations: analysis of the joint effect of variants within each gene (≥3 
variants) using SKAT-O. Significance level: P-value of <0.05 after multiple testing 
correction. 
 
Sensitivity analyses: the individual contribution of variants within GPR35 was 
assessed by removing one variant at a time and recalculating the association for 
GPR35 using SKAT-O. 
 
Functional 
annotations 
 
In silico prediction: SIFT, PolyPhen-2, MutPred, SNPs&GO, PON-P2, PredictSNP and F-
SNP. 
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Table MM9. Summary of the main materials and methods of Study IV 
Patients  
 
Spanish breast cancer cohort: 71 anthracycline-treated advanced breast cancer 
patients (53 controls v 18 cases) 
 
Belgium breast cancer cohort: 142 anthracycline-treated early breast cancer 
patients (86 controls v 56 cases) 
 
Spanish pediatric cancer patients: 93 anthracycline-treated pediatric oncology 
patients (58 controls v 35 cases) 
 
Patient 
definition 
 
Breast cancer patients 
 
Symptomatic case: anthracycline-treated patients with symptomatic cardiac 
failure grade 3–5 (CTCAE v.4.0) 
 
Asymptomatic case: anthracycline-treated patients with LV dysfunction 
evidenced by an asymptomatic decrease of left ventricular ejection fraction 
(LVEF) ≥10%. 
 
Control: anthracycline-treated patients with no symptoms or signs of cardiac 
complications and with normal echocardiograms (LVEF>60% at both baseline and 
follow-up and with a decline in LVEF≤5%) during and after anthracycline therapy. 
 
Spanish pediatric cancer patients see Table MM8 
 
Genotyping 
 
Exome array: analysis of 247,870 coding variants on the Illumina Human Exome 
Beadchip, which is enriched for low-frequency and rare coding variants (>80% 
variants with MAF ≤1%) 
 
Statistical 
analysis 
 
Single-variant associations: logistic regression analysis considering and additive 
genetic model. Significance level: P-value of <0.05 after multiple testing 
correction. 
 
Gene-based associations: analysis of the joint effect of variants within each gene 
(≥3 variants) using SKAT-O. Significance level: P-value of <0.05 after multiple 
testing correction. 
 
Sensitivity analyses: the individual contribution of variants within ETFB and 
WISP1 genes was assessed by removing one variant at a time and recalculating 
the association for the gene using SKAT-O. 
 
Functional 
annotations 
 
In silico prediction: SIFT, PolyPhen-2, MutPred, SNPs&GO, PON-P2, PredictSNP 
and F-SNP. 
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1. Results, Study I: identification of predictive and prognostic genetic variants for Ewing 
sarcoma  
The demographic and clinical characteristics of both cohorts are shown in Table R1. 
 
Table R1. Clinical characteristics of Ewing sarcoma patients 
 Discovery (N=106) Replication (N=389) 
Characteristic N %* N %* 
Age at diagnosis (years)   
Median 12.2 14.5 
Range 0.4-27.8 0.1-27.8 
Sex     
Female 42 39.6 156 40.1 
Male 64 60.4 233 59.9 
Primary site     
Upper extremities 9 8.7 39 10.2 
Lower extremities 48 46.2 129 33.9 
Axial 41 39.4 203 53.3 
Soft tissue 6 5.8 10 2.6 
Missing 2  8  
Metastasis at diagnosis     
No 62 59.6 255 67.3 
Yes 42 40.4 124 32.7 
Missing 2  10  
Response to treatment      
Good 55  70.5 148 64.3 
Poor 23  29.5 82 35.7 
Missing 28   159  
Relapse      
No 67 67.0 211 58.1 
Yes 33 33.0 152 41.9 
Missing 6  26  
Vital status     
Alive 67 67.0 229 61.7 
Dead 33 33.0 142 38.3 
Missing 6  18  
Follow-up (years)   
Median 93.7 70.3 
Range 7.8-300 12.3-312 
*Percentages are computed based on the total number of non-missing values 
 
The median age at diagnosis was 12.2 years in the discovery cohort and 14.5 years in the 
replication series. Consistent with previous reports61, Ewing sarcoma was slightly more common 
in men than in women. Axial and lower extremity primary sites were the most common 
locations of primary tumors, while Ewing sarcoma affecting soft tissue was only found in 16 
patients. At the time of diagnosis, 42 (40.4%) of the 104 evaluable Spanish patients and 124 
(32.7%) of the 379 evaluable European patients already presented metastases, while 33 (33%) 
and 152 (41.9%) patients, respectively, developed metastasis or local recurrences during follow-
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up. More than 60% of patients in both cohorts were good responders and were still alive at last 
follow-up, with a median follow-up after diagnosis of 93.7 months for the Spanish patients and 
70.3 months in the replication cohort. 
 
After filtering, 334 SNVs of the 384 genotyped variants were successfully analyzed (Figure 
R1). There was no evidence of departure from Hardy–Weinberg equilibrium for any of them. 
Data for two patients in the Spanish cohort and 55 patients in the replication cohort were 
excluded due to a low genotyping call rate (<0.90), leaving 104 and 334 patients, respectively. 
 
 
N=97 
 
334 SNVs 
N=305 
 
P<0.05 
 
    None  
Covariates: 
Age at diagnosis 
Metastasis at diagnosis 
Recurrence 
Country of origin 
Discovery 
set 
 
Replication 
set 
 
N=197 
 
Covariates: 
Age at diagnosis 
Metastasis at diagnosis 
P<0.05 
 rs7190447 
(P=2.44x10
-3
) 
43 SNVs 20 SNVs 
Covariates: 
Age at diagnosis 
Metastasis at diagnosis 
Recurrence 
 
P<0.05 
 
rs4148737 
(P=0.03) 
rs11188147 
(P=0.03) 
P<0.05 
 
Figure R1. Flow chart of Study I. 
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1.1. Associations with tumor response to treatment 
Associations with tumor response were assessed in 77 patients from the Spanish discovery 
cohort for which this information was available. After adjusting for age and the presence of 
metastasis at diagnosis, an association with P<0.05 was observed for 20 SNVs. However, none of 
these associations were replicated in the European cohort (N=197, P≥0.05) (Figure R1).  
 
Also including neoadjuvant therapy as an additional covariate in multivariable models made 
no substantial difference to the results obtained. 
1.2. Associations with overall survival 
Since adjustment for tumor response made no substantial difference to the estimated HR 
(based on an analysis of the cases for which this information was available), we present results 
without adjustment for this covariate, based on a larger sample size.  
 
We identified 43 SNVs associated with overall survival at P<0.05 in the Spanish cohort after 
adjusting for age at diagnosis, presence of metastasis at diagnosis, and recurrence (N=97) (Table 
R2). Associations with three of these were replicated in the European cohort (N=305) (Table R2, 
Table R3). The strongest evidence of association was found for the SNV rs7190447, an intronic 
polymorphism in ABCC6 (ATP-binding cassette sub-family C member 6). In both cohorts, a 
recessive model was the best fit; C-allele homozygotes had a higher risk of death [discovery 
phase: HR=14.30, 95%CI=1.53-134, P=0.020; replication phase: HR=9.28, 95%CI=2.20-39.2, P 
=0.0024, Figure R2A]. The 5-year survival for patients carrying 1 or 2 copies of the G allele was 
74% in the discovery cohort and 65% in the replication series, while no individual carrying the CC 
genotype lived for 5 years following diagnosis (Table R3).  
 
The G allele of rs4148737, an intronic variant in ABCB1 (ATP-binding cassette sub-family B 
member 1), was associated with poorer overall survival under a recessive model [discovery 
phase: HR=2.96, 95%CI=1.08-8.10, P=0.034; replication phase: HR=1.60, 95%CI=1.05-2.44, 
P=0.029, Table R2, Table R3, Figure R2B]. The estimated 5-year survival for cases with AA/AG 
and GG genotypes was 75% and 66%, respectively, in the discovery cohort, and 66% and 55%, 
respectively, in the European cohort (Table R3).  
 
Finally, the minor T allele for a SNV located 2.7kb downstream of the CYP2C8 (cytochrome 
P450 family 2 subfamily C member 8) gene, rs11188147, was associated with an increased risk of 
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death under a recessive model [discovery phase: HR=2.49, 95%CI=1.06-5.87, P=0.037; replication 
phase: HR=1.77, 95%CI=1.06-2.96, P=0.030, Table R2, Table R3, Figure R2C]. The 5-year survival 
for CC/CT and TT carriers was 76% and 67%, respectively, in the discovery cohort, and 65% and 
58%, respectively in the replication series (Table R3).  
 
In order to evaluate the possible functional significance of the replicated and strongly 
correlated variants we applied the HaploReg web tool and considered ENCODE data. Functional 
annotations of SNVs rs7190447, rs4148737 and rs11188147 and correlated variants (r2≥0.8) are 
shown in Table R4 and Figure R3, Figure R4 and Figure R5.  
 
SNV rs7190447 (ABCC6) was found to be in perfect LD with rs7192303, an intronic 
polymorphism located 122 bp upstream. The genomic region containing rs7192303 is enriched 
with specific histone marks associated with transcribed regions in a hepatocellular carcinoma 
cell line, with weak enhancers in a skeletal muscle myoblast cell line, and with a DNase 
hypersensitive cluster in 123 different cell types (Table R4 and Figure R3). The strongest and 
most robust chromatin immunoprecipitation (ChIP)-seq signal is observed for CCCTC-binding 
factor (CTCF) binding in a large number of ENCODE cell lines (69) (Table R4 and Figure R3). 
Remarkably, strong signals for cohesin subunits Rad21 and SMC3, were also observed. The 
genomic region containing rs7192303 also has the potential to form chromatin loops, through 
CTCF binding, with intronic regions of ABCC6 and ABCC1, both located upstream, in a breast 
cancer cell line (MCF-7) (Figure R4). We explored expression quantitative trait loci (eQTLs) using 
Genotype-Tissue Expression (GTEx) data, and interestingly, we found statistically significant 
differences in ABCC6 gene expression by rs7192303 genotype in the liver (P=0.019, effect 
size=0.23). These findings suggest rs7192303 as the most plausible causal variant for the 
observed association with overall survival. 
 
The intronic variant rs4148737 (ABCB1) resides in a weakly transcribed region in a 
hepatocellular carcinoma cell line, but also overlaps with a weak enhancer in GM12878 and in a 
RUNX3 ChIP-seq cluster in the same lymphoblastoid cell line. It was predicted to overlap with a 
DNAse hypersensitive region in a lymphoblastoid cell line and in cerebellar and hippocampal 
astrocytic cell lines, and to alter EBF, ERalpha-a, Hic1 regulatory motifs (Table R4 and Figure R5). 
None of the nine intronic SNVs in high LD (r2≥0.84) with this variant had stronger functional 
evidence reported (Table R4). According to GTEx data, rs4148737 influences ABCB1 expression 
in testis (P=0.000016, effect size= -0.44). 
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No strong functional evidence was observed for SNV rs11188147 (CYP2C8) or for any of the 
18 variants that are in high LD with it (r2≥0.83) (Table R4). No significant differences in CYP2C8 
expression were found for any tissues available in GTEx. 
 
 
 
 
 
 
Main results Study I 
We identified associations with overall survival (P<0.05) for three SNVs in the Spanish 
cohort that were replicated in the European cohort. The strongest association 
observed was with rs7190447, located in the ATP-binding cassette subfamily C 
member 6 (ABCC6) gene [discovery: hazard ratio (HR)=14.30, 95% confidence interval 
(CI)=1.53–134, P=0.020; replication: HR=9.28, 95%CI=2.20–39.2, P=0.0024] and its 
correlated variant rs7192303, which was predicted to have a plausible regulatory 
function. We also replicated associations with rs4148737 in the ATP-binding cassette 
subfamily B member 1 (ABCB1) gene (discovery: HR=2.96, 95% CI=1.08–8.10, P=0.034; 
replication: HR=1.60, 95%CI=1.05–2.44, P=0.029), and rs11188147 in cytochrome P450 
family 2 subfamily C member 8 gene (CYP2C8) (discovery: HR=2.49, 95% CI=1.06–5.87, 
P=0.037; replication: HR=1.77, 95% CI=1.06–2.96, P=0.030). None of the associations 
with tumor response were replicated. 
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 Table R2. Analysis of associations between variants and overall survival 
      Discovery (N=97) Replication (N=305) 
Gene Chr. Variant Position * Location Model P Minor allele HR 95%CI P Minor allele HR 95%CI 
ABCC1 16 rs212081 16225971 Intronic Recessive 2.59x10
-4
 T 6.62 2.40-18.3 0.46 T 1.19 0.75-1.90 
SLCO6A1 5 rs981988 101819981 Intronic Recessive 1.52x10
-3
 G 54.2 4.59-639 0.11 G 0.20 0.03-1.41 
GSTP1 11 rs7927381 67346743 4.3 kb upstream Recessive 1.52x10
-3
 T 54.2 4.59-639 0.28 T 3.06 0.39-23.8 
ABCB1 7 rs7787082 87157051 Intronic Additive 1.91x10
-3
 A 0.29 0.13-0.64 0.90 A 1.00 0.71-1.42 
ABCC3 17 rs12451302 48751164 Intronic Recessive 2.62x10
-3
 G 5.16 1.77-15.0 0.29 G 0.80 0.52-1.22 
CYP2C9 10 rs4918758 96697252 2 kb upstream Recessive 2.98x10
-3
 C 5.11 1.74-15.0 0.09 C 1.55 0.93-2.59 
ABCC3 17 rs3785912 48756937 Intronic Recessive 4.06x10
-3
 A 5.99 1.77-20.3 0.25 A 0.70 0.38-1.29 
ABCC1 16 rs3888565 16183045 Intronic Additive 4.69x10
-3
 A 0.28 0.12-0.68 0.25 A 0.83 0.59-1.15 
CYP3A5 7 rs28365067 99272310 Intronic Additive 5.84x10
-3
 T 4.42 1.54-12.7 0.89  T 1.04 0.62-1.74 
ABCC1 16 rs35621 16168608 Intronic Additive 7.27x10
-3
 T 0.21 0.07-0.66 0.97 T 0.99 0.68-1.46 
ABCB1 7 rs2214102 87229501 5´ UTR Recessive 8.15x10
-3
 A 28.4 2.38-339 - - - 
ABCC1 16 rs16967755 16199255 Intronic Additive 0.01 G 0.31 0.13-0.76 0.64 G 1.07 0.80-1.45 
ABCC6 16 rs16967488 16252696 Intronic Dominant 0.01 C 2.80 1.24-6.35 0.73 C 1.07 0.74-1.53 
ALDH1A1 9 rs348481 75514436 1.1 kb downstream Recessive 0.01 C 8.03 1.53-42.0 0.99 C 0.99 0.31-3.15 
ABCC2 10 rs717620 101542578 5´ UTR Recessive 0.02 A 15.8 1.72-146 0.91 A 0.93 0.23-3.77 
ABCC1 16 rs35626 16170615 Intronic Additive 0.02 T 0.41 0.20-0.85 0.90 T 0.98 0.74-1.30 
CYP2C9 10 rs11597626 96604273 Intronic Dominant 0.02 G 0.37 0.17-0.84 0.89 G 1.03 0.71-1.48 
CYP2C9 10 rs12251688 96693727 4.6 kb upstream Dominant 0.02 T 0.38 0.17-0.84 0.83 T 1.04 0.72-1.49 
CYP3A4 7 rs4646437 99365083 Intronic Dominant 0.02 T 3.06 1.20-7.79 0.43 T 1.19 0.77-1.83 
ABCC6 16 rs7190447 16289126 Intronic Recessive 0.02 C 14.30 1.53-134 2.44x10
-3
 C 9.28 2.20-39.2 
Continue on next page 
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 Table R2. Analysis of associations between variants and overall survival (continued) 
      Discovery (N=97) Replication (N=305) 
Gene Chr. Variant Position * Location Model P Minor allele HR 95%CI P Minor allele HR 95%CI 
ABCC1 16 rs12922404 16060994 Intronic Dominant 0.02 T 2.61 1.16-5.89 0.17 T 1.29 0.89-1.88 
ABCB1 7 rs2235048 87138511 Intronic Recessive 0.02 C 2.88 1.16-7.12 0.46 C 0.85 0.55-1.31 
ABCB1 7 rs17064 87133470 3´ UTR Additive 0.02 T 4.08 1.22-13.7 0.96 T 0.99 0.60-1.61 
ABCC6 16 rs2238469 16283071 Intronic Recessive 0.03 A 4.36 1.17-16.3 0.15 A 0.23 0.03-1.73 
ABCC3 17 rs8079432 48749883 Intronic Additive 0.03 G 2.77 1.11-6.91 0.68 G 0.91 0.57-1.45 
ABCC4 13 rs9590220 95906694 Intronic Additive 0.03 T 0.38 0.16-0.91 0.13 T 1.28 0.93-1.75 
ABCB1 7 rs10264990 87202615 Intronic Recessive 0.03 C 3.21 1.11-9.26 0.10 C 1.54 0.92-2.59 
GSTP1 11 rs614080 67347287 3.8 kb upstream Recessive 0.03 G 2.56 1.09-6.04 0.52 G 0.85 0.52-1.39 
ABCC1 16 rs212087 16230290 Intronic Recessive 0.03 T 0.34 0.13-0.91 0.10 T 1.46 0.93-2.30 
ABCB1 7 rs4148737 87171152 Intronic Recessive 0.03 G 2.96 1.08-8.10 0.03 G 1.60 1.05-2.44 
ABCG2 4 rs2725264 89026109 Intronic Additive 0.04 G 2.60 1.06-6.36 0.41 G 0.83 0.53-1.29 
CYP1B1 2 rs4646429 38306935 3.6 kb upstream Additive 0.04 A 0.44 0.20-0.95 0.95 A 0.99 0.73-1.34 
CYP2C8 10 rs11188147 96793820 2.7 kb downstream Recessive 0.04 T 2.49 1.06-5.87 0.03 T 1.77 1.06-2.96 
MPO 17 rs7208693 56357818 Missense Additive 0.04 A 2.17 1.04-4.51 0.76 A 0.93 0.54-1.47 
ABCC1 16 rs4148354 16174506 Intronic Dominant 0.04 G 0.42 0.19-0.96 0.87 G 1.07  0.69-1.57 
CYP2C8 10 rs1934956 96828160 Intronic Recessive 0.04 T 4.95 1.06-23.2 0.47 T 1.44 0.53-3.96 
CYP2A6 19 rs8192729 41350996 Intronic Additive 0.05 A 2.99 1.02-8.75 0.92 A 1.03 0.62-1.69 
ABCC1 16 rs2299670 16220858 Intronic Additive 0.05 G 0.51 0.26-0.99 0.69 G 1.06 0.79-1.43 
SOD1 21 rs2070424 33039320 Intronic Additive 0.05 G 3.22 1.02-10.2 0.06 G 1.54 0.98-2.41 
LPO 17 rs8178407 56344656 Intronic Dominant 0.05 G 2.61 1.01-6.77 0.77 G 0.95 0.66-1.37 
ABCC1 16 rs11075295 16177687 Intronic Recessive 0.05 G 9.14 1.02-82.1 0.96 G 0.98 0.36-2.65 
ABCB1 7 rs13237132 87191669 Intronic Additive 0.05 G 1.80 1.00-3.22 0.20 G 1.19 0.91-1.54 
ABCC4 13 rs9590211 95892414 Intronic Dominant 0.05 A 2.14 1.00-4.57 0.71 A 0.93 0.63-1.37 
HRs are per copy of the specified minor allele. Variants shown in bold were those associated with overall survival in both cohorts at P<0.05. * Chromosome positions are based on Genome Reference 
Consortium Human Build 37 (GRCh37/hg19). Abbreviations: Chr, chromosome; kb, kilobases; HR, hazard ratio; CI, confidence interval. 
Continued 
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Table R3. Associations between variants and overall survival in Ewing sarcoma patients 
       Discovery (N=97) Replication (N=305) 
Gene Chr. Variant Position * Location Model MAF Genotype N 5-year 
OS 
P HR 95%CI N 5-year 
OS 
P HR 95%CI 
ABCC6 16 rs7190447 16289126 Intronic Recessive 0.07 
GG/GC 96 74% 
0.020 14.3 1.53-134 
303 65% 
0.0024 9.28 2.20-39.2 
CC 1 - 2 - 
per allele C     
ABCB1 7 rs4148737 87171152 Intronic Recessive 0.43 
AA/AG 80 75% 
0.034 2.96 1.08-8.10 
251 66% 
0.029 1.60 1.05-2.44 
GG 17 66% 54 55% 
per allele G     
CYP2C8 10 rs11188147 96793820 
2.7 kb 
downstream 
Recessive 0.39 
CC/CT 72 76% 
0.037 2.49 1.06-5.87 
263 65% 
0.030 1.77 1.06-2.96 
TT 25 67% 42 58% 
per allele T     
HRs are per copy of the specified minor allele. * Chromosome positions are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19). Abbreviations: Chr., chromosome; kb, kilobases; 5-year 
OS, 5-year overall survival; HR, hazard ratio; CI, confidence interval 
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A)                                                                             B)                                                                                C) 
Figure R2. Kaplan-Meier survival curves for Ewing sarcoma patients (discovery and replication cohorts combined) according to genotype for (A) rs7190447 in ABCC6 (NGG/GC=399, NCC=3, χ
2 = 14.84, 
Plog-rank=1.17×10
−4
); (B) rs4148737 in ABCB1 (NAA/AG=326, NGG=76, χ
2
=3.73, Plog-rank=0.053); and (C) rs11188147 in CYP2C8 (NCC/CT=333, NTT=69, χ
2 = 0.15, Plog-rank = 0.69).  
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Table R4. Analysis of functional annotations of rs7190447, rs4148737 and rs11188147 and correlated variants (r
2
≥0.8) 
Variant Correlated variant LD (r
2
) 
Enhancer 
histone marks 
DNase Proteins bound Motifs changed 
rs7190447 - - - HA-sp CTCF GATA, Pou3f2 
rs7206048 rs7190447 0.96 K562 GM12892 MAFK Egr-1,GATA 
rs6498619 rs7190447 1 K562 - - Pax-5 
rs8044613 rs7190447 1 - - - Evi-1,Pou2f2 
rs11862259 rs7190447 1 - - - Mef2, NF-AT1 
rs7184822 rs7190447 0.98 - - - 22 altered motifs 
rs7186376 rs7190447 1 - - - 
ERalpha-a, HNF4, 
TLX1::NFIC 
rs7187235 rs7190447 1 - - - AP-1 
rs7186601 rs7190447 1 - - - 
BDP1_disc2, GCNF, 
Nr2f2, p300_known1 
rs7192303 rs7190447 1 HSMM 
PanIsletD, AG09309, 
AG10803, HA-h, HA-sp, 
HGF, HIPEpiC, 
HNPCEpiC, HPdLF, 
HVMF 
CTCF, SMC3, ZNF143, 
RAD21, 
FOXA1,FOXA2, 
GATA3 
INSM1 
rs7199104 rs7190447 1 - - - Foxa,Foxj2, Osf2 
rs4148737 - - GM12878 GM12865,HA-h,HAc - EBF, ERalpha-a, Hic1 
rs35572298 rs4148737 0.84 - - - 8 altered motifs 
rs35280822 rs4148737 0.89 - - - Homez,Lhx3 
rs12154941 rs4148737 0.91 - - - AP-1,Zfx 
rs4148736 rs4148737 1 - - - GR,Nanog 
rs6961419 rs4148737 1 - 
HConF,HFF-Myc,NHDF-
neo 
- - 
rs6961882 rs4148737 1 - - - 6 altered motifs 
rs4148735 rs4148737 1 GM12878 Melano - GR, p300 
rs1922242 rs4148737 1 - - - 5 altered motifs 
Continue on next page 
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Table R4. Analysis of functional annotations of rs7190447, rs4148737 and rs11188147 and correlated variants (r
2
≥0.8) (continued) 
Variant Correlated variant LD (r
2
) 
Enhancer 
histone marks 
DNase Proteins bound Motifs changed 
rs2091766 rs4148737 0.88 - - - 8 altered motifs 
rs11188147 - - - - - - 
rs1578436 rs11188147 1 - - - 9 altered motifs 
rs7073968 rs11188147 1 - - - HNF4, NF-I 
rs10882517 rs11188147 1 - - - Foxa, GZF1, Pou1f1 
rs11188149 rs11188147 0.99 - - - Pax-4 
rs947173 rs11188147 0.99 - - - BCL, BDP1, NRSF 
rs1891070 rs11188147 0.99 - - - Foxp1, Hdx 
rs11572133 rs11188147 0.99 - - - NRSF, Sin3Ak-20 
rs12773510 rs11188147 0.99 - - - 11 altered motifs 
rs199539470 rs11188147 0.95 - - - 10 altered motifs 
rs58385086 rs11188147 0.99 - - - 11 altered motifs 
rs11188156 rs11188147 0.98 - - - DMRT3,Gfi1b 
rs10882521 rs11188147 0.93 - - - 4 altered motifs 
rs9702453 rs11188147 0.83 - - - HNF4, Pdx1 
rs145809484 rs11188147 0.90 - - - GCM, Gcm1 
rs143042734 rs11188147 0.88 - - - 5 altered motifs 
rs13313110 rs11188147 0.98 - - - Gfi1,Hsf,TATA 
rs3752988 rs11188147 0.99 - - - Ik-2,Mef2 
rs10882525 rs11188147 0.99 - - - 4 altered motifs 
The replicated variants associated with overall survival (in bold) and SNVs in strong (r
2
>0.8) linkage disequilibrium (LD) with the replicated variants were analyzed using HaploReg to explore if 
they affected chromatin states or altered regulatory motifs or binding sites. AG09309, adult toe fibroblast cells; AG10803, abdominal skin fibroblast cells; GM12865, lymphoblastoid cells; 
GM12878, lymphoblastoid cells; GM12892, lymphoblastoid cells; HAc, human cerebellar astrocytic cells; HA-h, human hippocampal astrocytic cells; HA-sp, human spinal cord astrocytic cells; 
HConF, conjunctival fibroblast cells; HFF-Myc, foreskin fibroblast cells expressing canine cMyc; HGF, gingival fibroblasts cells; HIPEpiC, iris pigment epithelial cells; HNPCEpiC, non-pigment 
ciliary epithelial cells; HPdLF, periodontal ligament fibroblasts cells; HSMM, skeletal muscle myoblast cells; HVMF, villous mesenchymal fibroblast cells; K562, erythrocytic leukemia cells; 
Melano, human epidermal melanocyte cells; NHDF-neo,neonatal dermal fibroblast cells; PanIsletD, dedifferentiated human pancreatic islets 
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 Figure R3. ENCODE functional evidence displayed in the UCSC Genome Browser for rs7190447 and nearby SNVs. (A) Genomic location of the ABCC6 gene. Multiple DNase-seq and transcription factor ChIP-seq clusters can be 
observed. (B) Genomic location of rs7190447 (highlighted). A DNase hypersensitivity region was observed in 123 
ENCODE cells around rs7190447 and overlapping with rs7192303 (highlighted), an intronic polymorphism located 122 
bp upstream from rs7190447 and in perfect LD. Multiple transcription factors binding clusters can be observed in a 
large number of cells (identified by single-letter abbreviations). Gray boxes indicate the extent of the hypersensitive 
region for DNaseI hypersensitivity clusters or transcription factor occupancy, with the darkness of the box 
proportional to the maximum signal strength observed in any cells contributing to the cluster. The number to the left 
of a DNaseI hypersensitivity box shows how many cells are hypersensitive in the region. Within a ChIP-seq cluster, 
green highlighting indicates the highest scoring site of a Factorbook-identified canonical motif for the corresponding 
factor. Chromatin states characterized by combinations of histone marks are also shown in different human cell lines. 
Each chromatin state is associated with a different segment color. Blue, insulator; light green, weak transcribed; dark 
green, transcriptional transition; yellow, weak enhancer. The genomic region containing rs7190447 and rs7192303 is 
also enriched for CTCF-mediated chromatin interactions in MCF-7 breast cancer cells. MCF-7 CTCF ChIA-PET 
interactions are shown as a density graph of signal enrichment based on aligned read density. Due to space 
limitations, only a subset of cells where a CTCF-ChIP-seq peak is detected and CTCF ChIA-PET interactions are shown. 
GM12878, lymphoblastoid cells; K1-hESC, embryonic stem cells; K562, erythrocytic leukemia cells; HepG2, 
hepatocellular carcinoma cells; HUVEC, umbilical vein endothelial cells; HMEC, mammary epithelial cells; HSMM, 
skeletal muscle muscle myoblast cells; NHEK, normal epidermal keratinocytes cells. Abbreviations: SNP, single 
nucleotide polymorphism; Txn, transcription. 
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Figure R4. CTCF-mediated chromatin interactions for rs7190447 and rs7192303 (ABCC6) determined by chromatin interaction paired-end tag (ChiAPET) data from ENCODE. UCSC Genome 
Browser image of the genomic region containing rs7190447 (our replicated variant) and rs7192303 (the variant in perfect LD with it) showing ChIA-PET interactions and enrichment for CTCF 
in MCF-7 breast cancer cells. CTCF-mediated chromatin interactions are represented by two blocks, one at each end, connected by a horizontal line. The density graph shows the CTCF signal 
enrichment based on aligned read density. Not all MCF-7-CTCF ChIA-PET interactions are shown in full for the genomic region and the chromatin interactions have been adapted (red lines 
connecting blocks) to highlight relevant interactions only. 
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Figure R5. ENCODE functional evidence displayed in the UCSC Genome Browser for rs4148737 and nearby 
variants. (A) Genomic location of the ABCB1 gene. Multiple DNase-seq and transcription factor ChIP-seq 
clusters can be observed. (B) Genomic location of rs4148737 (highlighted). Two DNase hypersensitivity 
regions are observed in five ENCODE cell lines around rs4148737, one of them overlapping. rs4148737 resides 
in a RUNX3 ChIP-seq cluster in lymphoblastoid cells (identified by G letter). Gray boxes indicate the extent of 
the hypersensitive region for DNaseI hypersensitivity clusters or transcription factor occupancy, with the 
darkness of the box proportional to the maximum signal strength observed in any cells contributing to the 
cluster. The number to the left of a DNaseI box shows how many cells are hypersensitive in the region. Within 
a ChIP-seq cluster, green highlighting indicates the highest scoring site of a Factorbook-identified canonical 
motif for the corresponding factor. Chromatin states characterized by combinations of histone marks are also 
shown in different human cell lines. Each chromatin state is associated with a different segment color. Yellow, 
weak enhancer; light green, weak transcribed.  GM12878, lymphoblastoid cells; K1-hESC, embryonic stem 
cells; K562, erythrocytic leukemia cells; HepG2, hepatocellular carcinoma cells; HUVEC, umbilical vein 
endothelial cells; HMEC, mammary epithelial cells; HSMM, skeletal muscle muscle myoblast cells; NHEK, 
normal epidermal keratinocytes cells. Abbreviations: SNP, single nucleotide polymorphism; Txn, transcription. 
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2. Results, Study II: identification of genetic variants predictive of susceptibility to 
capecitabine-induced hand-foot syndrome (CiHFS) 
The demographic and clinical characteristics of the discovery (N=166) and replication (N=85) 
cohorts are shown in Table R5.  
 
Both cohorts included adult breast and colorectal cancer patients treated with capecitabine 
but the discovery cohort enrolled more breast cancer patients (72% v 32%). Gender showed 
more female patients in the discovery cohort (86%), but more males in the replication cohort 
(59%). In total, 45% of patients developed grade 3 CiHFS with a median capecitabine cumulative 
dose at the development of severe toxicity of 134,400 mg/m2. Over 85% of patients in both 
cohorts received a standard capecitabine treatment. 
Three patients in the discovery cohort failed genotyping (call rate<0.95) and 3 patients were 
excluded as ethnic outliers based on inspection of plots of the two first principal components, 
leaving 160 patients (85 cases and 75 controls) for further analysis (Figure R6). 
Q-Q plot showed no obvious population stratification (Figure R7).
Table R5. Clinical characteristics of the capecitabine-treated cancer patients 
 Discovery (N=166) Replication (N=85) 
Characteristic N %* N %* 
Age at diagnosis (years)     
Median 63 64 
Range 29-88 36-87 
Sex     
Female 142 86 50 41 
Male 23 14 35 59 
Missing 1    
Primary diagnosis (tumor type)     
Breast cancer 119 72 27 32 
Colorectal cancer 46 28 58 68 
Capecitabine treatment regimen     
Standard 146 88 72 85 
Continuous 20 12 13 15 
CiHFS grade     
Grade 0 78 47 61 72 
Grade 3 88 53 24 28 
Capecitabine cumulative dose 
(mg/m
2
) (median, range) 
    
Grade 0 
260,166.5 
 (33,333-1,775,000) 
30,1000  
(35,000-1,766,800) 
Grade 3
a
 116,673.5 (15,000-455,000) 161,000 (33,600-542,500) 
*Percentages are computed based on the total number of non-missing values. a. Median (and range) 
capecitabine cumulative dose to the development of grade 3 CiHFS.  
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 Figure R6. Principal component analysis (PCA) of genetic data for the 163 capecitabine-treated patients from the discovery cohort and 
variants which passed quality control (520,052). We plotted principal component 1 and principal component 2. 
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Figure R7. Quantile-quantile (Q-Q) plot. Q-Q plot showing the distributions of observed −log10(P-values) from Cox regression analysis adjusted for sex, 
tumor type and treatment regimen for 520,052 variants which passed QC in the discovery cohort plotted against expected −log10(P-values) (λ=0.981). 
Smaller P-values than would be expected by chance are observed at the tail of the plot. λ= 0.981 indicates no obvious population stratification. 
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2.1. GWAS and fine-mapping  
Of variants on the Human610 array, 3,171 failed genotyping (call rate <0.95), 65,496 were 
excluded by MAF (MAF<0.05), as well as 210 variants whose genotype frequencies departed 
from Hardy-Weinberg equilibrium (P<10-6), leaving a total of 520,052 variants for further 
analysis.  
 
We carried out single-variant associations using Cox regression analyses, modeling the 
cumulative dose of capecitabine required for the development of grade 3 CiHFS, and adjusting 
for gender, tumor type and treatment regimen; and found 10 independent genetic variants that 
reached a P<10-5 (Figure R8 and Table R6). These 10 SNVs were genotyped in the replication 
cohort (N=85 patients) and associations with grade 3 CiHFS were assessed. The intergenic 
variant rs6093063 (G>T) was consistently associated with risk of grade 3 CiHFS (Table R6), with 
an estimated HR of 2.27 (95%CI=1.20–4.30, P=0.011). The combined analysis of the 245 subjects 
from both series gave an HR of 2.16 (95%CI=1.63–2.88, P=1.32×10-7). The Kaplan-Meier analyses 
showing the association of the intergenic variant rs6093063 (G>T) in both cohorts, modeling the 
cumulative dose of capecitabine until the development of CiHFS grade 3 is shown in Figure R9.  
 
 
 
 
 
Figure R9. Kaplan–Meier analysis of cumulative dose of capecitabine until the development of severe CiHFS grade 3 
according to rs6093063 (G>T) genotypes in the 245 patients from the combined cohort (χ
2
=27.06, Plog-rank=1.3x10
−6
, 
NGG=170, NGT=63, NTT=11). 
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Figure R8. Manhattan plot of the GWAS in the discovery cohort showing association between the genotypes of 520,052 variants and risk of CiHFS. The −log10(P-values)  
from Cox regression analysis adjusted for sex, tumor type and treatment regimen was plotted against its physical chromosomal position. Variants above the black line 
represent those with a P <10
−5
. 
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Variant rs6093063 is located in a LD block of 38,501 bp spanning the chromosome 20 
positions 59,707,264-59,745,765 (GRCh37/hg19) at the 20q13.33 locus. In order to fine-map the 
rs6093063 association with CiHFS we subsequently genotyped 34 SNVs and imputed 80 
additional variants in the 245 subjects from both cohorts and tested their associations with 
CiHFS. Of the 10 variants with P<10-5 in the combined analysis of these 114 (Table R7), 
rs6129058 showed the strongest evidence of association with grade 3 CiHFS (HR=2.40; 95%CI 
=1.78–3.25; P=1.2x10-8) (Table R7, Table R8, and Figure R10). 
 
Table R6. Association analysis results for ten variants with P<10
-5
 in the discovery analysis 
Variant Chr. Position * Cohort MAF P HR  95%CI 
rs7428377 3 30299265 
Discovery 0.10 8.27x10
-6
 2.82 1.79-4.46 
Replication 0.05 0.95 0.95 0.21-4.24 
Combined 0.09 2.99x10
-6
 2.47 1.61-3.78 
rs10516179 4 6086752 
Discovery 0.09 5.51x10
-6
 2.81 1.80-4.40 
Replication 0.14 0.78 0.87 0.34-2.24 
Combined 0.11 1.23x10
-3
 1.97 1.30-2.97 
rs12511120 4 8656976 
Discovery 0.07 1.45x10
-6
 3.51 2.10-5.87 
Replication 0.09 0.29 1.59 0.66-3.81 
Combined 0.07 4.33x10
-5
 2.3 1.54-3.44 
rs1852869 4 160319418 
Discovery 0.44 8.22x10
-6
 2.08 1.51- 2.88 
Replication 0.47 0.37 1.38 0.68-2.80 
Combined 0.45 1.03x10
-5
 1.9 1.42- 2.52 
rs1121941
a
 6 123241136 
Discovery 0.21 5.88x10
-6
 2.46 1.66-3.63 
Replication 0.25 0.44 1.31 0.65-2.63 
Combined 0.22 2.82x10
-4
 1.8 1.31-2.47 
rs2420903 10 122802506 
Discovery 0.40 4.41x10
-6
 0.47 0.34-0.65 
Replication 0.44 0.76 0.88 0.39-1.98 
Combined 0.41 9.20x10
-6
 0.52 0.39-0.69 
rs2619170 15 95213582 
Discovery 0.07 3.93x10
-7
 4.12 2.38-7.12 
Replication 0.11 0.38 1.56 0.57-4.24 
Combined 0.08 1.35x10
-5
 2.8 1.76- 4.46 
rs7236593 18 11272254 
Discovery 0.11 9.67x10
-6
 2.57 1.69-3.92 
Replication 0.12 0.04 0.27 0.07-0.99 
Combined 0.11 2.83x10
-3
 1.82 1.22-2.71 
rs13381276 18 76252393 
Discovery 0.10 1.59x10
-6
 3.27 2.01-5.31 
Replication 0.20 0.66 1.16 0.58-2.30 
Combined 0.13 4.47x10
-4
 1.86 1.31-2.62 
rs6093063 20 59723157 
Discovery 0.17 5.88x10
-6
 2.17 1.55-3.04 
Replication 0.18 0.01 2.27 1.20-4.30 
Combined 0.17 1.32x10
-7
 2.17 1.63-2.88 
HRs are per copy of the specified minor allele. The replicated variant rs6093063 is shown in bold. SNVs were 
genotyped in the replication cohort by using KasPar assays. * Chromosome positions are based on Genome 
Reference Consortium Human Build 37 (GRCh37/hg19). a. rs1121941 is in total LD (r
2
=1) with rs4962257. 
Abbreviations: Chr., chromosome. 
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We next conducted haplotype analyses based on the four most strongly CiHFS-associated 
variants (P<5x10-7; Table R8, and Figure R10), which revealed one rare (h1) and one more 
common (h2) haplotypes (Table R9). The rare haplotype (h1) carried the risk alleles at 
rs6129058, rs56152339 and rs6065060, but not at rs6093063. The HR estimate for this 
haplotype relative to the reference haplotype (no risk alleles) was lower compared to that for h2 
(HR h1=1.82 v HR h2=2.48), which carried the risk alleles in all four variants, but the confidence 
intervals were entirely overlapping. Haplotype analyses suggest that the four novel risk variants 
associated with susceptibility to CiHFS could be causal, either individually or in combination. 
2.2. Risk haplotype is associated with reduced CDH4 mRNA expression 
To explore how the identified variants confer susceptibility to CiHFS, we first examined the 
genomic landscape of the risk variant-containing 20q13.33 locus. The closest gene, located ~90 
kb away, is CDH4 and encodes R-cadherin. Cadherin family members are master regulators of 
the cohesiveness of epithelial layers, and genetic defects in cadherin genes have been linked to 
inherited skin disorders183–187. Although R-cadherin has not been previously implicated in skin 
physiology, immunohistochemical approaches revealed that R-cadherin mainly localized in the 
Figure R10. Association and recombination plot of the LD block containing the replicated variant rs6093063 (shaded 
region) and ±50kb boundaries. Plot shows the genomic region associated with CiHFS and the –log10 association P-
values of genotyped and imputed variants (MAF>5%). Circles and diamonds indicate genotyped and imputed variants, 
respectively. Recombination rates are also shown. Variant colour indicates the strength of LD (r
2
) with rs6093063. 
Recombination rates are based on 1000 Genomes Project and genomic coordinates are based on Genome Reference 
Consortium Human Build 37 (GRCh37/hg19). 
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suprabasal granular layer of the stratified human epidermis (Figure R11A and Figure R12B). This 
distribution differed from that documented for other cadherin family members (Figure R11B and 
Figure R12). This result argued for a potential involvement of CDH4 gene in CiHFS. 
Table R7. Strongest associated variants (P<10
-5
) associated with CiHFS appearance after fine-
mapping 
Variant  Chr. Position * Type P HR 95%CI 
rs6071509 20 59713172 Genotyped 1.01x10
-6
 2.12 1.57 - 2.87 
rs68114568 20 59715943 Genotyped 6.46 x10
-7
 2.11 1.575 - 2.84 
rs1074095 20 59718453 Genotyped 6.46 x10
-7
 2.11 1.57 - 2.84 
rs6093063 20 59723157 Genotyped 1.32 x10
-7
 2.17 1.63 - 2.88 
rs73611504 20 59728958 Imputed 5.07 x10
-8
 2.32 1.72 - 3.15 
rs6129058 20 59732322 Genotyped 1.17 x10
-8
 2.40 1.78- 3.25 
rs56152339 20 59732787 Genotyped 7.38 x10
-8
 2.30 1.70 - 3.12 
rs6065060 20 59735681 Genotyped 7.59 x10
-8
 2.30 1.70- 3.12 
rs6101248 20 59738006 Genotyped 1.39 x10
-6
 2.14 1.57- 2.92 
rs6071520 20 59738531 Genotyped 1.13 x10
-6
 2.23 1.62 - 3.08 
Additive model of inheritance was considered. Type indicates whether SNVs were genotyped or imputed. HRs 
are per copy of the specified minor allele. * Chromosome positions are based on Genome Reference 
Consortium Human Build 37 (GRCh37/hg19). Abbreviations: Chr., chromosome. 
 
 
 
       
       
Table R8. Association results for the two stages and the combined analysis at the 20q13.33 locus 
for the 3 most strongly associated variants and the original GWAS hit** 
Variant  Position * Cohort MAF P HR 95%CI 
rs6093063
**
 20:59723157 
Discovery 0.17 5.9 x10
-6
 2.17 1.55-3.04 
Replication 0.18 0.011 2.27 1.20-4.30 
Combined 0.17 1.3 x10
-7
 2.17 1.63-2.88 
rs6129058 20:59732322 
Discovery 0.18 1.3 x10
-6
 2.46 1.71-3.54 
Replication 0.21 2.9 x10
-3
 2.70 1.40-5.19 
Combined 0.19 1.2 x10
-8
 2.40 1.78-3.25 
rs56152339 20:59732787 
Discovery 0.18 4.8 x10
-6
 2.35 1.63-3.39 
Replication 0.19 6.8 x10
-3
 2.45 1.28-4.69 
Combined 0.19 7.4 x10
-8
 2.30 1.70-3.12 
rs6065060 20:59735681 
Discovery 0.18 4.8 x10
-6
 2.35 1.63-3.40 
Replication 0.20 6.9 x10
-3
 2.49 1.28-4.69 
Combined 0.19 7.6 x10
-8
 2.30 1.70-3.12 
Additive model of inheritance was considered. HRs are per copy of the minor allele. * Chromosome positions 
are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19). ** rs6093063.  
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Table R9. Haplotype analyses including the four most strongly associated variants 
Haplotypes 
rs6093063 
(G>T) 
rs6129058
(G>T) 
rs56152339 
(T>A) 
rs6065060
(T>A) 
Haplotype 
frequency 
P HR 95%CI 
Reference [GGTT] 0 0 0 0 0.80 - -  
1 [GTAA] 0 1 1 1 0.02 0.24 1.82 0.67-4.92 
2 [TTAA] 1 1 1 1 0.17 1.43x10
-8
 2.48 1.81-3.39 
All Others Rare 0.01 0.48 1.51 0.48-4.76 
Each haplotype was compared to the ancestral haplotype carrying the common alleles of all 4 variants (reference). Variants rs56152339 and rs6065060 
were almost perfectly correlated with each other 
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eQTL analyses in normal human tissues samples revealed a significant association between 
the presence of the risk haplotype (h2) and reduced CDH4 mRNA expression compared to the 
reference haplotype (P=0.017; Figure R13). 
2.3. The risk allele containing locus interacts with the CDH4 promoter 
ChIP-seq data available in ENCODE for normal human epidermal keratinocytes (NHEK) 
showed no significant transcription factor binding or defined enhancer overlapping with our risk 
variants. However, binding sites of CTCF and cohesin were present close to the locus (Figure 
R14A, top). As these factors are involved in chromatin 
Figure R11. R-cadherin distribution in the stratified human epidermis. Immunohistochemical analyses of (A) R-
cadherin (RCad) and (B) E-cadherin (ECad) in human control skin. A magnification of the selected areas is shown. 
Arrowhead indicates localization of R-cadherin at cell-cell contacts in suprabasal layers of the epidermis. Scale bar, 50 
μm. Abbreviations: epi, epidermis; derm, dermis.  
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Figure R12. Immunohistochemical analyses of four cadherins. A) E-cadherin, B) R-cadherin, C) P-cadherin and D) N-
cadherin in normal skin samples from breast cancer patients prior capecitabine treatment. R-cadherin was found to 
have a different localization in skin tissue (highly expressed in the suprabasal granular layers of the epidermis) 
compared to E-cadherin (strongly expressed throughout the entire epidermis) and P-cadherin (only expressed in the 
basal layers of the epidermis). N-cadherin is not expressed in skin and was used as a negative control. Scale bar, 50 
μm. 
Figure R13. Association between risk locus haplotypes and CDH4 mRNA expression levels. Boxplot of the CDH4 
mRNA levels normalized to β-actin in 44 normal human livers. Natural log transformed expression levels are 
represented. Differences in mRNA levels were assessed using the Student’s t test (Nreference=67, Nh2=18, P=0.017). 
*indicates P<0.05. Haplotypes h1 (N=1) and “others” (N=2) were not included in the analysis. 
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folding and DNA looping188–190, we hypothesized that regulation of CHD4 expression may require 
specific chromatin contacts involving the risk locus. To test this, we employed circularized 
chromosome conformation capture, followed by high-throughput sequencing analyses (4C-seq) 
in keratinocyte cell lines homozygous for the reference and h2 haplotypes, setting the viewpoint 
at the CDH4 promoter. By means of 4C-seq we could detect chromatin contacts between the 
risk locus and the CDH4 promoter in keratinocytes homozygous for the risk alleles (Figure R14A, 
bottom). Interestingly, the interaction was much less apparent in another keratinocyte cell line 
homozygous for the reference haplotype (Figure R14B). Similar results were obtained using a 
second viewpoint at the CDH4 promoter (Figure R15). These results suggest a mechanism by 
which the presence of the risk alleles can affect CDH4 gene expression. Taken together the 
results from eQTL and 4C-seq analyses, we concluded that CDH4 is a strong candidate to be 
involved in CiHFS. 
2.4. CDH4-deficiency leads to decreased levels of involucrin 
To explore the contributions of CDH4 gene to the proper differentiation of keratinocytes, we 
next turned to keratinocytes cultured in vitro, both under proliferative conditions and upon 
calcium-induced differentiation. Proliferative keratinocytes are normally found in the basal 
layers of the epidermis and move to suprabasal layers upon differentiation. In culture, 
keratinocytes proliferate and grow in a monolayer in low calcium medium but the addition of 
calcium promotes cell-cell contact formation and differentiation into postmitotic 
keratinocytes158. So, keratinocytes were switched to a calcium containing media to induce 
differentiation and expression of R-cadherin was evaluated at different time points of the 
calcium switch and compared to low calcium conditions. Immunoblot analyses revealed that R-
cadherin was highly expressed upon differentiation (Figure R16), consistent with its primary 
localization at the suprabasal layer of the epidermis (Figure R11A and Figure R12B). This 
increase in R-cadherin expression was more noticeable after 12 hours of calcium addition. 
 
 
A
D E         
B C
Figure R16. R-cadherin protein levels in human keratinocytes. Western blot (WB) analysis of R-cadherin (RCad) 
levels in HaCaT keratinocytes both in low calcium conditions (LC) and at different time points of a calcium switch 
time course.  
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Figure R14. Chromatin interactions at the 20q13.33 between the CDH4 promoter and the CiHFS susceptibility locus. (A) Detail of the 20q13.33 CiHFS 
susceptibility locus located ~ 90kb upstream of the CDH4 gene promoter showing, from the top down, chromosomal coordinates, a track for HMR conserved 
transcription factor binding sites (TFBS), a track with chromatin states defined in NHEK cells from ENCODE/Broad (colour code appears below), the binding sites 
for CTCF and cohesin Rad21 from ChIP-seq experiments from ENCODE, the positions of the four most strongly associated variants (blue arrowheads) and the 
contact profile from a viewpoint located in the CDH4 gene promoter (Vp, red) in  cells homozygous for the risk haplotype (h2). This profile was generated using 
a 20 kb window size in the main trend subpanel. High contact probability (red) is observed between the CDH4 promoter and the region containing CiHFS 
associated variants. (B) Using the same viewpoint in a different keratinocyte cell line homozygous for the reference haplotype, this interaction is clearly 
decreased. Similar results were obtained with a second viewpoint around the CDH4 promoter (Figure R15). 
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Figure R15. Chromatin interactions at the 20q13.33 between the CDH4 promoter and the CiHFS susceptibility locus were validated with an independent 
viewpoint. Representation of the 20q13.33 CiHFS susceptibility locus showing, from the top down, chromosomal coordinates, a track for HMR conserved 
transcription factor binding sites (TFBS), a track with chromatin states defined in NHEK cells from ENCODE/Broad (colour code appears below), the positions of 
the four most strongly associated variants (blue arrowheads) and the contact profile from a second viewpoint located close to the CDH4 gene promoter (Vp, red 
arrow) in cells homozygous for the risk haplotype (A) or for the reference haplotype (B), as in Figure R14.   
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We next assessed the consequences of decreasing R-cadherin in keratinocyte differentiation 
using a specific short hairpin RNA (shRNA) expressed in a retroviral vector. The knock‐down was 
efficient, as observed by qRT‐PCR (Figure R17A) and western blot (Figure R17B). Importantly, E-
cadherin mRNA and protein levels did not change after knocking‐down CDH4 (Figure R17A and 
R17B). Of note, keratins 5 and 14 are the main structural protein products in proliferating basal 
keratinocytes; while upon differentiation epidermal keratinocytes express differentiation 
markers of suprabasal layers such as keratin 1 , keratin 10 filaggrin, loricrin and involucrin191. So 
next, we evaluated the levels of the above mentioned markers of proliferation and terminal 
epidermal keratinocytes differentiation by qRT-PCR and by immunoblot analyses. 
 
 
 
 
  
 
 
We found that CDH4-deficiency did not have an effect on the expression of keratin 5 (Figure 
R17B), measured 48 hours after calcium addition.  In addition, we observed no changes in the 
expression of keratin 1, keratin 10, filaggrin or loricrin (Figure R18A and R18C). However, both 
mRNA (Figure R18B) and protein levels (Figure R18C) of involucrin were clearly reduced in the 
two stable CDH4 knock-down clones compared to control cells.  
 
 2.5. R-cadherin and involucrin levels in skin are inversely correlated with risk of CiHFS 
To assess the implications of these findings in the susceptibility of CiHFS, we next evaluated 
by immunohistochemistry the association of the risk alleles identified in our series with the 
expression of R-cadherin and involucrin in the epidermis from breast cancer patients sampled 
Figure R17. Consequences of CDH4-deficiency for CDH1 (E-cadherin) and keratin 5 (k5) expression. (A) qRT-PCR 
analyses of CDH4 (R-cadherin) and CDH1 (E-cadherin) mRNA levels in scramble control cells and two different CDH4 
KD clones after 48 h of calcium treatment. Data was normalized to control values and represented as mean ± s.e.m 
and assessed using the Student’s t test (N=5 independent experiments). ** P<0.005, *** P<0.0001. (C)  Western blot 
(WB) analyses of R-cadherin (RCad), E-cadherin (ECad) and keratin 5 (K5) in scramble control cells and two CDH4 KD 
clones after 48 h of calcium treatment. Abbreviations: s.e.m, standard error of the mean.  
A                                                                                   B 
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prior capecitabine treatment. The presence of the risk alleles correlated with reduced levels of 
R-cadherin (Figure R19A), in agreement with CDH4 mRNA expression; and involucrin (Figure 
R19B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R18. Consequences of CDH4-deficiency for the expression of differentiation markers keratin 1, keratin 10, 
filaggrin, loricrin and involucrin. (A) qRT-PCR analyses of CDH4 (R-cadherin), FLG (filaggrin), KRT1 (keratin 1), KRT10 
(keratin 10) and (B) IVN (involucrin) mRNA levels in scramble control cells and two different CDH4 KD clones after 48 h 
of calcium treatment. Data was normalized to control values and represented as mean ± s.e.m and assessed using the 
Student’s t test (N=5 independent experiments). ** P<0.005, *** P<0.0001. (C) Western blot (WB) analyses of R-
cadherin (RCad), loricrin, filaggrin and involucrin in scramble control cells and two different CDH4 KD clones after 48 h 
of calcium treatment. Abbreviations: s.e.m, standard error of the mean.  
A                                                                                  
B                                                                                  
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Figure R19. Boxplot of the R-cadherin and involucrin expression in the epidermis from 16 breast cancer patients 
prior capecitabine treatment. R-cadherin (RCad) (A) and involucrin (B) expression was quantified as positive 
immunohistochemically staining intensity in suprabasal layers of 16 skin samples from breast cancer patients prior 
capecitabine treatment suffering CiHFS grade 0 (N=4) or CiHFS grade 3 (N=12). Skin samples were taken before 
capecitabine treatment. Differences in R-cadherin and involucrin expression between the reference and risk h2 
haplotypes were assessed using the Student’s t test. (Nreference=23, Nh2=4, PR-cadherin=0.156, Pinvolucrin=0.224). Haplotypes 
h1 (N=1) and “others” haplotypes (N=2) were not included in the analysis. 
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Moreover, we also observed an association of the expression of R-cadherin and involucrin 
with the risk of suffering this adverse event, wherein before starting the treatment, the skin of 
the patients exhibiting severe toxicity (grade 3), expressed lower R-cadherin and involucrin 
levels compared to that of patients suffering no toxicity (grade 0) (Figure R20A and 20B, 
respectively). 
A
D E         
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Figure R20.  Boxplot of the R-cadherin and involucrin expression in the epidermis from 16 breast cancer patients 
prior capecitabine treatment. R-cadherin (RCad) (A) and involucrin (B) expression was quantified as positive 
immunohistochemically staining intensity in suprabasal layers of 16 skin samples from breast cancer patients prior 
capecitabine treatment suffering CiHFS grade 0 (N=4) or CiHFS grade 3 (N=12). Skin samples were taken before 
capecitabine treatment. Differences in R-cadherin and involucrin expression between CiHFS grades 0 and 3 were 
assessed using the Student’s t test (PR-cadherin=0.221; *Pinvolucrin =0.001). 
  
         A                                                      B                            
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Main results Study II 
We discovered and replicated a cluster of four highly correlated variants associated 
with susceptibility to CiHFS at 20q13.33 locus (top hit=rs6129058, HR=2.40, 
95%CI=1.78–3.20; P=1.17x10-8). Using 4C-sequencing, we identified a chromatin 
contact between the locus containing the risk alleles and the promoter of CDH4, 
located 90 kb away. The risk haplotype was associated with decreased levels of CDH4 
mRNA and the protein it encodes, R-cadherin, which mainly localizes in the granular 
layer of the epidermis. In human keratinocytes, CDH4 downregulation resulted in 
reduced expression of involucrin, while there were no changes in the expression of 
others differentiation markers such as, keratin 1, keratin 10, filaggrin or loricrin. 
Interestingly, immunohistochemical analyses revealed that skin from patients with 
severe CiHFS exhibited low levels of R-cadherin and involucrin before capecitabine 
treatment.  
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3. Results, Study III: identification of genetic variants predictive of susceptibility to chronic 
anthracycline-induced cardiotoxicity (AIC) in pediatric oncology patients 
The demographic and clinical characteristics of the 93 Spanish anthracycline-treated pediatric 
cancer patients are shown in Table R10.  
 
Controls were significantly younger than cases at diagnosis (median age 5.1 and 10.4 years, 
respectively, P=0.004) and gender distribution in our cohort showed more female patients in 
controls than in cases (43% v 29%); although patients with younger ages and women are 
significantly particularly vulnerable to AIC104. There were fewer cases than controls diagnosed 
with leukemia (37% v 88%; P<0.001) but more with pediatric bone tumors (34% v 5.2% with 
osteosarcoma; P<0.001 and 29% v 6.9% with Ewing sarcoma; P=0.007). Cumulative anthracycline 
Table R10. Clinical characteristics of the anthracycline-treated pediatric cancer patients 
 Controls (N=58) Cases (N=35)  
Characteristic N %* N %* P 
Age at diagnosis (years)     0.004 
Median 5.1 10.4  
Range 1.4-16.9 1.2-21.1  
Sex     0.19 
Female 25 43 10 29  
Male 33 57 25 71  
Primary diagnosis (tumor type)      
Leukemia 51 88 13 37 <0.001 
Osteosarcoma 3 5.2 12 34 <0.001 
Ewing Sarcoma 4 6.9 10 29 0.007 
Radiotherapy involving the heart
a
 3 6.7 6 19 0.15 
Cumulative anthracycline dose (mg/m
2
)
b
     <0.001 
Mean 130 360  
Range 49.2-562 105-780  
≤ 200 43 74 8 23  
> 200 15 26 27 77  
Anthracycline type      
Doxorubicin 50 86 34 97 0.31 
Daunorubicin 8 14 1 2.9 0.15 
Epirubicin 5 8.6 - - 0.15 
Concomitant therapy      
Cyclophosphamide 55 95 27 77 0.06 
Vincristine 54 93 32 91 0.42 
Etoposide 14 24 13 37 0.24 
Bleomycin 2 3.4 13 37 <0.001 
Follow-up (years)     0.06 
Median 8.3 10.5 0.06 
Range 1-24.1 1-27.5  
Age, cumulative anthracycline dose and follow-up were analyzed by Wilcoxon-Mann-Whitney U test. Sex, 
tumor type, radiotherapy involving the heart, anthracycline type and concomitant therapy were analyzed by 
Fisher’s exact test. * Percentages are computed based on the total number of non-missing values. a 
Radiotherapy involving the heart includes mediastinal and mantle radiation and total body irradiation. b 
Cumulative anthracycline dose was calculated using doxorubicin equivalents. Bold fold indicates statistically 
significant P-values (P<0.05).  
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dose was higher in cases than in controls (360 mg/m2 v 130 mg/m2 P<0.001), with doxorubicin 
being the most frequent anthracycline drug administered. Remarkably, patients diagnosed with 
pediatric bone tumors received higher cumulative anthracycline doses than those diagnosed 
with leukemia [median cumulative anthracycline dose (mg/m2)= 439 v 132, respectively]. 
Regarding concomitant therapy, bleomycin was more often administered in cases than in 
controls (37% v 3.4%; P<0.001) and there was a trend toward a significant difference in use of 
cyclophosphamide as concomitant therapy (95% v 77%; P=0.06).  
 
Three patients (1 case and 2 controls) failed genotyping (call rate<0.95) and 7 patients (4 
cases and 3 controls) were excluded as ethnic outliers based on inspection of plots of the two 
first principal components, leaving 83 patients for further analysis (Figure R21). 
3.1. Single-variant associations 
Of the 247,870 variants on the array, 246,060 passed quality control and 53,136 were 
polymorphic. Age at diagnosis, cumulative anthracycline dose and bleomycin concomitant 
administration were included as covariates for logistic regression analyses. After verifying that 
the association of tumor type with AIC was exclusively explained by the cumulative anthracycline 
dose, this clinical variable was not included as covariate. The strongest evidence of association 
was found for the variant rs858345 located in the ENPP1 (ectonucleotide 
pyrophosphatase/phosphodiesterase 1) gene at chromosome 6 (P=2.79x10-4, OR=11.3) (Figure 
R22). As could be expected, given the small number of patients relative to the number of genetic 
variants tested, this variant did not survive a correction for multiple comparisons (PFDR=0.96). 
3.2. Gene-based associations 
We then carried out gene-based tests by using SKAT-O55,166 to further investigate the join 
effects of variants within each gene and considering age at diagnosis, cumulative anthracycline 
dose and bleomycin concomitant administration as covariates. In total, we tested 4,883 genes of 
17,677 covered by at least one variant on the array.  
 
We identified GPR35 (G protein-coupled receptor 35) as the gene most significantly 
associated with chronic AIC (P=7.0x10-6) in pediatric patients and this association remained 
statistically significant after correction for multiple testing (corrected PFDR=0.03). While the SKAT-
O does not provide any parameter estimates and in order to evaluate the contribution of each 
GPR35 variant, we removed one variant at a time and re-calculated the association for the gene 
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using SKAT-O. Sensitivity analyses revealed variant rs12468485 (p.Thr253Met; c.758C>T) 
(MAF=0.04) made the greatest contribution to the observed association (Figure R23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The minor T allele of this variant was almost exclusively present in cases (MAFCASES=0.09 v 
MAFCONTROLS=0.009), with only one CT carrier (2%) among controls compared to 6 CT carriers 
(19%) in cases. No TT carriers were found in our series of anthracycline-treated pediatric cancer 
patients (Table R11). The majority (67%) of cases carrying the CT genotype had an extreme 
chronic AIC phenotype: LV dysfunction, mostly symptomatic, evidenced after treatment with 
anthracycline doses well below the average for cases (CT cases=155mg/m2 v all other cases=360 
mg/m2). To assess whether the model with the variant rs12468485 was more informative than 
the model with only non-genetic variables (age at diagnosis, cumulative anthracycline dose and 
bleomycin concomitant therapy) we used likelihood ratio tests. We
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Figure R23. Contribution of individual GPR35 variants on statistical significances for the GPR35 gene. Top: genomic 
location of GPR35 displayed in the UCSC Genome Browser. Exon location and amino acid substitution of each of the 
7 coding polymorphic variants covered by the Illumina HumanExome BeadChip array are depicted. Bottom: P-values 
for the GPR35 association in SKAT-O gene-based tests after removing one variant (black line) at a time and 
recalculating the association for GPR35. Grey line indicates the P-value for the GPR35 association with chronic AIC 
including all 7 coding variants (P=7.0x10
-6
). Abbreviations: Prot, protein. 
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A)                                                                                                                 B) 
Figure R21. Principal component analysis of genetic data. We carried out PCA analysis using the 90 anthracycline-treated pediatric samples that passed quality control (A) and both 90 
anthracycline-treated pediatric samples and 277 HapMap samples (European, African and East Asian samples) (B) genotyped on the Illumina HumanExome-12v1_A Beadchip by Illumina. 
We plotted principal component 1 and principal component 2.  
 
A)                                                                                                                              B)  
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Figure R22. Manhattan plot showing association between the genotypes of the 53,136 polymorphic variants and risk of chronic AIC. The −log10(P-values) from single-
variant analysis by logistic regression adjusted for age at diagnosis, cumulative anthracycline dose and bleomycin concomitant administration is plotted against its physical 
chromosomal position. The most significantly associated variant was rs858345 in chromosome 6 (P=2.79 x10
-4
). Red line: P=10
−4
. 
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Table R11. Allelic distribution of the 7 polymorphic GPR35 variants covered by the Illumina HumanExome BeadChip array 
Variant Function Chr. Location* Genotype 
Cases (N=31) 
N/% 
Controls (N=52) 
N/% 
MAF  
cases 
MAF 
controls 
MAF 
rs6437353 (A>G) 
Missense 
(p.Arg13His) 
2 241558397 
AA 9 (29%) 11 (21%)    
AG 16 (52%) 29 (56%) 0.45 0.51 0.49 
GG 6 (19%) 12 (53%)    
rs35146537 (G>A) 
Missense 
(p.Ala56Thr) 
2 241569442 
GG 30 (97%) 52 (100%)    
GA 1 (3%) - 0.02 - 0.006 
AA - -    
rs139197368 (G>A) 
Missense 
(p.Val60Ile) 
  GG 31 (100%) 51 (98%)    
2 241569454 GA - 1 (2%) - 0.01 0.006 
  AA - -    
rs3749171 (C>T) 
Missense 
(p.Thr139Met) 
2 241569692 
CC 26 (84%) 35 (67%)    
CT 4 (13%) 15 (29%) 0.1 0.18 0.15 
TT 1 (3%) 2 (4%)    
rs61734452 (A>G) 
Missense 
(p.Asn200Asp) 
2 241569874 
AA 30 (97%) 51 (98%)    
AG 1 (3%) 1 (2%) - 0.01 0.006 
GG - -    
rs12468485 (C>T) 
Missense 
(p.Thr253Met) 
2 241570127 
CC 25 (81%) 51 (98%)    
CT 6 (19%) 1 (2%) 0.09 0.009 0.04 
TT - -    
rs3749172 (A>C) 
Missense 
(p.Ser325Cys) 
2 241570249 
AA 8 (26%) 16 (31%)    
AC 14 (45%) 27 (52%) 0.52 0.43 0.46 
CC 9 (29%) 9 (17%)    
*Chromosome positions are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19). Variant rs12468485 is shown in bold. 
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obtained that the model including the variant rs12468485 and clinical factors provides a 
significant improvement over the model with only clinical variables (P=8.6x10-5). 
 
In order to evaluate the impact of the missense variant rs12468485 (p.Thr253Met) on GPR35 
protein structure or function, we applied six in silico prediction algorithms (Table R12). 
p.Thr253Met was classified as pathogenic by PolyPhen-2 and MutPred, and was predicted by F-
SNPs to a have a potentially regulatory role in splicing (Table R12). 
3.3. GPR35 sequencing 
Due to the incomplete coverage in the exome array of coding variants in GPR35, we 
sequenced the exonic region of the gene in our series of anthracycline-treated pediatric cancer 
patients. We identified 17 coding variants, 6 of which had been genotyped on the exome array. 
Of the other 11, 2 were in complete LD with the variant rs12468485 and 2 had call rate<0.90 and 
were not analysed further. Of the remaining 7 coding variants identified (r2<0.36 with variant 
rs12468485) in GPR35 (Table R13), 4 were synonymous and 3 missense, and all had MAF<5% 
(MAF ranging from 0.7%-2%). 
 
 
 
 
 
 
 
 
 
 
 
Of these 7 new GPR35 variants, only rs35155396 was associated with risk independently of 
clinical factors (P=5.16x10-3), but not independently of rs12468485 (P=0.99).  
 
Table R13. Additional GPR35 coding variants identified by sequencing 
Variant Position Function MAF 
rs138283952 chr2:241569810 Synonymous 0.007 
rs142918765 chr2:241570284 Synonymous 0.007 
rs147336244 chr2:241569669 Synonymous 0.006 
rs34778053 chr2:241569742 
Missense 
(p.Arg156Ser) 
0.01 
rs35155396 chr2:241569585 Synonymous 0.02 
rs61734453 chr2:241569745 
Missense 
(p.Gly157Arg) 
0.006 
rs763867971 chr2:241570132 
Missense 
(p.Arg286Cys) 
0.007 
Chromosome positions are based on Genome Reference Consortium Human Build 37 
(GRCh37/hg19) 
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Table R12. In silico prediction of the functional effect of rs12468485 (p.Thr253Met) 
       F-SNP prediction 
Variant 
SIFT 
prediction 
Polyphen-2 
prediction 
MutPred 
prediction 
SNPs&GO 
Prediction 
PON-P2 
prediction 
PredictSNP 
prediction 
ESEfinder 
prediction 
ESRSearch 
prediction 
PESX 
prediction 
RESCUE_ESE 
prediction 
rs12468485 
(p.Thr253Met) 
Tolerated 
Possibly  
damaging 
Pathogenic Neutral Neutral Neutral Changed Changed Changed Changed 
Bold type indicates a likely pathogenic effect or a change in splicing predicted by each in silico algorithm. Predictions are on GPR35 protein with Uniprot identifier Q9HC97. 
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3.4. Gene-enrichment and pathway analysis  
Finally, to gain further insight into the nature of the biological pathways impacting on AIC we 
performed a gene enrichment analysis using the bioinformatics tool DAVID168 based on the list of 
significant genes (P<0.05) with at least 3 variants identified in the SKAT-O analysis. Ten clusters 
with an enrichment score (ES) ≥1.3 (indicating biological significance) were found, but only 2 
clusters had categories with significant P-values after FDR correction (Table R14). These clusters 
revealed overrepresentation of glycoproteins, receptors, N-linked glycosylation sites and plasma 
membrane components.  
On the other hand, no pathways were associated with AIC risk after multiple testing 
correction (P≥0.05). 
 
 
 
 
Main results Study III 
We identified a novel significant association for GPR35 (G protein-coupled receptor 35) 
by gene-based testing, a gene with potential roles in cardiac physiology and pathology 
(P=7.0x10-6), which remained statistically significant after correction for multiple 
testing (PFDR=0.03). The greatest contribution to this observed association was made by 
rs12468485, a missense variant (p.Thr253Met, c.758C>T, MAF=0.04), the T allele being 
associated with increased risk of chronic AIC and more severe symptomatic cardiac 
manifestations at low anthracycline doses in pediatric cancer patients. No single-
variant showed an association with chronic AIC. 
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Table R14. Functional Annotation Clustering from the DAVID tool (Enrichment score ≥ 1.3). 
Annotation cluster 1 Enrichment score: 3.1 
Category Term Count P Genes PFDR 
SP_PIR_KEYWORDS Glycoprotein 125 9.2x10
-7
 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, CHRNA9, CD44, LRRC52, PI16, 
ODZ3, GRID1, CLCA1, OR10S1, SLCO4A1, SPARCL1, PTPRN2, PLXNB2, CDHR2, SLC22A20, 
HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, CHGB, DST, FGFR4, PANX1, AMTN, OR2T1, KEL, 
ENPP3, ITGAM, CRB2, P2RY2, ENTPD7, BAI2, SFTPD, B3GNT3, EGF, GCNT1, ADAM28, 
EPB41, ITGA3, OR5AC2, GPR35, SLC4A11, P2RX3, NOTCH4, TSC2, OR51A7, UTP14C, 
COL20A1, CHRNG, ARSB, ARSD, CLSTN2, CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, 
C14ORF135, SMPDL3A, NMUR2, POMT1, OR6P1, ANO2, CTBS, USH2A, OR2AE1, OR10J1, 
NCR3, CD86, TNFRSF10C, CLECL1, TAS2R19, ZPBP2, GRM6, ERN1, KCNH8, C4ORF29, 
PLA2G3, WFIKKN2, LRRC32, CPN2, NUP214, C1QTNF6, FCN2, COL6A2, FUT3, UGT2A1, 
COL6A1, CCBP2, HRG, PLA2R1, DKKL1, SLC39A4, QSOX1, SOAT1, TMC6, MOGAT1, CES1, 
OR8G2, FBN1, FUCA2, MAN1C1, COL5A1, PLG, OR51M1, CDH13, PROM2, GPR110, 
SLC17A2, ANXA11, GPR113, MEP1B, GPR111, MEGF6, ABCC8, GFRA2, ABCC6, GPR116 
1.7x10
-4
 
UP_SEQ_FEATURE 
N-linked 
glycosylation sites 
(GlcNAc...) 
116 1.7x10
-5
 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, CHRNA9, CD44, LRRC52, PI16, 
ODZ3, GRID1, CLCA1, OR10S1, SPARCL1, SLCO4A1, PTPRN2, PLXNB2, CDHR2, SLC22A20, 
HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, DST, FGFR4, PANX1, OR2T1, KEL, ENPP3, ITGAM, 
CRB2, P2RY2, ENTPD7, BAI2, SFTPD, B3GNT3, EGF, GCNT1, ADAM28, ITGA3, OR5AC2, 
GPR35, SLC4A11, P2RX3, NOTCH4, OR51A7, UTP14C, COL20A1, CHRNG, ARSB, ARSD, 
CLSTN2, CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, C14ORF135, SMPDL3A, NMUR2, 
POMT1, OR6P1, ANO2, CTBS, USH2A, OR2AE1, OR10J1, NCR3, CD86, CLECL1, TAS2R19, 
ZPBP2, GRM6, ERN1, KCNH8, C4ORF29, PLA2G3, WFIKKN2, LRRC32, CPN2, C1QTNF6, FCN2, 
COL6A2, FUT3, UGT2A1, COL6A1, CCBP2, HRG, PLA2R1, DKKL1, SLC39A4, QSOX1, TMC6, 
MOGAT1, CES1, OR8G2, FBN1, FUCA2, MAN1C1, PLG, OR51M1, CDH13, PROM2, GPR110, 
SLC17A2, GPR113, MEP1B, GPR111, MEGF6, ABCC8, GFRA2, ABCC6, GPR116 
1.2x10
-2
 
Continue on next page 
Results Study III 
 
138 
 
 
 
 
 
 
 
Category Term Count P Genes PFDR 
SP_PIR_KEYWORDS Receptor 55 3.3x10
-5
 
TRPV3, GRIN3B, OR8S1, FCRL3, LPHN2, OR4D2, CHRNA9, CD44, NMUR2, OR6P1, GRID1, 
OR10S1, PLXNB2, PTPRN2, PPARGC1A, OR2AE1, OR10J1, TRPM2, NCR3, TNFRSF10C, CD86, 
TAS2R19, LILRB4, GRM6, LRP11, GPR50, OR8B4, FGFR4, OR2T1, PAQR7, ITGAM, P2RY2, 
BAI2, CCBP2, PLA2R1, TRIP11, OR8G2, ITGA3, PTPN12, OR5AC2, OR51M1, GPR35, EPS8, 
GPR110, P2RX3, NOTCH4, GPR113, GPR111, MS4A10, ABL1, ABCC8, OR51A7, GFRA2, 
CHRNG, GPR116 
2.5x10
-3
 
GOTERM_CC_FAT Plasma membrane 107 5.3x10
-5
 
LMO7, OR8S1, GRIN3B, LPHN2, OR4D2, CHRNA9, CD44, WNK4, GRID1, CLCA1, OR10S1, 
MYH1, PTPRN2, CDHR2, HLA-C, CTNNA3, LILRB4, GPR50, OR8B4, KBTBD10, DST, SNTG2, 
HDLBP, FGFR4, PANX1, AMTN, OR2T1, KEL, ENPP3, MAP4K2, PAQR7, ITGAM, KCNS3, CRB2, 
PLCH2, P2RY2, TRO, BAI2, B3GNT3, EGF, SLC28A3, ADAM28, EPB41, LPP, KCNB1, ITGA3, 
OR5AC2, GPR35, SLC4A11, EPS8, P2RX3, NOTCH4, TSC2, MAP7, OR51A7, PLA2G4E, CHRNG, 
TM7SF4, CLSTN2, CLSTN3, KCNJ12, CDSN, FCRL3, NMUR2, SDPR, OR6P1, KCNG4, RHOF, 
USH2A, OR2AE1, TRPM2, OR10J1, NCR3, CD86, TNFRSF10C, CLECL1, SLC26A9, GRM6, 
PLA2G3, NKD2, LRRC32, TAP2, COL6A2, COL6A1, CCBP2, PLA2R1, SLC39A4, OR8G2, 
PPP1R9B, COG4, OR51M1, CDH13, PROM2, ERBB2IP, NRAP, GPR110, SLC17A2, GPR113, 
MEP1B, ANXA13, GPR111, SYNM, TAPBPL, ABCC8, GFRA2, ABCC6, GPR116 
1.5x10
-2
 
Continue on next page 
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Annotation cluster 2 Enrichment score: 2.19 
Category Term Count P Genes PFDR 
SP_PIR_KEYWORDS Glycoprotein 125 9.2x10
-7
 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, CHRNA9, CD44, 
LRRC52, PI16, ODZ3, GRID1, CLCA1, OR10S1, SLCO4A1, SPARCL1, PTPRN2, 
PLXNB2, CDHR2, SLC22A20, HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, CHGB, DST, 
FGFR4, PANX1, AMTN, OR2T1, KEL, ENPP3, ITGAM, CRB2, P2RY2, ENTPD7, BAI2, 
SFTPD, B3GNT3, EGF, GCNT1, ADAM28, EPB41, ITGA3, OR5AC2, GPR35, 
SLC4A11, P2RX3, NOTCH4, TSC2, OR51A7, UTP14C, COL20A1, CHRNG, ARSB, 
ARSD, CLSTN2, CLSTN3, TMEM161A, CDSN, FCRL3, RSPO4, C14ORF135, 
SMPDL3A, NMUR2, POMT1, OR6P1, ANO2, CTBS, USH2A, OR2AE1, OR10J1, 
NCR3, CD86, TNFRSF10C, CLECL1, TAS2R19, ZPBP2, GRM6, ERN1, KCNH8, 
C4ORF29, PLA2G3, WFIKKN2, LRRC32, CPN2, NUP214, C1QTNF6, FCN2, COL6A2, 
FUT3, UGT2A1, COL6A1, CCBP2, HRG, PLA2R1, DKKL1, SLC39A4, QSOX1, SOAT1, 
TMC6, MOGAT1, CES1, OR8G2, FBN1, FUCA2, MAN1C1, COL5A1, PLG, OR51M1, 
CDH13, PROM2, GPR110, SLC17A2, ANXA11, GPR113, MEP1B, GPR111, MEGF6, 
ABCC8, GFRA2, ABCC6, GPR116 
SP_PIR_KEYWORDS 
UP_SEQ_FEATURE 
N-linked 
glycosylation sites 
(GlcNAc...) 
116 1.7x10
-5
 
FSTL4, OR8S1, GRIN3B, SLC7A4, MMRN2, LPHN2, OR4D2, CHRNA9, CD44, 
LRRC52, PI16, ODZ3, GRID1, CLCA1, OR10S1, SPARCL1, SLCO4A1, PTPRN2, 
PLXNB2, CDHR2, SLC22A20, HLA-C, PNPLA3, TNFAIP6, LRP11, OR8B4, DST, 
FGFR4, PANX1, OR2T1, KEL, ENPP3, ITGAM, CRB2, P2RY2, ENTPD7, BAI2, SFTPD, 
B3GNT3, EGF, GCNT1, ADAM28, ITGA3, OR5AC2, GPR35, SLC4A11, P2RX3, 
NOTCH4, OR51A7, UTP14C, COL20A1, CHRNG, ARSB, ARSD, CLSTN2, CLSTN3, 
TMEM161A, CDSN, FCRL3, RSPO4, C14ORF135, SMPDL3A, NMUR2, POMT1, 
OR6P1, ANO2, CTBS, USH2A, OR2AE1, OR10J1, NCR3, CD86, CLECL1, TAS2R19, 
ZPBP2, GRM6, ERN1, KCNH8, C4ORF29, PLA2G3, WFIKKN2, LRRC32, CPN2, 
C1QTNF6, FCN2, COL6A2, FUT3, UGT2A1, COL6A1, CCBP2, HRG, PLA2R1, DKKL1, 
SLC39A4, QSOX1, TMC6, MOGAT1, CES1, OR8G2, FBN1, FUCA2, MAN1C1, PLG, 
OR51M1, CDH13, PROM2, GPR110, SLC17A2, GPR113, MEP1B, GPR111, MEGF6, 
ABCC8, GFRA2, ABCC6, GPR116 
UP_SEQ_FEATURE 
Gene-set enrichment analysis of gene-based P-values from SKAT-O was performed using the functional annotation clustering analysis module of the bioinformatic tool DAVID. Each annotation term 
group is assigned an enrichment score to rank overall importance. Only annotation clusters with ES≥1.3 (indicating biological significance) and significant P-values after FDR correction are shown. The 
significance of gene-term enrichment was assessed with a modified Fisher´s exact test and P-values are corrected using Benjamini-Hochberg’s by false discovery rate (FDR-BH) procedure. 
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4. Results, Study IV: identification of genetic variants predictive of susceptibility to chronic 
anthracycline-induced cardiotoxicity (AIC) in breast and pediatric oncology patients 
The demographic and clinical characteristics of the Spanish and Belgium adult breast cancer 
patients are shown in Table R15. 
  
Table R15. Clinical characteristics of the anthracycline-treated breast cancer patients 
 Spanish breast cancer 
patients (N=71) 
Belgium breast cancer 
patients (N=142) 
 Controls 
(N=53) 
Cases  
(N=18) 
Controls 
(N=86) 
Cases 
(N=56) 
Characteristic 
N 
%* 
N 
%* 
N 
%* 
N 
%* 
Age at diagnosis (years)          
Median 49 59.5 52 49 
Range 27-73 36-72 32-70 34-74 
Primary diagnosis (tumor type)         
Ductal 42 79 13 72 59 69 42 75 
Lobular 8 15 4 22 7 8.1 4 7.1 
Others 3 5.7 1 5.6 20 23 10 18 
Tumor grade         
1 1 1.9 - - 6 7 3 5.4 
2 36 68 14 78 29 34 19 34 
3 16 30 4 22 51 59 34 61 
Left-sided radiotherapy 25 47 6 33 49 60 27 48 
Anthracycline type         
Doxorubicin 53 100 18 100 - - - - 
Epirubicin - - - - 86 100 56 100 
Anthracycline setting         
Neoadjuvant 25 47 13 72 71 83 4 7.1 
Adjuvant 28 53 5 28 15 17 52 93 
Cumulative anthracycline dose          
Median (mg/m
2
) 298.6 298.4 300 300 
Mean (mg/m
2
) 282.9 298.1 353.5 428.6 
Range (mg/m
2
) 150-375 200-588 300-600 300-600 
LVEF at baseline (%)     
Median 68 75 65 60 
Range 60-83 55-81 60-81 60-86 
LVEF at follow-up (%)         
Median 65  59.5  60 15 
Range 60-82 24-70 60-81 10-58 
Follow-up (years)     
Median 4.76 5.74 7.1 8.04 
Range 2-16 1.19-10.07 1.38-14.6 1.94-13.43 
* Percentages are computed based on the total number of non-missing values. 
 
In the Spanish breast cancer cohort, 18 patients (25%) developed AIC, whereas in the Belgium 
cohort, 56 patients (39%) experienced cardiotoxicity. Controls were significantly younger than 
cases at diagnosis in the discovery (median age 49 v 59.5 years, respectively; P=0.023), but 
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patients have similar age in the Belgium (52 v 49 years, respectively; P=0.24). Patients in the 
Spanish cohort were treated with doxorubicin, while Belgium breast cancer patients were 
treated with epirubicin. Cumulative anthracycline doses were significantly different between 
cases and controls in the Belgium cohort (P=0.001), with 82% of controls receiving 300 mg/m2 of 
epirrubicin and with a median cumulative dose of 353.5 mg/m2, compared to a median 
cumulative dose of 428.6 mg/m2 in cases (54% of cases received 300 mg/m2 of epirrubicin and 
41% of cases received 600 mg/m2). 
 
In the Spanish breast cancer cohort 1 case was failed heterozigosity and 9 patients (2 cases 
and 7 controls) were excluded as ethnic outliers based on inspection of plots of the two first 
principal components, leaving 61 patients for further analysis (Figure R24). 
4.1. Single-variant associations 
Of the 247,870 variants on the array, 246,060 passed quality control and 48,451 were 
polymorphic. Age at diagnosis was included as covariate for logistic regression analyses. The 
strongest evidence of association was found for the variant rs1243647 located in the POLE (DNA 
polymerase epsilon) gene at chromosome 14 (P=8.6x10-4, OR=15.1) (Figure R25). As could be 
expected and as in the single-variant analyses performed in the pediatric cohort (Study III), given 
the small number of patients relative to the number of genetic variants tested, this variant did 
not survive a correction for multiple comparisons (PFDR=0.96). 
4.2. Gene-based associations 
We then carried out gene-based tests in the Spanish breast cancer cohort by using SKAT-
O55,166 to further investigate the join effects of variants within each gene and considering age at 
diagnosis, as covariate. In total, we tested 4,288 genes of 17,677 covered by at least one variant 
on the array.  
 
The two genes most significantly associated with chronic AIC in the Spanish breast cancer 
patients were ETFB (electron transfer flavoprotein beta subunit), a cardiac protein involved in 
mitochondrial energy production192 (P=4.2x10-4) and WISP1 (WNT1 inducible signaling pathway 
protein 1), which has been shown to inhibit the doxorubicin-induced cardiomyocyte death193 
(P=5.2x10-4); although they did not remain statistically significant after correction for multiple 
testing (PFDR=0.77). Given that these genes are, a priori, good candidates for influencing the 
development of chronic AIC and the SKAT-O does not provide any parameter estimates; we 
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assessed the individual contribution of variants within ETFB and WISP1. Variant rs79338777 
(p.Pro52Leu; c.155C>T) in ETFB (Figure R26) and variants rs149172980 (p.Thr13Ile; c.38C>T), 
rs72731540 (p.Val184Ile; c.550G>A) and rs143089011 (p.Ala196Thr; c.586G>A) in WISP1 (Figure 
R27) made the greatest contribution to the observed association. The minor T allele of the ETFB 
variant rs79338777 variant was almost exclusively present in cases (MAFCASES=13% v 
MAFCONTROLS=2%), with 4 CT carriers (27%) among cases compared to 2 CT carriers (4%) in 
controls (Table R16). WISP1 variants rs149172980 and rs143089011 were found in heterozygosis 
in only 1 case (3% of cases) out of the 61 Spanish breast cancer patients (MAFCASES=3%) with no 
patients carying the minor allele in homozygosis. The minor A allele of the WISP1 rs72731540 
variant was found only in cases, with only 2 GA carriers (13%) (MAFCASES=7%) (Table R16). 
 
Next we decided to evaluate the distribution of the allele frequencies of these 4 low-
frequency variants in two independent cohorts of anthracycline-treated cancer patients: in 142 
Belgium breast cancer patients and in the Spanish pediatric cancer seires used in Study III. As in 
the Spanish breast cancer cohort, the minor T allele of the variant rs79338777 (ETFB) was found 
more often in Belgium breast cancer cases than in controls (9 CTCASES (16%) v 6 CTCONTROLS (7%); 
MAFCASES=8% v MAFCONTROLS=4%). Regarding WISP1 variants, the minor A allele of the rs72731540 
variant was consistently and mostly found in cases in the Belgium cohort controls (4 GACASES (7%) 
v 2 CTCONTROLS (2%); MAFCASES=4% v MAFCONTROLS=1%) (Table R17). Unfortunately, for the other two 
WISP1 variants, we found that rs149172980 and rs143089011 were monomorphic in the 
Belgium cohort.  
 
Consistently with what we found in the Spanish and Belgium breast cancer series, the minor 
allele of variants rs79338777 (ETFB) and rs72731540 (WISP1) was more common in cases than in 
pediatric controls (rs79338777, 9 CTCASES (29%) v 7 CTCONTROLS (13%), MAFCASES=18% v 
MAFCONTROLS=7%; rs72731540, 2 GACASES (6%) v 2 GACONTROLS (4%), MAFCASES=3% v MAFCONTROLS=2%) 
(Table R17). Variants rs149172980 and rs143089011 in WISP1 were also monomorphic in 
children.  
 
When we combined the three cohorts to show overall significance levels (N=286), we 
obtained that variants rs79338777 (ETFB) and rs72731540 (WISP1) were significantly associated 
with risk of chronic AIC [rs79338777 (ETFB), OR=3.55, P=7.71×10-4, 95%CI=1.70–7.42; 
rs72731540 (WISP1), OR=5.85, P=0.0084, 95%CI=1.57–21.7] (Table R17). Overall, it was found 
that the risk allele for rs79338777 (ETFB) to be 2.89 times more frequent in cases than in 
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controls (MAFCASES=12% v MAFCONTROLS=4%) and 3.61 times (MAFCASES=4% v MAFCONTROLS=1%) for 
rs72731540 (WISP1). 
 
In order to evaluate the impact of the low-frequency missense variants rs79338777 
(p.Pro52Leu) and rs72731540 (p.Val184Ile) on ETFB and WISP1 protein structure or function, 
respectively, we applied six in silico prediction algorithms. rs79338777 (ETFB) was classified as 
pathogenic by Predict-SNP, and SIFT and as possibly damaging by PolyPhen-2; whereas 
rs72731540 (WISP1) was classified as non-pathogenic by all the prediction methods (Table R18). 
4.3. Gene-enrichment and pathway analysis  
Finally, to gain further insight into the nature of the biological pathways impacting on AIC we 
performed a gene enrichment analysis using the bioinformatics tool DAVID168 based on the list of 
significant genes (P<0.05) with at least 3 variants identified in the SKAT-O analysis. 2 clusters 
with an enrichment score (ES) ≥1.3 (indicating biological significance) with significant P-values 
after FDR correction were found (Table R19). These clusters revealed overrepresentation of 
glycoproteins, N-linked glycosylation sites, cytoplasmic and extracellular components.  
 
On the other hand, no pathways were associated with AIC risk after multiple testing 
correction (P≥0.05). 
Main results Study IV 
By gene-based testing we identified novel associations for two genes, ETFB (electron 
transfer flavoprotein beta subunit), a cardiac protein involved in mitochondrial energy 
production (P=4.2x10-4) and WISP1 (WNT1 inducible signaling pathway protein 1), 
which has been shown to inhibit doxorubicin-induced cardiomyocyte death (P=5.2x10-
4). The low-frequency alleles of ETFB variant rs79338777 (p.Pro52Leu; c.155C>T) and 
WISP1 rs72731540 (p.Val184Ile; c.550G>A) variant were associated with increased risk 
of chronic AIC in the three cohorts when analyzed separately and when combined 
(rs79338777, OR=3.55, P=7.71×10-4, 95%CI=1.70–7.42; rs72731540, OR=5.85, 
P=0.0084, 95%CI=1.57–21.7). 
Results Study IV 
 
144 
 
Figure R24. Principal component analysis of genetic data. We carried out PCA analysis using the 70 anthracycline-treated Spanish breast cancer samples that passed quality control (A) and both 
70 anthracycline-treated breast cancer samples and 277 HapMap samples (European, African and East Asian samples) (B) genotyped on the Illumina HumanExome-12v1_A Beadchip by Illumina. 
We plotted principal component 1 and principal component 2. Abbreviations: SBCP, Spanish breast cancer patients. 
 
A)                                             B) 
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Figure R25. Manhattan plot showing association between the genotypes of the 48,451 polymorphic variants and risk of chronic AIC in the Spanish breast cancer patient 
cohort. The −log10(P-values) from single-variant analysis by logistic regression adjusted for age at diagnosis is plotted against its physical chromosomal position. The most 
significantly associated variant was rs1243647 in chromosome 14 (P=8.6 x10
-4
). Red line: P=10
−4
. 
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Figure R26. Contribution of individual ETFB variants on statistical significances for the ETFB gene. Top: genomic 
location of ETFB displayed in the UCSC Genome Browser. Exon location and amino acid substitution of each of 
the 4 coding polymorphic variants covered by the Illumina HumanExome BeadChip array are depicted. Bottom: 
P-values for the ETFB association in SKAT-O gene-based tests after removing one variant (black line) at a time 
and recalculating the association for ETFB. Grey line indicates the P-value for the ETFB association with chronic 
AIC including all 4 coding variants (P=4.2x10
-4
).  
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Figure R27. Contribution of individual WISP1 variants on statistical significances for the WISP1 gene. Top: 
genomic location of WISP1 displayed in the UCSC Genome Browser. Exon location and amino acid substitution of 
each of the 5 coding polymorphic variants covered by the Illumina HumanExome BeadChip array are depicted. 
Bottom: P-values for the ETFB association in SKAT-O gene-based tests after removing one variant (black line) at a 
time and recalculating the association for WISP1. Grey line indicates the P-value for the WISP1 association with 
chronic AIC including all 5 coding variants (P=5.2x10
-4
). rs3736261 is a synonymous variant.  
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Table R16. Allelic distribution of the polymorphic ETFB and WISP1 variants covered by the Illumina HumanExome BeadChip array in the Spanish breast cancer cohort 
Variant Gene Function Chr. Location* Genotype 
Cases (N=15) 
N/% 
Controls (N=46) 
N/% 
MAF  
cases 
MAF 
controls 
MAF 
rs1130426 (C>T) ETFB 
Missense 
(p.Thr245Met) 
19 51850290 
CC 7 (27%) 15 (33%)    
CT 4 (46%) 23 (50%) 0.5 0.42 0.43 
TT 7 (27%) 8 (17%)    
rs147353781 (C>T) ETFB 
Missense 
(p.Arg189Cys) 
19 51856469 
CC 14 (97%) 46 (100%)    
CT 1 (3%) - 0.03 - 0.008 
TT - -    
rs140608276 (G>A) ETFB 
Missense 
(p.Val79Ile) 
  GG 14 (97%) 46 (100%)    
19 51857658 GA 1 (3%) - 0.03 - 0.008 
  AA - -    
rs79338777 (C>T) ETFB 
Missense 
(p.Pro52Leu) 
19 51857738 
CC 11 (73%) 44 (96%)    
CT 4 (27%) 2 (4%) 0.13 0.02 0.04 
TT - -    
rs149172980 (C>T) WISP1 
Missense 
(p.Thr13Ile) 
  CC 14 (97%) 46 (100%)    
8 134203425 CT 1 (3%) - 0.03 - 0.008 
  TT - -    
rs72731540 (G>A) WISP1 
Missense 
(p.Val184Ile) 
8 134233024 
GG 13 (87%) 46 (100%)    
GA 2 (13%) - 0.07 - 0.04 
AA - -    
rs143089011 (G>A) WISP1 
Missense 
(p.Ala196Thr) 
8 
 GG 14 (97%) 46 (100%)    
134233060 GA 1 (3%) - 0.03 - 0.008 
 AA - -    
rs35513885 (G>T) WISP1 
Missense 
(p.Ala205Ser) 
8 134237635 
GG 13 (87%) 40 (87%)    
GT 2 (13%) 5 (11%) 0.07 0.08 0.07 
TT - 1 (2%)    
rs3739261 (T>C) WISP1 Synonymous 8 134239770 
TT 8 (53%) 19 (41%)    
TC 4 (27%) 23 (50%) 0.33 0.34 0.34 
CC 3 (20%) 4 (9%)    
*Chromosome positions are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19) 
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Table R17. Association of ETFB and WISP1 variants with anthracycline-induced cardiotoxicity 
   Belgium breast cancer patients (N=142) Spanish pediatric oncology patients (N=83) 
Overall combined logistic regression 
N=286 
Variant Gene Genotype 
Cases 
(N=56) 
N/% 
Controls 
(N=86) 
N/% 
MAF  
cases 
MAF 
controls 
MAF 
Cases 
(N=31) 
N/% 
Controls 
(N=52) 
N/% 
MAF  
cases 
MAF 
controls 
MAF P OR 95%CI MAF 
rs79338777 
(C>T) 
ETFB 
CC 47 (84%) 78 (91%)    21 (68%) 45 (87%)        
CT 9 (16%) 6 (7%) 0.08 0.04 0.05 9 (29%) 7 (13%) 0.18 0.07 0.11 7.71×10
-4
 3.55 1.70–7.42 0.07 
TT - 1 (1%)    1 (3%) -        
rs72731540 
(G>A) 
WISP1 
GG 52 (93%) 83 (97%)    29 (94%) 50 (96%)        
GA 4 (7%) 2 (2%) 0.04 0.01 0.02 2 (6%) 2 (4%) 0.03 0.02 0.02 0.0084 5.85 1.57–21.7 0.02 
AA - -    - -        
WIPS1 variants rs149172980 and rs143089011 were monomorphic in the Belgium breast cancer and in the Spanish pediatric cohorts 
Table R18. In silico prediction of the functional effect of ETFB rs79338777 and WISP1 rs72731540 
Variant 
SIFT 
prediction 
Polyphen-2 
prediction 
MutPred 
prediction 
SNPs&GO 
Prediction 
PON-P2 
prediction 
PredictSNP 
prediction 
rs79338777 
(p.Pro52Leu) 
Deleterious Possibly damaging Non pathogenic - - Deleterious 
rs72731540 
(p.Val184Ile) 
Tolerated Benign Neutral Neutral Neutral Neutral 
Bold type indicates a likely pathogenic effect. Predictions are on ETFB protein with Uniprot identifier P38117-2 and WISP1 protein with Uniprot identifier O95388. 
rs79338777 is located in the ETFB isoform 2, which is not available in the SNPs&GO and PON-P2 web servers 
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Table R19. Functional Annotation Clustering from the DAVID tool (Enrichment score ≥ 1.3). 
Annotation cluster 1 Enrichment score: 2.79 
Category Term Count P Genes PFDR 
UP_SEQ_FEATURE 
N-linked 
glycosylation sites 
(GlcNAc...) 
72 1.8x10
-5
 
PVR, QRFPR, SLC8A3, A2M, OR10A4, SLC44A2, LTBP1, GBGT1, MMP8, FAM20C, CHPF2, 
RAET1E, WISP1, POMT1, VNN1, CEACAM5, LBP, CHST15, COL11A1, LAG3, CEACAM20, 
MATN4, KCND1, PCDHB6, OLFML2B, PCDHB4, CILP, BTNL2, PCDHGB6, SLC22A20, PKD2L1, 
OR6V1, GLRA4, LAMC1, GLP1R, TG, HLA-DQB1, CALCR, GPR108, FGFR4, SLC2A11, 
SERPINA10, BTN2A1, OR51F2, PSAPL1, CLEC10A, OR2G2, VWA5B1, DISP1, OR6A2, NUP210, 
UPK1A, BTN1A1, GALNS, EGF, PCSK6, ST6GAL2, CPA6, FOXRED2, OR6C74, STAB2, GPR151, 
SERPINI2, PXDNL, LAMA4, SLC4A11, STAB1, SLC17A1, P2RX2, DSC2, ADRA1A, ABCC2 
4.7x10-3 
UP_KEYWORDS Glycoprotein 74 3.8x10
-5
 
PVR, QRFPR, SLC8A3, A2M, OR10A4, SLC44A2, LTBP1, GBGT1, MMP8, FAM20C, CHPF2, 
RAET1E, WISP1, POMT1, VNN1, CEACAM5, LBP, CHST15, ANO7, COL11A1, LAG3, 
CEACAM20, MATN4, KCND1, PCDHB6, OLFML2B, PCDHB4, CILP, BTNL2, PCDHGB6, 
SLC22A20, PKD2L1, OR6V1, GLRA4, LAMC1, GLP1R, TG, HLA-DQB1, CALCR, GPR108, FGFR4, 
SLC2A11, SERPINA10, BTN2A1, OR51F2, PSAPL1, CLEC10A, OR2G2, DISP1, VWA5B1, OR6A2, 
NUP210, UPK1A, BTN1A1, GALNS, UGT2A2, EGF, PCSK6, ST6GAL2, CPA6, FOXRED2, 
OR6C74, STAB2, GPR151, SERPINI2, PXDNL, LAMA4, SLC4A11, STAB1, SLC17A1, P2RX2, 
DSC2, ADRA1A, ABCC2 
3.4x10-3 
Continue on next page 
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Category Term Count P Genes PFDR 
UP_SEQ_FEATURE 
Topological domain: 
cytoplasmic 
 
59 1.5x10
-4
 
PVR, QRFPR, SLC8A3, OR10A4, SLC44A2, GBGT1, TRPV3, CHPF2, RAET1E, CHST15, ANO7, 
ATP8B3, LAG3, CEACAM20, ATG9B, TRPM5, ATP4A, KCND1, PCDHB6, PCDHB4, BTNL2, 
PCDHGB6, SLC22A20, PKD2L1, TRPM1, LAX1, SUSD5, ERN2, OR6V1, GLRA4, GLP1R, HLA-
DQB1, CALCR, FGFR4, SLC2A11, CLDN19, BTN2A1, OR51F2, CLEC10A, OR2G2, NUP210, 
UPK1A, OR6A2, BTN1A1, EGF, ST6GAL2, NOX5, OR6C74, GJB3, GJB4, STAB2, GPR151, 
OR10H3, SLC4A11, STAB1, P2RX2, ADRA1A,DSC2, ABCC2 
0.028 
GOTERM_CC_FAT Plasma membrane 107 5.3x10
-5
 
LMO7, OR8S1, GRIN3B, LPHN2, OR4D2, CHRNA9, CD44, WNK4, GRID1, CLCA1, OR10S1, 
MYH1, PTPRN2, CDHR2, HLA-C, CTNNA3, LILRB4, GPR50, OR8B4, KBTBD10, DST, SNTG2, 
HDLBP, FGFR4, PANX1, AMTN, OR2T1, KEL, ENPP3, MAP4K2, PAQR7, ITGAM, KCNS3, CRB2, 
PLCH2, P2RY2, TRO, BAI2, B3GNT3, EGF, SLC28A3, ADAM28, EPB41, LPP, KCNB1, ITGA3, 
OR5AC2, GPR35, SLC4A11, EPS8, P2RX3, NOTCH4, TSC2, MAP7, OR51A7, PLA2G4E, CHRNG, 
TM7SF4, CLSTN2, CLSTN3, KCNJ12, CDSN, FCRL3, NMUR2, SDPR, OR6P1, KCNG4, RHOF, 
USH2A, OR2AE1, TRPM2, OR10J1, NCR3, CD86, TNFRSF10C, CLECL1, SLC26A9, GRM6, 
PLA2G3, NKD2, LRRC32, TAP2, COL6A2, COL6A1, CCBP2, PLA2R1, SLC39A4, OR8G2, 
PPP1R9B, COG4, OR51M1, CDH13, PROM2, ERBB2IP, NRAP, GPR110, SLC17A2, GPR113, 
MEP1B, ANXA13, GPR111, SYNM, TAPBPL, ABCC8, GFRA2, ABCC6, GPR116 
1.5x10
-2
 
Continue on next page 
Continued 
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Annotation cluster 2 Enrichment score: 2.15 
Category Term Count P Genes PFDR 
UP_SEQ_FEATURE 
Topological domain: 
cytoplasmic 
59 1.4x10
-4
 
PVR, QRFPR, SLC8A3, OR10A4, SLC44A2, GBGT1, TRPV3, CHPF2, RAET1E, CHST15, ANO7, 
ATP8B3, LAG3, CEACAM20, ATG9B, TRPM5, ATP4A, KCND1, PCDHB6, PCDHB4, BTNL2, 
PCDHGB6, SLC22A20, PKD2L1, TRPM1, LAX1, SUSD5, ERN2, OR6V1, GLRA4, GLP1R, HLA-
DQB1, CALCR, FGFR4, SLC2A11, CLDN19, BTN2A1, OR51F2, CLEC10A, OR2G2, NUP210, 
UPK1A, OR6A2, BTN1A1, EGF, ST6GAL2, NOX5, OR6C74, GJB3, GJB4, STAB2, GPR151, 
OR10H3, SLC4A11, STAB1, P2RX2, ADRA1A, DSC2, ABCC2 
0.028 
UP_SEQ_FEATURE 
Topological domain: 
extracellular 
50 8.8x10
-4
 
PVR, QRFPR, SLC8A3, SLC44A2, OR10A4, TRPV3, RAET1E, ANO7, ATP8B3, LAG3, CEACAM20, 
TRPM5, PCDHB6, PCDHB4, BTNL2, PCDHGB6, SLC22A20, PKD2L1, TRPM1, LAX1, SUSD5, 
OR6V1, GLRA4, GLP1R, CALCR, HLA-DQB1, FGFR4, SLC2A11, CLDN19, BTN2A1, OR51F2, 
CLEC10A, OR2G2, UPK1A, OR6A2, BTN1A1, EGF, NOX5, GJB3, OR6C74, GJB4, STAB2, 
GPR151, OR10H3, SLC4A11, STAB1, P2RX2, ADRA1A, DSC2, ABCC2 
0.029 
Gene-set enrichment analysis of gene-based P-values from SKAT-O was performed using the functional annotation clustering analysis module of the bioinformatic tool DAVID. Each annotation term 
group is assigned an enrichment score to rank overall importance. Only annotation clusters with ES≥1.3 (indicating biological significance) and significant P-values after FDR correction are shown. The 
significance of gene-term enrichment was assessed with a modified Fisher´s exact test and P-values are corrected using Benjamini-Hochberg’s by false discovery rate (FDR-BH) procedure. 
Continued 
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Progress made in oncology treatment over the last half of the century has led to an increase 
in cure rates and overall survival. Although more patients are surviving cancer than ever before 
and even with current therapies, some cancer patients, such as those with metastatic and/or 
recurrent/refractory Ewing sarcoma58, have a dismal prognosis; and/or suffer ADRs which 
compromise treatment efficacy and patient´s quality of life (such as CiHFS84,85) and many are left 
with irreversible, life-threatening and long-lasting toxicities (such as chronic AIC104). The 
prediction of drug efficacy and drug side effects to allow therapy individualization is very 
important in cancer chemotherapy, given that antineoplastic agents are, in general, nonspecific 
with a narrow therapeutic index5; and cancer incidence is expected to rise over the next several 
decades194.  
 
Large interpatient variability observed in both, the efficacy and toxicities associated with 
chemotherapeutics drugs, although is multifactorial can be explained in part by the host genetic 
background. In this thesis we particularly focused on the identification of germline genetic 
variants that predict treatment outcome in children diagnosed with Ewing sarcoma, an 
aggressive pediatric tumor with a huge unmet need to improve the outcome in patients with 
metastatic disease and also in the recurrent setting58 (Study I). In addition, we focused on the 
identification of genetic variants associated with increased risk to develop CiHFS (a common skin 
adverse event and the most frequent cause for capecitabine dose reduction or therapy 
discontinuation84) (Study II) and chronic AIC (a serious adverse drug reaction limiting 
anthracycline use and causing substantial morbidity and mortality114) (Study III and Study IV). 
1. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma 
treatment outcome (Study I) 
Over the last four decades, the outcome of patients with localized Ewing sarcoma has 
improved considerably; however, drug-resistant disease at diagnosis or at relapse remains a 
major cause of mortality among pediatric patients diagnosed with Ewing sarcoma56,140. Although 
candidate gene approaches have been broadly used in oncology and numerous studies of 
somatic prognostic biomarkers have been performed in Ewing sarcoma; there is a lack of studies 
exploring how germline genetic variation in genes that play an important role in the 
pharmacokinetics of the commonly used cytotoxics in Ewing sarcoma therapy would affect both, 
treatment efficacy and patients´ overall survival. Owing to these, we performed the first study 
considering an integrated pathway-based approach and assessed associations with treatment 
outcome in a discovery cohort of 106 Spanish children diagnosed with Ewing sarcoma with 
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replication in a large independent cohort of 389 pediatric Ewing sarcoma patients from across 
Europe.  
 
We identified variants significantly associated with tumor response in the discovery cohort, 
but we were not able to replicate these associations in the European cohort. This lack of 
association with tumor response could be explained by treatment heterogeneity in the 
neoadjuvant setting within each cohort and between patient series. However, including 
neoadjuvant therapy as an additional covariate in statistical analyses between genotypes and 
tumor response made no substantial difference to the results obtained. Lack of association could 
be also explained by considering together patients with localized and metastatic disease. We 
decided to consider metastatic patients and non-metastatic patients together, but including 
metastasis as covariate, to increase both the sample size and the statistical power; but still 
sample size might be underpowered to detect associations with tumor response. 
 
In addition, we tested associations between SNV genotypes and overall survival. We 
identified and replicated the associations for three common variants, rs7190447, rs4148737 and 
rs11188147, located in ABCC6, ABCB1 and CYP2C8 genes, respectively. Both ABCC6 and ABCB1 
genes are members of the ATP-binding cassette (ABC) transporter superfamily. These 
transporters translocate a variety of substrates, including chemotherapeutic agents through 
biomembranes against a concentration gradient, with ATP hydrolysis providing the driving force. 
The major physiological role of ABC transporters is to protect normal cells and tissues against 
exogenous toxins, thereby also affecting to the uptake and distribution of anticancer drugs in 
the human body. Importantly, overexpression of some ABC members, such as ABCB1, ABCC1 or 
ABCG2 contribute to chemoresistance by active extrusion of cytotoxic agents from the tumor 
cell195,196. Little is known about the physiological role of ABCC6, including its natural substrates or 
its role in drug excretion197. ABCC6 is mainly expressed in the basolateral membrane of 
hepatocytes and in proximal kidney tubules198. Basolateral efflux transporters mediate the 
removal of endogenous and xenobiotics compounds from hepatocytes into blood. The role of 
ABC transporters located at the basolateral membrane of hepatocytes in detoxification of drugs 
it has been suggested to be minor compared to proteins located at the canalicular membrane, 
but is not well understood. It has been found that the expression of basolateral ABC proteins, 
such as ABCC1 and ABCC3 is increased when hepatic bile excretion is blocked (cholestasis), 
favoring renal elimination198,199. In contrast to ABCC1 and ABCC3, ABCC6 is significantly 
expressed in normal liver and its expression is not induced in ABCC2-deficient rats or during 
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cholestasis. Given this constitutive expression, a “housekeeping” function has been proposed for 
ABCC6 in hepatocytes200, but it has to be further explored. On the other hand, the role of ABCC6 
in renal drug handling remains to be defined201. Regarding the role of this gene in multidrug 
resistance, ABCC6 can mediate the transport of several chemotherapeutic agents including 
etoposide, doxorubicin and actinomycin-D (drugs administered to Ewing sarcoma patients) and 
cisplatin, although the levels of resistance are significantly lower to those observed for ABCC1 
and ABCC2202,203. In addition, RNA expression profiling revealed that ABCC6 is expressed in 
tumors of patients with localized Ewing sarcoma (but at low levels compared to liver and 
kidney)204, so a role for ABCC6 in multidrug resistance of Ewing sarcoma cells could not be ruled 
out. To date, it remains to be determined whether intronic polymorphisms in ABCC6 have an 
impact on gene expression and, hence their effect on drug disposition205,206. Recent studies have 
demonstrated that variants in non-transcribed regions can influence gene expression through 
regulatory mechanisms207. ENCODE and HaploReg data suggest that the genomic region 
containing rs7192303 (in perfect LD with our replicated variant, rs7190447) might be regulatory. 
Based on these data, the SNV rs7192303 can potentially affect CTCF and cohesin binding to DNA. 
The mammalian genome is organized by large regions [topologically associating domains (TADs)] 
defined by high levels of chromatin interaction within the region and little or no interaction with 
neighbouring regions208,209. Approximately 70% of chromatin looping events, which facilitate 
gene regulation by distant regulatory elements, occur within TADs. The typical length scale of 
chromatin looping is 10–200 kb, whereas that of TADs can be as large as 2000 kb210. CTCF is a 
highly conserved protein that has been classically considered an insulator211; whereas cohesin is 
a ring-shaped complex with a crucial role in establishing sister chromatid cohesion212. In addition 
to these well-established functions, CTCF and cohesin colocalize and cooperate to control gene 
expression and genomic organization. CTCF is involved in promoting long-range interactions and 
DNA looping and TAD boundaries are typically defined by CTCF binding sites. A large number of 
cohesin-binding sites colocalize with CTCF-binding sites and it has been shown that cohesin is 
required for the stabilization of chromatin loops at certain loci. Both, cohesin and CTCF 
contribute to long-range chromatin contacts within the TADs211,213,214. CTCF-mediated chromatin 
interactions determined by chromatin interaction analysis with paired-end tag (ChIA-PET) in 
ENCODE have been analyzed to date in five different human cancer cell lines [(K562 (chronic 
myeloid leukemia), HCT116 (colorectal cancer), HeLa-S3 (cervical cancer), MCF-7 (breast cancer), 
and NB4 (promyelocytic)], but none of them are hepatic or Ewing sarcoma cell lines. However, 
ChIA-PET analysis in MCF-7 cells revealed that the rs7192303 overlapping region has the 
potential to form a CTCF-mediated chromatin loop with an upstream intronic region of ABCC6 
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gene and with an intronic region of the upstream gene ABCC1. Interestingly, rs7192303 is an 
eQTL in the liver. Although ChIP-seq for CTCF and cohesin or 4C-seq experiments in hepatocytes 
and Ewing sarcoma cells should be performed in order to confirm the specific interactions 
affected by rs7192303; we hypothesize that differences in ABCC6 expression caused by changes 
in CTCF and/or cohesin binding due to rs7192303 could affect the efflux of ABCC6 target-drugs 
used in Ewing sarcoma standard treatment, thus affecting systemic bioavailability of anticancer 
agents and intracellular drug levels in tumor cells; which ultimately determines treatment 
response and patient survival. 
 
ABCB1 (P-glycoprotein) was the first ABC transporter identified and has become the most 
studied gene in the field of multidrug resistance. ABCB1 is expressed in the intestine, liver, 
kidney, the blood-brain and placental barriers, with apical membrane localization. The 
expression pattern and the broad substrate specificity, make ABCB1 a major player in drug 
absorption, disposition and elimination199,215. Of the drugs administered to Ewing sarcoma 
patients, etoposide, vincristine, doxorubicin and actinomycin-D are transported by this pump216. 
ABCB1 mRNA and/or protein expression has been frequently detected in tumor samples and 
reported to be associated with clinical outcome in several reports216,217. Along with ABCC1, 
ABCB1 is the only ABC gene that has been investigated in some detail in Ewing sarcoma; 
however, the findings of published studies are contradictory with two suggesting that ABCB1 
protein expression in Ewing sarcoma tumors is not predictive of prognosis218,219, and a third 
significantly linking protein expression in tumors to poor response to therapy220. Genetic 
polymorphisms in ABCB1 have been reported to change mRNA/protein expression and function, 
however little attention has been given to intronic and non-coding variants in this gene, and 
their possible link to cancer221. Consistent with a previous study performed by my own group in 
which a significant association for the minor G allele of rs4148737 with poorer overall survival in 
pediatric osteosarcoma patients was reported141, in the current thesis we observed that the GG 
genotype was associated with higher risk of death, suggesting that rs4148737 may be important 
as a prognostic marker after treatment in the two most common pediatric bone tumors 
(osteosarcoma and Ewing sarcoma). In addition, rs4148737 was predicted to affect RUNX3 
binding to DNA. It has recently been shown that Ewing sarcoma tumors express RUNX3 and that 
RUNX3 binds to EWS/FLI. In addition, suppression of RUNX3 causes a reduced growth of Ewing 
sarcoma cell lines and disrupts the expression of EWS/FLI-regulated genes, indicating an 
oncogenic role for RUNX3 in Ewing sarcoma tumors222. 
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CYP2C8 is a member of the human CYP2C enzyme family, which collectively are significant 
contributors to drug disposition and are responsible for the metabolism of about 20% of 
clinically available drugs. It is highly expressed in liver, but is also found in extrahepatic sites such 
as the kidney, brain, uterus, mammary gland, ovary, heart, adrenal gland and duodenum. 
CYP2C8 plays a major role in the oxidative metabolism of many drugs (e.g., thiazolidinediones, 
meglitinides, nonsteroidal anti-inflammatory drugs), but also chemotherapeutics, including two 
of those used in Ewing sarcoma treatment (cyclophosphamide and ifosfamide)223–226. Although it 
has been shown that there is great interindividual variation in the metabolism of CYP2C8-specific 
substrates and in CYP2C8 expression223,227, nothing has previously been reported about the 
impact of CYP2C8 polymorphisms and their implications for clinical outcome in patients treated 
with cyclophosphamide and ifosfamide. 
 
While one might expect the three replicated genetic variants also to be associated with 
tumor response, we didn´t observe this association. The evaluation of tumor response after 
administration of Ewing sarcoma neoadjuvant therapy, when chemotherapy treatment had not 
been completed, could explain the lack of observed association with this clinical feature, 
particularly bearing in mind that ABCB1 and ABCC6 not only transport neoadjuvant drugs but 
also adjuvant chemotherapeutics, and CYP2C8 is in part responsible for the oxidative 
metabolism of neoadjuvant and adjuvant Ewing sarcoma agents. Low statistical power because 
of low sample size of the study could be also a reason for the failure to identify associations. 
 
In conclusion, we have carried out a two-stage study using a multi-drug 
transport/metabolism pathway approach, and identified for the first time germline genetic 
variants in the ABCC6, ABCB1 and CYP2C8 genes significantly associated with overall survival in 
Ewing sarcoma patients. The results of our study, which have been replicated in a large cohort of 
patients, emphasize the clinical relevance of these genes as prognostic marker genes, although 
experimental verification of putative regulatory function for the identified variants will be 
required. 
 
 
2. Identification of genetic variants predictive of susceptibility to capecitabine-induced hand-
foot syndrome (CiHFS) (Study II) 
CiHFS is a common dose-limiting toxicity of capecitabine, occurring in more than 30% of 
patients. If not promptly managed, CiHFS can progress to an extremely painful and disabling 
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condition (grade 3 toxicity), causing impairment of function and significant discomfort, leading 
to treatment withdrawal, dose reduction and worsened quality of life of these patients (~17% of 
capecitabine-treated patients)80,84,85.  
 
The most comprehensive analysis performed to date of capecitabine toxicity 
pharmacogenetics is the QUASAR2 (Quick and Simple and Reliable trial) study97. They evaluated 
associations between previously reported variants (36 variants), all of them in genes involved in 
the biochemical pathway of capecitabine activation, action or degradation; with common 
capecitabine toxicities, including CiHFS, in 927 colorectal cancer patients treated with standard 
capecitabine regimen following surgery resection of stage II/III tumors. They also performed a 
meta-analysis of QUASAR2 and 16 published studies (N=4,855 patients) (included one study 
focused on candidate genes performed by my own group93) to examine candidate 
polymorphisms in capecitabine and 5-FU monotherapy but also in combination therapy 
protocols. They found only four variants: DPYD 2846TA, DPYD*2A, TYMS 5´ VNTR 2R/3R and 
TYMS 3´ UTR 6bp ins-del, significantly associated with global high grade capecitabine toxicity, 
especially those variants in the DPYD enzyme (combined OR: 5.51). These variants remain 
significantly associated when CiHFS was the only toxicity evaluated, but none of them was 
associated with global or any specific toxicity when combination regimens were administered. 
Interestingly, when they assessed the prediction capacity of global toxicity of DPYD and TYMS 
variants, they found that these variants had only a modest power to predict capecitabine 
toxicity. These results underscore that the interindividual variability in CiHFS susceptibility 
remains largely unexplained and the urgent need to identify valuable predictive markers to 
accurately stratify patients at high risk for CiHFS, but also to elucidate the precise molecular 
mechanisms underlying this common ADR. By combining GWAS analysis, fine-scale mapping, 
and functional analyses using human skin cells and tissues, we provide for the first time 
compelling evidence that CDH4 regulatory variants are involved in the development of CiHFS. 
More important, we found that levels of R-cadherin and involucrin are lower in the skin of 
patients who go on to develop severe CiHFS compared to patients who don’t, prior to 
capecitabine treatment; uncovering a novel mechanism of CiHFS susceptibility via the 
perturbation of the skin barrier function.  
 
Of note is in this study we considered exclusively patients showing extreme phenotypes; 
those patients suffering the most severe form of CiHFS toxicity (grade 3) and those not 
experiencing any toxicity during capecitabine treatment (grade 0). Given that CiHFS toxicity is 
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probably a polygenic trait and is measured using a scale-classification system, selecting most-
sensitive and most-resistant patients it deemed essential to evaluate only highly informative 
patients having an unequivocal phenotype; but also the use of this extreme phenotype sampling 
enriches the presence of causal variants in the patients, increasing the probability of discovering 
associations. On the other hand, patients included in the study were treated with capecitabine 
monotherapy, avoiding overlapping toxicities and interactions between drugs.  
 
The vast majority of disease-associated SNVs identified by using commercial probe-based 
genotyping array platforms are located in non-coding regions of the genome, equally 
proportioned between the intergenic and intronic regions36,228,229 and many are expected to be 
eQTLs230. Thus, it is likely that the underlying mechanism linking them to the disease is through 
gene regulation. Schaub et al.231 studied 4,724 SNVs from the GWAS catalog36 associated with 
470 different phenotypes using ENCODE data, and found that 36% of the variants are in DNase-
hypersensitive regions (regions that correspond to areas of open, accessible chromatin that 
contain binding motifs for transcription factors) and 20% are in a ChIP-seq cluster in at least one 
cell line. Ernst et al.232 generated a genome-wide map of nine chromatin marks across nine cell 
types to systematically characterize regulatory elements. They found a 2-fold enrichment for 
predicted strong enhancers among the associated SNVs from 426 GWAS and several of these 
variants created or disrupted transcription factor motifs in the identified enhancers. However, 
understanding how allele-specific genetic variation affects gene expression requires a complete 
and cell type specific picture of both the spatial organization and the functional features of each 
locus. Tang et al.233 used the ChIA-PET technique to comprehensively map the chromatin 
organization and specific interactions mediated by CTCF and also by RNA polymerase II. They 
found that SNVs located at chromatin contact boundary regions and within the core CTCF 
binding motif, can abrogate CTCF binding, looping, and chromatin topology. They also found that 
several of disease-associated SNVs resides in CTCT motifs, dramatically altering chromatin 
organization, sustaining the possibility that changes in chromatin topology driven by SNVs could 
be the primary molecular event underlying disease susceptibility. Interestingly, only 25% of SNVs 
found in 51 different lymphoblastoid cell lines genotyped as part of the 1000 Genomes project 
were located exactly in the core CTCF binding motif, but the vast majority were in nearby regions 
(within 1 kb of the motif)234. Although is not yet known the functional relevance for chromatin 
topology of SNVs that are nearby but not exactly map with CTCT motifs; several works suggest 
that flanking sequences outside the core binding motif can profoundly affect transcription factor 
binding to DNA (through affecting DNA shape properties such as minor groove width, roll; or 
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composition of poly(dA:dT) tracts)235,236. The four highly correlated variants associated with 
susceptibility to CiHFS identified in our study are nearby to CTCF or cohesin binding sites, but 
they did not overlap exactly with the core motifs; however, our 4C-seq experiments revealed a 
physical interaction between the CDH4 promoter and the risk alleles containing region in the 
presence of the risk alleles. This interaction was clearly decreased in a different keratinocyte cell 
line homozygous for the reference haplotype. Although this result is not sufficient to conclude 
that the presence of the risk alleles is responsible for the observed changes in the contact 
profile, it certainly points in this direction. One interesting possibility would be that the presence 
of these risk variants creates new binding sites of some of the aforementioned factors, 
generating a contact that negatively regulates CDH4 expression; although ChIP-seq experiments 
for CTCF and cohesin should be performed to explore this hypothesis. Importantly, we found 
that the haplotype carrying the risk alleles produced a significant decrease in CDH4 mRNA 
expression and correlated with reduced protein levels.  
CDH4 encodes R-cadherin. Cadherins constitute a large family of cell surface proteins, many 
of which participate in Ca2+-dependent cell-cell adhesion through the establishment of adherens 
junctions and desmosomes; playing a fundamental role in the preservation of proper tissue 
architecture and function237,238. The epidermis is composed of four functionally different layers 
of keratinocytes at different stages of differentiation, which undergo programmed 
differentiation to allow for constant renewal of the skin. Epidermal differentiation begins with 
the migration of keratinocytes from the basal layers, and ends with the formation of the 
cornified layer. Cell proliferation, differentiation and death occur sequentially, and each process 
is characterized by the expression of specific proteins, and specific diseases can result from 
abnormalities in these proteins191. Epidermal keratinocytes express two classic cadherins: E- and 
P-cadherin, with different epidermal expression patterns. While E-cadherin is found in all 
epidermal layers, P-cadherin is restricted to the basal layer, the innermost layer of the epidermis 
with keratinocytes in a proliferative stage239,240. On the other hand, mutations in cadherins are 
known to cause inherited skin disorders, such as the ectodermal dysplasia, ectrodactyly, and 
macular dystrophy syndrome or striate palmoplantar keratoderma, which is characterized by a 
thickening of the skin on the palms of the hands and the soles of the feet184. R-cadherin is highly 
expressed in brain and plays an essential role during brain segmentation and in neuronal 
outgrowth; and is important for kidney and striated muscle development241,242; however 
whether or not R-cadherin plays a role in skin physiology or pathology has not yet been 
investigated. We found that R-cadherin distribution in human epidermis differed from that for E 
and P-cadherin, with R-cadherin mainly localized in the suprabasal granular layer of the human 
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epidermis, where keratinocytes are in a differentiated stage. That R-cadherin is highly expressed 
by differentiated keratinocytes was confirmed by in vitro assays. Interestingly, we observed that 
decreased R-cadherin expression leads to a decrease of involucrin, at both mRNA and protein 
levels, but not affecting others differentiation markers. Involucrin is a structural protein of the 
cornified envelope, the outermost layer of the epidermis composed of terminally differentiated 
keratinocytes (corneocytes). The cornified envelope consists of keratins enclosed within tightly 
knit proteins, which are crosslinked by transglutaminases and surrounded by a lipid envelope; 
and is essential for the mechanical integrity and water impermeability of the skin191,238. Several 
lines of evidence suggest that involucrin is an early component in the assembly of the cornified 
envelope243,244, acting as a scaffold, to which other proteins such as cystatin α, elafin, small 
proline-rich proteins, and loricrin subsequently become crosslinked to complete the cornified 
envelope assembly. In addition, involucrin might be the preferred protein substrate for the 
covalent attachment of ceramides to form the exterior surface of the cornified envelope191,238. 
Surprisingly, mice lacking individual components of the cornified envelope, such as loricrin245, 
involucrin246, periplakin247 and envoplakin248, developed normally and possessed apparently 
normal epidermis and hair follicles and no obvious cornifed envelope abnormalities; while the 
combined loss of involucrin, envoplakin, and periplakin249 impairs the epidermal barrier; 
suggesting a compensatory redundancy between these proteins. Although involucrin deficiency 
may not directly alter skin function, consistent with the lack of symptoms we observed in the 
skin of the patients prior capecitabine treatment; mutations in the granular layer and cornified 
envelope components are thought to contribute to genetic susceptibility to chronic barrier 
defects, as in atopic dermatitis250,251; and altered expression of involucrin has been found in skin 
diseases characterized by disturbance of cornification, such as psoriasis252 and lamellar 
ichthyosis253. We hypothesize that reductions in involucrin may increase the cytotoxic effect of 
capecitabine leading to a breakdown of the skin epidermal barrier. This effect could be 
particularly dramatic in the palms of the hands and soles of the feet, due to their higher 
epidermal cell division rate, greater expression of capecitabine-metabolizing enzymes (including 
TYMP and DPYD), leading to the accumulation of capecitabine metabolites and catabolites; 
increased vascularization, pressure and temperature; as well as increased local drug elimination 
by the eccrine glands of these areas84,87.  
 
Taken together, our results reveal a novel implication of R-cadherin in the regulation of 
keratinocyte differentiation through involucrin expression, although further studies are needed 
to explore how R-cadherin goes beyond this structural function to regulate gene expression. 
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Importantly, R-cadherin and involucrin levels present in the skin of the patients sampled prior to 
capecitabine treatment inversely correlate with CiHFS upon treatment, which could be useful for 
patients risk stratification.  
 
In summary, using a multifaceted approach, we have unearthed a novel risk locus strongly 
associated with CiHFS susceptibility. Our results open new and unprecedented avenues for 
future research, to deepen our knowledge of the pathogenic mechanisms underlying CiHFS, and 
provide novel insight into the clinical application of the identified risk variants along with the R-
cadherin and involucrin expression as predictive biomarkers of CiHFS as a further step towards 
personalized cancer treatment. 
3. Role of low-frequency variants in susceptibility to chronic anthracycline–induced 
cardiotoxicity (AIC) (Study III and Study IV) 
Life-threatening or permanently disabling complications of therapy can occur despite the 
administration of medications at the recommended dose. Long-term cardiotoxicity is a well 
known complication of anthracycline treatment; however, clinicians remain unable to accurately 
stratify patients into high or low-risk groups for AIC and genetic factors influencing AIC 
susceptibility are still largely unexplained. In order to explore the contribution of coding variants, 
especially low-frequency and rare variants, to susceptibility to AIC we performed an exome array 
analysis considering variants on the Illumina HumanExome BeadChip array. Considering that 
children are particularly vulnerable to the cardiotoxic effect of anthracyclines, even more than 
adults and/or at lower doses, in Study III we focused on the identification of susceptibility 
variants in anthracycline-treated pediatric patients diagnosed with Ewing sarcoma, 
osteosarcoma or leukemia; while in Study IV, we focused on adult patients diagnosed with 
breast cancer, but also in pediatric patients.  
 
Regarding the demographic and clinical characteristics of the 93 anthracycline-treated 
pediatric cancer patients (Study III), of note is that controls were significantly younger than cases 
and gender distribution in our cohort showed more female patients in controls than in cases 
patients, although it is well known that younger patients and girls are particularly vulnerable to 
AIC. Remarkably, osteosarcoma and Ewing Sarcoma were primary diagnosis significantly more 
common in cases than in controls. High rates of osteosarcoma and Ewing Sarcoma among cases, 
may be explained because patients diagnosed with this type of pediatric bone tumors received 
higher cumulative anthracycline doses, than those diagnosed with leukemia [median cumulative 
anthracycline dose (mg/m2)= 446.2 (osteosarcoma); 361.2 (Ewing sarcoma) and 132 (leukemia)]. 
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Although we decided not to include the tumor type as a covariate in the corresponding 
statistical analyses given the greater anthracycline doses of solid tumors in our series and even 
we know about the multicollinearity issues; inclusion of primary diagnosis as an additional 
covariate in multivariable models made no substantial difference to the results obtained. 
Regarding the demographic and clinical characteristics of the breast cancer patients in Study IV, 
more patients in the Belgium cohort experienced chronic AIC compared to the Spanish breast 
cancer cohort, although Belgium patients were treated with epirrubicin, which has improved 
cardiac tolerability compared to doxorubicin109.  
 
Using standard single-variant association tests, none of the 246,060 variants analyzed was 
found to be statistically significantly associated with chronic AIC after correction for multiple 
comparisons, neither in pediatric patients (Study III) nor in breast cancer patients (Study IV). 
Because the number of rare variants is much larger and rare variants are less correlated with 
each other than common variants, more stringent significance thresholds that those typically 
employed in GWAS are required, reducing the statistical power (especially in cohorts with small 
sample size and few patient cases, as our patient series)53,254,255. Instead of testing each variant 
individually, we focused on gene-based tests that have greater statistical power to detect 
associations with rare variation and can evaluate the cumulative effect of multiple genetic 
variants (including both, common and rare) within a gene255. As it was mentioned in the 
introduction, some genes/regions may have a high proportion of causal variants and influence 
the phenotype in the same direction while others may have few causal variants or the causal 
variants may have different directions of association. Therefore, the use of methods optimal for 
both scenarios, such as the combined gene-based test SKAT-O applied in Study III and IV, is 
desirable55,166. 
 Using this kind of approach, we have identified GPR35 as the gene most significantly 
associated with chronic AIC in children (Study III). GPR35 belongs to the G-protein-coupled 
receptor family, which are membrane proteins mediating a wide range of physiological 
processes256. Although the exact functions of GPR35 are not known, several lines of evidence 
strongly suggest potential roles for this receptor in cardiac physiology and pathology. Sun et 
al.257 were the first to report a cardiovascular role for GPR35, with a common non-synonymous 
SNV (rs3749172) significantly associated with the burden of coronary artery calcification, a 
subclinical measure of atherosclerosis and coronary artery disease. Importantly, this variant, 
rs3749172, is the only genetic variant in GPR35 reported to be associated with cardiovascular 
disease to date, and no further studies have explored the contribution of genetic variants in 
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GPR35 to cardiovascular diseases. rs3749172 is covered by the exome array we used, however, 
this variant was not significantly associated with chronic AIC in children (OR=1.82, P=0.148, 
PFDR=0.96). GPR35 was later found to be up-regulated in failing myocardium of 12 patients with 
severe chronic heart failure by performing gene expression microarray analysis, and in the same 
study GPR35 knock-out mice showed higher systolic blood258. More recently, GPR35 has been 
characterized as a novel hypoxia-sensitive gene, with hypoxic conditions (mediated by hypoxia-
inducible factor 1 activation, HIF-1) causing increased expression at both mRNA and cell surface 
protein levels in neonatal mice cardiomyocytes. In a mouse surgical model of acute myocardial 
infarction and hypertrophy GPR35 behaved as a typical hypoxia response gene: its expression 
increased in early phases of cardiac infarction, but unaltered at later phases; suggesting that 
GPR35 is an early marker of progressive cardiac failure259. In vitro functional assays in neonatal 
rat cardiomyocytes demonstrated that GPR35 overexpression reduced cell viability and caused 
hypertrophy204, whereas in neonatal mouse cardiomyocytes promoted morphological changes, 
including membrane ruffling and retraction fibre formation259. Remarkably, several studies have 
linked GPR35 to inflammatory regulation260,260 and there is ample evidence to support the 
hypothesis that inflammation, as well as hypoxia, play a significant role in the pathogenesis and 
development of chronic cardiac complications, including cardiomyopathy261,262. These findings 
provide a possible explanation for the involvement of this receptor in cardiovascular disease. On 
the other hand, the cellular and biological effects of GPR35 on cardiovascular pathophysiology 
could be largely mediated by downstream signaling pathways such as Gα13, Gαi/o and RhoA, 
following receptor activation263–266. Interestingly, putative endogenous ligands of GPR35 have 
also been linked to cardiovascular disease: lysophosphatidic acid has been associated with 
regulation of blood pressure and atherosclerosis267; and levels of kynurenic acid and reverse 
thyroid hormone T3 were found to increase (and T3 to decrease) in spontaneously hypertension 
rats268 and in patients with chronic advanced heart failure269 or acute myocardial infarction270, 
respectively. While the SKAT-O does not provide any parameter estimates, like OR in logistic 
regression, we assessed the individual contribution of variants within GPR35. We found that 
rs12468485, a missense low-frequency variant (p.Thr253Met), strongly associated with the most 
severe cardiac manifestations (LV dysfunction, mostly symptomatic, evidenced after treatment 
with anthracycline doses well below the average for cases), was most influential. Although in 
silico prediction algorithms yielded discrepant results, rs12468485 was predicted to a have a 
potentially regulatory role in splicing. Due to the incomplete coverage of coding variants on the 
exome array, we sequenced the coding region of GPR35 in our series of 93 anthracycline-treated 
 Discussion 
 
167 
 
pediatric cancer patients but we were unable to identify additional independent association 
signals at the gene.  
 
On the other hand, gene-based analysis in anthracycline-treated breast cancer patients 
revealed that variant alleles of low-frequency missense variants in ETFB and WISP1 genes 
significantly increased chronic AIC risk (Study IV). ETFB is the β subunit of the heterodimer 
electron transfer flavoprotein (ETF) protein located in the inner mitochondrial membrane. ETF 
acts as an electron acceptor of energy production from amino acid and fatty acids that transfers 
electrons to the main respiratory chain via the ETF-ubiquinone oxidoreductase (ETF-QO)271. 
Anthracycline therapy is known to inhibit long chain fatty acid oxidation and transport across 
mitochondrial membrane272 and decrease ATP production273; and oxidative stress has been 
proposed as a major contributor to anthracycline mediated myocardial injury109,274. Analysis of 
protein expression in doxorubicin-treated adult rat cardiomyocytes revealed differential 
downregulation of ETFB275. In addition, proteomic analyses of cardiac proteins from mice treated 
with doxorubicin showed elevated oxidative modifications of cardiac proteins, including ETF-QO, 
and these oxidative modifications altered their enzymatic activity276, thus compromising ATP 
production in cardiac mitochondria. Taken together, these findings indicate that ETF is an 
important target in anthracycline-mediated oxidative stress. Remarkably, we found that 
rs79338777 variant allele carriers were scarce among control patients in the three independent 
cohorts we assessed, and the variant allele was significantly associated with higher risk of 
chronic ACT when the two breast cohorts and the pediatric series were analyzed together. This 
low-frequency missense variant was predicted to have a pathogenic effect by three of the in 
silico prediction algorithms used, including the consensus classifier.  
 
WISP1 is a member of the CYR61/CTGF/Nov family of growth factors which although 
expressed in the heart at low basal levels; it mediates cardiac remodeling after myocardial 
infarction277 and is upregulated in postinfarct myocardium278. More recently, Venkatesan et al193. 
reported that WISP1 inhibits doxorubicin-mediated cardiomyocyte death by blocking 
doxorubicin-induced p53 activation, p38 MAPK and JNK phosphorylation, Bax translocation to 
mitochondria, and cytochrome c release into cytoplasm. Collectively, these findings strongly 
indicate a pro-survival function for WISP1, antagonizing cardiomyocyte death in response to 
various adverse and stress conditions; including anthracycline administration. Although 
rs72731540 was predicted to be non-pathogenic, the majority of variant allele carriers suffered 
chronic AIC in all the three cohorts and the variant allele exhibit a significant greater risk of AIC. 
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rs79338777 in ETFB and rs72731540 in WISP1 were associated with risk independently of the 
age of tumor onset, pointing out oxidative stress and the prosurvival function mediated by 
WISP1 as shared molecular mechanisms between children and adults. On the contrary, the 
variant allele of rs12468485 in GPR35 was almost exclusively present in cases in the Spanish 
pediatric cancer cohort, while it was found in controls in the Spanish breast cancer series. The 
opposite direction of association for rs12468485 between children and adults, point out the 
possibility that the molecular mechanism underlying AIC and mediated by GPR35 could be 
exclusive or particularly relevant for cancer survivors of childhood cancers. 
 
Both studies are limited in its ability to look at single-associations for very rare variants and 
detection of low-frequency variants with moderate effects due to a small sample size of the 
cohorts and the incomplete coverage of all coding variants at each locus provided by the exome 
array. However, the strengths of both studies included the well-characterization of the series of 
patients included in both studies, with extensive patient, tumor and therapy-related 
information; and notable long-term follow-up of all individuals. 
 
In conclusion, we identified novel low-frequency coding variants associations and we 
extended the allelic spectrum of variation underlying chronic ACT susceptibility in children and in 
adults treated with anthracyclines. However, functional characterization of the observed 
associations and further replication in very large studies are required. 
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1. The studies carried out in this thesis have led to the identification of susceptibility genetic 
variants associated with treatment outcome in Ewing sarcoma patients and the 
development of adverse drug reactions in capecitabine-treated and anthracycline-treated 
cancer patients.  
 
2. We have identified three germline variants in ABCC6, ABCB1 and CYP2C8 associated with 
overall survival in Ewing sarcoma patients. These associations were replicated in a large 
independent cohort, highlighting the importance of these pharmacokinetic genes as 
prognostic markers in Ewing sarcoma. 
 
3. We have identified and replicated in an independent cohort a locus near the CDH4 gene, 
which encodes R-cadherin, a protein mainly localized in the granular layer of the epidermis, 
strongly associated with the development of severe capecitabine-induced hand-foot 
syndrome. 
 
4. We demonstrated that these risk variants prompted changes in CDH4 gene expression, 
possibly through changes in chromatin topology; uncovering a novel mechanism underlying 
individual genetic susceptibility to capecitabine-induced hand-foot syndrome through 
impairment of keratinocyte differentiation and function and skin barrier disruption.  
 
5. In the skin from breast cancer patients sampled prior to capecitabine administration, we 
have found that the levels of R-cadherin protein and involucrin, a protein of the cornified 
envelope essential for skin barrier function, were inversely correlated with the appearance 
of capecitabine-induced hand-foot syndrome.  
 
6. We have identified GPR35, a gene with important roles in cardiac physiology and pathology, 
and in particular rs12468485, a missense low-frequency variant, as an independent risk 
factor for chronic anthracycline-induced cardiotoxicity in pediatric oncology patients 
treated with anthracyclines.  
 
7. Using gene-based analyses, we have identified two novel genes: ETFB and WISP1 associated 
with risk of developing chronic anthracycline-induced cardiotoxicity in breast cancer 
patients. Further analyses revealed that the low-frequency missense variants rs79338777 in 
ETFB and rs72731540 in WISP1, significantly increased risk of chronic anthracycline-induced 
cardiotoxicity, independently of whether patients were adults or children at diagnosis.  
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8. Our results demonstrate the utility of whole-exome genotyping arrays to detect low-
frequency variants implicated in adverse drug events such as anthracycline-induced 
cardiotoxicity. 
 
9. While replication of these findings in large independent series of patients is essential before 
these genomic biomarkers can be used in clinical practice for cancer patients, our results open 
up a promising new avenue for the individualization of treatment strategies.  
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1. Los estudios llevados a cabo en esta tesis doctoral nos han permitido identificar 
variantes genéticas asociadas con la respuesta al tratamiento y supervivencia en 
pacientes infantiles diagnosticados con sarcoma de Ewing y a la aparición de efectos 
adversos producidos por los quimioterapéuticos capecitabina (síndrome mano-pie) y 
antraciclinas (cardiotoxicidad crónica).  
 
2. Hemos identificado 3 variantes germinales en los genes farmacocinéticos ABCC6, ABCB1 
y CYP2C8 asociados con supervivencia global en pacientes oncológicos infantiles 
diagnosticados con sarcoma de Ewing. Dichas asociaciones fueron validadas en un 
cohorte independiente, destacando la relevancia de los genes implicados en la 
farmacocinética para el pronóstico de dichos pacientes. 
 
3. Identificamos y replicamos un locus próximo al gen CDH4, el cual codifica para R-
cadherina, una proteína altamente expresada en la capa granular de la epidermis, 
fuertemente asociado con la aparición de síndrome mano-pie en su forma más severa.  
 
4. La presencia de las variantes de riesgo afecta a la expresión de CDH4, probablemente 
mediante la alteración de la topología de la cromatina. Dichos resultados, ponen de 
manifiesto un nuevo mecanismo molecular subyacente a la susceptibilidad para el 
desarrollo de síndrome mano-pie a través de la alteración de la diferenciación de los 
queratinocitos en la epidermis y la función de barrera de la misma.  
 
5. Por otro lado, en pacientes diagnosticados con cáncer de mama, previo al tratamiento 
con el fármaco capecitabina, hallamos que los niveles en la epidermis de las proteínas R-
cadherina e involucrina, una proteína esencial en la función de barrera del estrato 
córneo de la epidermis, se encontraban inversamente correlacionados con el desarrollo 
posterior de síndrome mano-pie en su manifestación más severa. 
 
6. Además identificamos a GPR35, un gen con un papel esencial tanto en la fisiología como 
en la patología cardiaca; y en particular, la variante codificante poco frecuente 
rs12468485, como factores de riesgo independientes para cardiotoxicidad crónica 
producida por antraciclinas en pacientes oncológicos infantiles. 
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7. Por último, identificamos dos nuevos genes, ETFB y WISP1, asociados con un mayor 
riesgo de desarrollar cardiotoxicidad crónica en pacientes de mama tratados con 
antraciclinas. Dentro de estos genes, las variantes codificantes poco frecuentes 
rs79338777 en ETFB y rs72731540 en WISP1 fueron identificadas como factores de 
riesgo independientemente de la edad del paciente en el diagnóstico.  
 
8. Estos resultados demuestran la utilidad de los arrays de genotipado centrados en 
variantes exónicas para la identificación de variantes de riesgo poco frecuentes.  
 
9. Para implementar en la clínica las variantes genéticas identificadas en esta tesis doctoral 
como biomarcadores genómicos, es por supuesto necesaria la validación de dichas 
variantes en cohortes de pacientes independientes con un gran tamaño muestral. Sin 
embargo, nuestros resultados constituyen un primer avance hacia la denominada medicina 
personalizada. 
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Background: Despite the effectiveness of current treatment protocols for Ewing sarcoma (ES), many patients still experi-
ence relapse, and survival following recurrence is <15%. We aimed to identify genetic variants that predict treatment
outcome in children diagnosed with ES.
Patients and methods: We carried out a pharmacogenetic study of 384 single-nucleotide polymorphisms (SNPs) in
24 key transport or metabolism genes relevant to drugs used to treat in pediatric patients (<30 years) with histologically
conﬁrmed ES. We studied the association of genotypes with tumor response and overall survival (OS) in a discovery
cohort of 106 Spanish children, with replication in a second cohort of 389 pediatric patients from across Europe.
Results: We identiﬁed associations with OS (P< 0.05) for three SNPs in the Spanish cohort that were replicated in the
European cohort. The strongest association observed was with rs7190447, located in the ATP-binding cassette subfamily C
member 6 (ABCC6) gene [discovery: hazard ratio (HR) = 14.30, 95% conﬁdence interval (CI) = 1.53–134, P = 0.020; replica-
tion: HR = 9.28, 95% CI = 2.20–39.2, P= 0.0024] and its correlated SNP rs7192303, which was predicted to have a plausible
regulatory function. We also replicated associations with rs4148737 in the ATP-binding cassette subfamily B member 1
(ABCB1) gene (discovery: HR = 2.96, 95% CI = 1.08–8.10, P= 0.034; replication: HR= 1.60, 95% CI = 1.05–2.44, P= 0.029),
which we have previously found to be associated with poorer OS in pediatric osteosarcoma patients, and rs11188147 in cyto-
chrome P450 family 2 subfamily C member 8 gene (CYP2C8) (discovery : HR= 2.49, 95% CI = 1.06–5.87, P= 0.037; replica-
tion: HR= 1.77, 95% CI = 1.06–2.96, P = 0.030), an enzyme involved in the oxidative metabolism of the ES chemotherapeutic
agents cyclophosphamide and ifosfamide. None of the associations with tumor response were replicated.
Conclusion: Using an integrated pathway-based approach, we identiﬁed polymorphisms in ABCC6, ABCB1 and CYP2C8
associated with OS. These associations were replicated in a large independent cohort, highlighting the importance of pharma-
cokinetic genes as prognostic markers in ES.
Key words: Ewing sarcoma, polymorphisms, pharmacokinetic genes, prognostic, pathway-based approach
introduction
Ewing sarcoma (ES) is relatively uncommon, despite being the
second most frequent primary malignant bone tumor in chil-
dren and adolescents, after osteosarcoma. It accounts for only
2% of all childhood cancers, with an annual incidence of ∼3
cases per million [1]. Interindividual variability in drug efﬁcacy
and toxicity, resulting in unpredictable patient response, is of
particular concern for chemotherapeutic drugs because these
agents have a narrow therapeutic window and must be given at
optimal doses [2]. In particular in ES, 30%–40% of patients with
a localized primary tumor and 60%–80% of patients with disse-
minated disease experience relapse after treatment and have a
dismal prognosis, with a likelihood of long-term survival after
recurrence lower than 15% [3, 4]. We hypothesized that genetic
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Cancer Genetics Programme, Spanish National Cancer Centre, Melchor Fernández
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variants in genes encoding drug transporters, drug-metabolizing
enzymes and/or drug targets might explain much of this vari-
ability in drug response [5, 6]. In order to identify prognostic
and predictive markers for ES, we conducted a pharmacogenetic
study genotyping 384 single-nucleotide polymorphisms (SNPs)
in 24 genes involved in the absorption, distribution, metabolism
and elimination of chemotherapeutic drugs used to treat ES
using a discovery cohort from Spain (n = 106), with replication
in an independent European cohort (n = 389).
materials andmethods
patients
Eligible patients had histologically conﬁrmed ES diagnosed before age 30
years. The discovery cohort consisted of 106 Spanish ES pediatric patients
recruited between 1993 and 2012 at the University Hospital La Paz and
University Hospital Niño Jesús in Madrid and at the University Clinic of
Navarra in Pamplona. The replication cohort consisted of 389 ES pediatric
patients from Austria (153), France (110), Italy (97) and Germany (29),
recruited in 1991–2010, 1999–2007, 1987–2010 and 1994–2008, respectively.
In both cohorts, patients were treated according to a multimodal protocol
consisting of multiagent chemotherapy mostly involving combinations of
vincristine (V), ifosfamide (I), doxorubicin (D), cyclophosphamide (C), eto-
poside (E) and/or actinomycin-D (A), combined with surgery and/or
radiation therapy. In the induction chemotherapy, three main protocols were
used: VIDE (63% of patients), VDC (17%) and VDC + VAI + VDC + IE
(14%) (supplementary Table S1, available at Annals of Oncology online).
Postoperative chemotherapy typically consisted of the administration of the
VAC or the VAI regimen. Of patients in the replication cohort with metasta-
sis at diagnosis and/or non-resectable primary tumor, 18% were treated with
high-dose chemotherapy. None of the patients in the discovery cohort
received high-dose chemotherapy.
Relevant clinical information was abstracted from medical records (sup-
plementary Table S2, available at Annals of Oncology online). Where pos-
sible, tumor response to treatment, deﬁned as the percentage of necrosis
induced in the tumor after neoadjuvant chemotherapy, was determined his-
tologically. Overall survival (OS) was calculated as the time from tumor diag-
nosis until death from any cause or date last known to be alive.
Written informed consent was obtained from adult patients and from the
parents or legal guardians of children. The study was approved by the ethics
committees of all participating universities and hospitals.
candidate genes and SNP genotyping
We selected 24 genes reported to be involved in the pharmacokinetics of
the six agents commonly used in chemotherapy regimen for ES, based on
the information available in the database PharmaGKB [7] (supplementary
Table S3, available at Annals of Oncology online). A total of 384 SNPs were
selected across these candidate genes, as previously described [8].
Germline DNA, isolated from peripheral blood lymphocytes from partici-
pants in the discovery and replication cohorts, was genotyped using a custo-
mized Illumina GoldenGate VeraCode SNP genotyping assay (Illumina, San
Diego, CA) on the BeadXpress platform according to the published protocol.
Genotypes were called using GenomeStudio software. We excluded SNPs
with a call rate <0.95 with minor allele frequency <0.05, whose genotype dis-
tribution deviated from the Hardy–Weinberg equilibrium (P < 10−6), with
Mendelian allele-transmission errors, or with discordant genotypes between
duplicate samples. Samples with a call rate <0.90 were excluded.
statistical analysis
We studied the association of SNPs with tumor response and OS. Patients
were divided into two categories: good responders, with tumor necrosis
≥90%; and poor responders, with tumor necrosis <90% [9]. Odds ratios and
95% conﬁdence intervals (CIs) for good tumor response by genotype were
estimated using logistic regression analysis. SNPs for which associations with
P < 0.05 were observed were assessed in the European replication cohort.
We also tested associations between SNP genotypes and OS using the Cox
regression analysis. SNPs with P < 0.05 in the discovery set were assessed in
the replication cohort.
Clinical factors with associated P < 0.05 in univariable analyses (supple-
mentary Table S2, available at Annals of Oncology online) with tumor re-
sponse or OS were included as covariates in corresponding multivariable
analyses.
In addition to the additive genetic model, we considered dominant and
recessive models.
Analysis were carried out using PLINK [10] (v. 1.07) or SPSS software
(v. 18.0; SPSS Inc., Chicago, IL).
functional annotations
We used information from the Encyclopedia of DNA Elements (ENCODE)
[11] using custom tracks on the UCSC Genome browser [12] and HaploReg
[13] to investigate whether the risk-associated SNPs or their correlated SNPs
(r2≥ 0.8) had potential regulatory functions.
results
The demographic and clinical characteristics of both cohorts
are shown in supplementary Table S4, available at Annals of
Oncology online. After ﬁltering, 334 SNPs of the 384 genotyped
were successfully analyzed (Figure 1). There was no evidence of
departure from the Hardy–Weinberg equilibrium for any. Data
for two patients in the Spanish cohort and 55 patients in the
replication cohort were excluded due to a low genotyping call
rate (<0.90), leaving 104 and 334 patients, respectively.
associations with tumor response to treatment
Associations with tumor response were assessed in 77 patients
from the Spanish discovery cohort for which this information
was available. After adjusting for age and the presence of metas-
tasis at diagnosis, an association with P < 0.05 was observed for
20 SNPs. However, none of these associations were replicated in
the European cohort (n = 197, P≥ 0.05) (Figure 1).
Also including neoadjuvant therapy as an additional covariate
in multivariable models made no substantial difference to the
results obtained (data not shown).
associations with OS
Since adjustment for tumor response made no substantial differ-
ence to the estimated HR (based on an analysis of the cases for
which this information was available), we present results without
adjustment for this covariate, based on a larger sample size.
We identiﬁed 43 SNPs associated with OS at P < 0.05 in the
Spanish cohort after adjusting for age at diagnosis, presence of
metastasis at diagnosis and recurrence (n = 97) (supplementary
Table S5, available at Annals of Oncology online). Associations
with three of these were replicated in the European cohort
(n = 305) (Table 1, supplementary Table S5 and Figure S1, avail-
able at Annals of Oncology online). The strongest evidence of
association was found for the SNP rs7190447, an intronic poly-
morphism in ABCC6. In both cohorts, a recessive model was
the best ﬁt; C-allele homozygotes had a higher risk of death
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(discovery phase: HR = 14.30, 95% CI = 1.53–134, P = 0.020;
replication phase: HR = 9.28, 95% CI = 2.20–39.2, P = 0.0024,
supplementary Figure S1A, available at Annals of Oncology
online). The 5-year survival for patients carrying 1 or 2 copies
of the G allele was 74% in the discovery cohort and 65% in the
replication series, while no individual carrying the CC genotype
lived for 5 years following diagnosis (Table 1).
The G allele of rs4148737, an intronic SNP in ABCB1, was
associated with poorer OS under a recessive model (discovery
phase: HR = 2.96, 95% CI = 1.08–8.10, P = 0.034; replication
phase: HR = 1.60, 95% CI = 1.05–2.44, P = 0.029, supplementary
Figure S1B, available at Annals of Oncology online). The esti-
mated 5-year survival for cases with AA/AG and GG genotypes
was 75% and 66%, respectively, in the discovery cohort, and
66% and 55%, respectively, in the European cohort (Table 1).
Finally, the minor T allele for an SNP located 2.7 kb down-
stream of the CYP2C8 gene, rs11188147, was associated with an
increased risk of death under a recessive model (discovery
phase: HR = 2.49, 95% CI = 1.06–5.87, P = 0.037; replication
phase: HR = 1.77, 95% CI = 1.06–2.96, P = 0.030, supplementary
Figure S1C, available at Annals of Oncology online). The 5-year
survival for CC/CT and TT carriers was 76% and 67%, respect-
ively, in the discovery cohort, and 65% and 58%, respectively, in
the replication series (Table 1).
functional annotations
Functional annotations of SNPs rs7190447, rs4148737 and
rs11188147 and correlated variants (r2≥ 0.8) are shown in sup-
plementary Table S6 and Figures S2–S4, available at Annals of
Oncology online.
SNP rs7190447 was found to be in perfect linkage disequilib-
rium (LD) with rs7192303, an intronic polymorphism located
122 bp upstream. The genomic region containing rs7192303 is
enriched with speciﬁc histone marks associated with transcribed
regions in a hepatocellular carcinoma cell line, with weak enhan-
cers in a skeletal muscle myoblast cell line, and with a DNase
hypersensitive cluster in 123 different cell types (supplementary
Table S6 and Figure S1, available at Annals of Oncology online).
The strongest and most robust ChIP-seq signal is observed for
CTCF binding in a large number of ENCODE cell lines (69)
(supplementary Table S6 and Figure S2, available at Annals of
Oncology online). Strong signals for cohesin subunits RAD21
and SMC3 were also observed. The genomic region containing
rs7192303 also has the potential to form chromatin loops,
through CTCF binding, with intronic regions of ABCC6 and
ABCC1, both located upstream, in a breast cancer cell line
(MCF-7) (supplementary Figure S3, available at Annals of
Oncology online). We explored expression quantitative trait loci
using Genotype-Tissue Expression (GTEx) data, and found
rs4148737
(P = 0.03)
rs11188147
(P = 0.03)
SNPs assessed
Discovery set
Replication set
334 SNPs
Quality control filtering:
Call rate > 0.95
MAF > 0.05
Association with tumor
response
Association with OS
N = 77
P < 0.05
Covariates:
Age at diagnosis
Metastasis at diagnosis
Covariates:
Age at diagnosis
Metastasis at diagnosis
Covariates:
Age at diagnosis
Metastasis at diagnosis
Recurrence
Covariates:
Age at diagnosis
Metastasis at diagnosis
Recurrence
Country of origin
20 SNPs
N = 97
43 SNPs
N = 197
P < 0.05
N = 305
384 SNPs
None rs7190447(P = 2.44 × 10–3)
P < 0.05
P < 0.05
Figure 1. Flow chart of the study. SNPs, single-nucleotide polymorphisms; OS, overall survival; MAF, minor allele frequency.
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statistically signiﬁcant differences in ABCC6 gene expression by
rs7192303 genotype in esophagus muscularis, liver and vagina
(P = 0.017, 0.019 and 0.048, respectively) (data not shown).
These ﬁndings suggest rs7192303 as the most plausible causal
SNPs for the observed association with OS.
The intronic SNP rs4148737 resides in a weakly transcribed
region, but also overlaps with a weak enhancer in GM12878 and
in a RUNX3 ChIP-seq cluster in the same lymphoblastoid cell
line. It was predicted to overlap with a DNAse hypersensitive
region in a lymphoblastoid cell line and in cerebellar and hippo-
campal astrocytic cell lines, and to alter EBF, ERα-a, Hic1 regu-
latory motifs (supplementary Table S6 and Figure S4, available
at Annals of Oncology online). None of the nine intronic SNPs
in high LD (r2≥ 0.84) with this SNP had stronger functional
evidence reported (supplementary Table S6, available at Annals
of Oncology online). According to GTEx data, rs4148737 inﬂu-
ences ABCB1 expression in testis (P = 0.022), breast (P = 0.033)
and muscle skeletal (P = 0.038).
No strong functional evidence was observed for SNP
rs11188147 or for any of the 18 variants that are in high LD
with it (r2≥ 0.83) (supplementary Table S6, available at Annals
of Oncology online). No signiﬁcant differences in CYP2C8 ex-
pression were found for any tissues available in GTEx.
discussion
To date, most research has focused on polymorphisms, mainly
SNPs, in candidate genes as potential biomarkers of toxicity and
efﬁcacy for anticancer agents; however, genetic variants in a
single gene would explain only a small proportion of the interin-
dividual variability observed in drug efﬁcacy and toxicity. The
evaluation of genetic variants in all the genes within a biological
or pharmacological pathway may identify additional predictive
and prognostic variants and thereby improve our ability to per-
sonalize treatment by predicting drug response [14]. We have
assessed associations with treatment outcome in children diag-
nosed with ES for 334 SNPs in 24 genes involved in the pharma-
cokinetics of chemotherapeutic agents used in ES therapy. This
is the ﬁrst pharmacogenetic study carried out for this disease to
consider an integrated pathway-based approach.
We have identiﬁed and replicated associations with OS for
three variants: rs7190447, rs4148737 and rs11188147, located in
ABCC6, ABCB1 and CYP2C8.
Both ABCC6 and ABCB1 are members of the ATP-binding
cassette (ABC) transporter superfamily, which have been impli-
cated in mediating multidrug resistance in tumor cells reducing
effectiveness of chemotherapeutics and decreasing survival [15].
ABCC6-transfected Chinese hamster ovary cells exhibited en-
hanced resistance to a variety of antineoplastics, including drugs
administered to ES patients (etoposide, doxorubicin and actino-
mycin-D) [16]. In addition, ABCC6 is expressed in tumors of
patients with localized ES [17], so a role for ABCC6 in multidrug
resistance of ES cells is plausible. It remains to be determined
whether intronic polymorphisms in ABCC6 have an impact on
gene expression and hence an effect on pharmacodynamics [15].
Recent studies have demonstrated that variants in non-transcribed
regions can inﬂuence gene expression through regulatory mechan-
isms [18]. ENCODE and HaploReg data suggest that the genomic
region containing the SNP rs7192303 (in perfect LD with our
T
a
b
le
1
.
A
ss
oc
ia
ti
on
s
be
tw
ee
n
SN
P
s
an
d
O
S
in
E
S
pa
ti
en
ts
G
en
e
C
hr
SN
P
ID
Po
si
ti
on
a
Lo
ca
ti
on
M
od
el
M
A
F
D
is
co
ve
ry
(n
=
97
)
R
ep
lic
at
io
n
(n
=
30
5)
G
en
ot
yp
e
n
5-
ye
ar
O
S
P
va
lu
e
H
R
95
%
C
I
n
5-
ye
ar
O
S
P
va
lu
e
H
R
95
%
C
I
A
B
C
C
6
16
rs
71
90
44
7
16
28
91
26
In
tr
on
ic
R
ec
es
si
ve
0.
07
G
G
/G
C
96
74
%
30
3
65
%
C
C
1
–
2
–
Pe
r
al
le
le
C
0.
02
0
14
.3
1.
53
–1
34
0.
00
24
9.
28
2.
20
–3
9.
2
A
B
C
B
1
7
rs
41
48
73
7
87
17
11
52
In
tr
on
ic
R
ec
es
si
ve
0.
43
A
A
/A
G
80
75
%
25
1
66
%
G
G
17
66
%
54
55
%
Pe
r
al
le
le
G
0.
03
4
2.
96
1.
08
–8
.1
0
0.
02
9
1.
60
1.
05
–2
.4
4
C
Y
P2
C
8
10
rs
11
18
81
47
96
79
38
20
2.
7
kb
do
w
ns
tr
ea
m
R
ec
es
si
ve
0.
39
C
C
/C
T
72
76
%
26
3
65
%
T
T
25
67
%
42
58
%
Pe
r
al
le
le
T
0.
03
7
2.
49
1.
06
–5
.8
7
0.
03
0
1.
77
1.
06
–2
.9
6
A
ss
oc
ia
ti
on
s
be
tw
ee
n
SN
P
s
an
d
O
S
w
er
e
as
se
ss
ed
in
cl
ud
in
g
im
po
rt
an
t
cl
in
ic
al
co
va
ri
at
es
(a
ge
an
d
m
et
as
ta
si
s
at
di
ag
no
si
s
an
d
re
cu
rr
en
ce
)
in
th
e
C
ox
re
gr
es
si
on
an
al
ys
es
.
T
hr
ee
m
od
el
s
of
in
he
ri
ta
nc
e
w
er
e
ev
al
ua
te
d.
O
nl
y
SN
P
as
so
ci
at
io
ns
w
it
h
P
<
0.
05
in
th
e
di
sc
ov
er
y
co
ho
rt
an
d
re
pl
ic
at
ed
in
th
e
E
ur
op
ea
n
co
ho
rt
ar
e
sh
ow
n.
H
R
s
ar
e
pe
r
co
py
of
th
e
sp
ec
ifi
ed
m
in
or
al
le
le
.
SN
P,
si
ng
le
-n
uc
le
ot
id
e
po
ly
m
or
ph
is
m
s;
M
A
F,
m
in
or
al
le
le
fr
eq
ue
nc
y;
5-
ye
ar
O
S,
5-
ye
ar
ov
er
al
ls
ur
vi
va
l;
O
S,
ov
er
al
ls
ur
vi
va
l;
H
R
,h
az
ar
d
ra
ti
o;
C
I,
co
nf
id
en
ce
in
te
rv
al
.
a C
hr
om
os
om
e
po
si
ti
on
s
ar
e
ba
se
d
on
G
en
om
e
R
ef
er
en
ce
C
on
so
rt
iu
m
H
um
an
B
ui
ld
37
(G
R
C
h3
7/
hg
19
).
Volume 27 | No. 9 | September 2016 doi:10.1093/annonc/mdw234 | 
Annals of Oncology original articles
 at Institute of Cancer Research on N
ovem
ber 17, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
replicated SNP, rs7190447) might be regulatory; SNP rs7192303
could affect CTCF binding to DNA and it is through CTCF that
the overlapping genomic region could form a chromatin loop with
upstream intronic regions of ABCC6 and ABCC1. CTCF encodes
an 11 zinc ﬁnger DNA-binding protein involved in diverse
genomic regulatory functions, and it has recently been shown that
CTCF regulates various aspects of gene expression and the estab-
lishment of genome topology by mediating long-range chromatin
interactions [19]. We hypothesize that differences in ABCC6 ex-
pression caused by changes in CTCF binding due to rs7192303
could affect the efﬂux of ABCC6 target-drugs used in ES standard
treatment, thus affecting intracellular drug levels in ES tumor cells,
which ultimately determines the effectiveness of chemotherapy. On
the other hand, the highest levels of ABCC6 mRNA and protein
expression have been detected in the liver and kidney [20] and,
based on the GTEx data, the liver is one of the tissues where
rs7192303 genotypes potentially inﬂuence ABCC6 expression.
ABC efﬂux pumps located in hepatocytes and kidney proximal
tubule cells are crucial for drug elimination [21, 22]; while little is
known about the physiological role of ABCC6 [23], altered expres-
sion of this protein in hepatocytes may have an impact on the sys-
temic bioavailability of drugs, and therefore on treatment response
and patient survival.
To date, ABCB1 and ABCC1 are the only ABC genes that
have been investigated in some detail in ES; however, the ﬁnd-
ings are contradictory. Although a signiﬁcant association
between protein expression and poorer response to therapy in
pre- and post-therapeutic ES has been described [24], ABCB1
mRNA and protein expression was not predictive of prognosis
[25, 26]. Genetic polymorphisms in ABCB1 have been reported
to change mRNA/protein expression and function; however, little
attention has been given to intronic and non-coding SNPs in this
gene, and their possible link to cancer [27]. Consistent with a pre-
vious study in which we reported a signiﬁcant association for the
minor G allele of rs4148737 with poorer OS in pediatric osteosar-
coma patients, the most common pediatric bone tumor
(HR = 3.66, 95% CI = 1.85–6.11, P = 6.9 × 10−5) [8], in the
current work, we observed that the GG genotype was associated
with higher risk of death, suggesting that rs4148737 may be im-
portant as a prognostic marker after treatment in pediatric bone
tumors.
CYP2C8 plays a role in the oxidative metabolism of some
drugs used in ES treatment, in particular cyclophosphamide and
ifosfamide [28]. Although it has been shown that there is great
interindividual variation in the metabolism of CYP2C8-speciﬁc
substrates and in CYP2C8 expression [29], nothing has previ-
ously been reported about the impact of CYP2C8 polymorph-
isms and their implications for clinical outcome in patients
treated with cyclophosphamide and ifosfamide.
While one might expect the three replicated genetic variants
also to be associated with tumor response, we did not observe
this association. The evaluation of tumor response after ad-
ministration of ES neoadjuvant therapy, when chemotherapy
treatment had not been completed, could explain the lack of
observed association with this clinical feature, particularly
bearing in mind that ABCB1 and ABCC6 not only transport
neoadjuvant drugs but also adjuvant chemotherapeutics, and
CYP2C8 is in part responsible for the oxidative metabolism of
neoadjuvant and adjuvant ES agents. On the other hand, lack of
replication could be ascribed to treatment heterogeneity
between patients included in the two cohorts. We evaluated
associations between SNP genotypes and tumor response, in-
cluding neoadjuvant therapy as a covariate, in addition to age
and metastasis at diagnosis, in order to assess the possibility that
different neoadjuvant regimens could affect association with
tumor response. Although we obtained the same signiﬁcant
associations in the discovery cohort, none were replicated in the
European cohort (data not shown). Small sample size could be
also a reason for the failure to replicate associations.
conclusion
We have identiﬁed genetic variants in the ABCC6, ABCB1 and
CYP2C8 genes that were signiﬁcantly associated with OS in ES
patients. These ﬁndings highlight the clinical relevance of these
genes as prognostic markers, although experimental veriﬁcation
of putative regulatory function will be required.
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SUPPLEMENTARY FIGURE LEGENDS  
 
Supplementary Figure S1. Kaplan-Meier survival curves for ES patients (discovery and replication 
cohorts combined) according to genotype for (A) rs7190447 in ABCC6 (NGG/GC=399, NCC=3, 
χ2  =  14.84, Plog-rank=1.17×10
−4); (B) rs4148737 in ABCB1 (NAA/AG=326, NGG=76, χ
2=3.73, Plog-
rank=0.053); and (C) rs11188147 in CYP2C8 (NCC/CT=333, NTT=69, χ
2  =  0.15, Plog-rank  =  0.69).  
 
Supplementary Figure S2. ENCODE functional evidence displayed in the UCSC Genome Browser 
for rs7190447 and nearby SNPs. (A) Genomic location of the ABCC6 gene. Multiple DNase-seq 
and transcription factor ChIP-seq clusters can be observed. (B) Genomic location of rs7190447 
(highlighted). A DNase hypersensitivity region was observed in 123 ENCODE cells around 
rs7190447 and overlapping with rs7192303 (highlighted), an intronic polymorphism located 122 
pb upstream from rs7190447 and in perfect linkage disequilibrium (LD). Multiple transcription 
factors binding clusters can be observed in a large number of cells (identified by single-letter 
abbreviations). Gray boxes indicate the extent of the hypersensitive region for DNaseI 
hypersensitivity clusters or transcription factor occupancy, with the darkness of the box 
proportional to the maximum signal strength observed in any cells contributing to the cluster. 
The number to the left of a DNaseI hypersensitivity box shows how many cells are hypersensitive 
in the region. Within a ChIP-seq cluster, green highlighting indicates the highest scoring site of a 
Factorbook-identified canonical motif for the corresponding factor (http://genome.ucsc.edu/). 
Chromatin states characterized by combinations of histone marks are also shown in different 
human cell lines. Each chromatin state is associated with a different segment color. Blue, 
insulator; light green, weak transcribed; dark green, transcriptional transition; yellow, weak 
enhancer. The genomic region containing SNPs, rs7190447 and rs7192303 is also enriched for 
CTCF-mediated chromatin interactions in MCF-7 breast cancer cells. MCF-7 CTCF ChIA-PET 
interactions are shown as a density graph of signal enrichment based on aligned read density. 
Due to space limitations, only a subset of cells where a CTCF-ChIP-seq peak is detected and CTCF 
ChIA-PET interactions are shown. GM12878, lymphoblastoid cells; K1-hESC, embryonic stem 
cells; K562, erythrocytic leukemia cells; HepG2, hepatocellular carcinoma cells; HUVEC, umbilical 
vein endothelial cells; HMEC, mammary epithelial cells; HSMM, skeletal muscle muscle myoblast 
cells; NHEK, normal epidermal keratinocytes cells. Abbreviations: Txn: transcription. 
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Supplementary Figure S3. CTCF-mediated chromatin interactions for rs7190447 and rs7192303 
determined by chromatin interaction paired-end tag (ChiAPET) data from ENCODE. UCSC 
Genome Browser image of the genomic region containing rs7190447 (our replicated SNP) and 
rs7192303 (the SNP in perfect LD with it) showing ChIA-PET interactions and enrichment for 
CTCF in MCF-7 breast cancer cells. CTCF-mediated chromatin interactions are represented by 
two blocks, one at each end, connected by a horizontal line. The density graph shows the CTCF 
signal enrichment based on aligned read density. Not all MCF-7-CTCF ChIA-PET interactions are 
shown in full for the genomic region and the chromatin interactions have been adapted (red 
lines connecting blocks) to highlight relevant interactions only. 
 
 
Supplementary Figure S4. ENCODE functional evidence displayed in the UCSC Genome Browser 
for rs4148737 and nearby SNPs. (A) Genomic location of the ABCB1 gene. Multiple DNase-seq 
and transcription factor ChIP-seq clusters can be observed. (B) Genomic location of rs4148737 
(highlighted). Two DNase hypersensitivity regions are observed in five ENCODE cell lines around 
rs4148737, one of them overlapping. rs4148737 resides in a RUNX3 ChIP-seq cluster in 
lymphoblastoid cells (identified by G letter). Gray boxes indicate the extent of the hypersensitive 
region for DNaseI hypersensitivity clusters or transcription factor occupancy, with the darkness 
of the box proportional to the maximum signal strength observed in any cells contributing to the 
cluster. The number to the left of a DNaseI box shows how many cells are hypersensitive in the 
region. Within a ChIP-seq cluster, green highlighting indicates the highest scoring site of a 
Factorbook-identified canonical motif for the corresponding factor (http://genome.ucsc.edu/). 
Chromatin states characterized by combinations of histone marks are also shown in different 
human cell lines. Each chromatin state is associated with a different segment color. Yellow, weak 
enhancer; light green, weak transcribed. GM12878, lymphoblastoid cells; K1-hESC, embryonic 
stem cells; K562, erythrocytic leukemia cells; HepG2, hepatocellular carcinoma cells; HUVEC, 
umbilical vein endothelial cells; HMEC, mammary epithelial cells; HSMM, skeletal muscle muscle 
myoblast cells; NHEK, normal epidermal keratinocytes cells. Abbreviations: Txn: transcription. 
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Supplementary Table S1. Neoadjuvant treatment given to ES patients 
 Discovery 
(N=106) 
Replication (N=389) 
Neoadjuvant 
chemotherapy 
Spain (106) 
Germany 
(29) 
Italy (97) 
Austria 
(153) 
France 
(110) 
N (%) N (%) N (%) N (%) N (%) 
VIDE 27 (25%) 15 (52%) - 153 (100%) 110 (100%) 
VDC 79 (75%) - 3 (3%) - - 
VDC+VAI+VDC+IE - - 70 (72%) - - 
VDI+C*E*+VDI+C*E - - 15 (15%) - - 
VDCA+I - - 5 (5%) - - 
VDIA - 4 (14%) -  - - 
EVDIA - 4 (14%) - - - 
VDIA+EVDIA  1 (3%) - - - 
VIDE+VAI - 3 (10%) - - - 
VIDE+VAI+VAC - 1 (3%) - - - 
Other - 1 (3%) - - - 
Missing - - 4 (4%) - - 
Abbreviations: V, vincristine; I; ifosfamide; D, doxorubicin; E, etoposide; E* high-dose etoposide, A, actinomycin-
D; C, cyclophosphamide; C* high-dose cyclophosphamide. Other: chemotherapy regimen involving vincristine, 
doxorubicin, etoposide and cisplatin. 
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Supplementary Table S2. Clinical information recorded from ES patients and associations in univariable analyses 
with tumor response and OS 
 Tumor response OS 
 Discovery Replication Discovery Replication 
Clinical information P P P P 
Age at diagnosis 0.039 0.002 0.048 0.038 
Gender 0.52 0.38 0.55 0.79 
Primary tumor site 0.29 0.99 0.33 0.69 
Metastasis at diagnosis  0.001 0.042 1.67x10
-6
 6.8x10
-12
 
Neoadjuvant therapy 0.55 0.54 0.15 0.15 
Response to treatment NA NA 0.029 6.0x10
-5
 
Recurrence* 0.093 0.082 1.67x10
-6
 8.7x10
-22
 
Vital status NA NA NA NA 
Overall survival (OS) NA NA NA NA 
Country of origin NA 0.90 NA 0.81 
Information on age at diagnosis, sex, primary tumor site, existence of metastasis at diagnosis, tumor response, treatment protocol, 
vital status and development of recurrence was abstracted retrospectively from medical records. *Recurrence was defined as any 
evidence of new disease during/after the completion of therapy, including both locoregional and distant disease relapses. 
Associations between clinical factors were assessed in univariable analyses with tumor response by logistic regression analyses 
and with OS by Cox regression analyses in the discovery and replication cohorts. Clinical factors with associated P<0.05 (in bold) 
in univariable analyses with tumor response or OS were included as covariates in corresponding multivariable analyses. Country of 
origin was included as covariate in analyses with OS in the replication cohort due to incomplete information regarding adjuvant 
therapy protocols. Abbreviations: OS, overall survival; NA, not applicable 
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Supplementary Table S3. Candidates genes studied 
Category Genes 
Transporters 
ABCA3, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC6, 
ABCG2, SLC31A1, SLCO6A1, SLC19A1 
Phase I metabolism enzymes 
MPO, SOD1, ALDH1A1, CYP3A4, CYP3A5, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19 
Phase II metabolism enzymes GSTM1, GSTP1, GSTT1 
24 candidate genes reported to be involved in the pharmacokinetics of the 6 agents (vincristine, 
ifosfamide, doxorubicin, cyclophosphamide, etoposide and actinomycin-D) commonly used in 
chemotherapy regimens for ES, were selected based on the information available in the database 
PharmaGKB 
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Supplementary Table S4. Clinical characteristics of ES patients 
 Discovery (N=106) Replication (N=389) 
Characteristic N %* N %* 
Age at diagnosis (years)     
Median 12.2 14.5 
Range 0.4-27.8 0.1-27.8 
Sex     
Female 42 39.6 156 40.1 
Male 64 60.4 233 59.9 
Primary site     
Upper extremities 9 8.7 39 10.2 
Lower extremities 48 46.2 129 33.9 
Axial 41 39.4 203 53.3 
Soft tissue 6 5.8 10 2.6 
Missing 2  8  
Metastasis at diagnosis     
No 62 59.6 255 67.3 
Yes 42 40.4 124 32.7 
Missing 2  10  
Response to treatment     
Good 55 70.5 148 64.3 
Poor 23 29.5 82 35.7 
Missing 28  159  
Relapse      
No 67 67.0 211 58.1 
Yes 33 33.0 152 41.9 
Missing 6  26  
Vital status     
Alive 67 67.0 229 61.7 
Dead 33 33.0 142 38.3 
Missing 6  18  
Follow-up (years)     
Median 93.7 70.3 
Range 7.8-300 12.3-312 
* Percentages are computed based on the total number of non-missing values*Percentages are computed based 
on the total number of non-missing values. 
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 Supplementary Table S5. Analysis of associations between SNPs and OS 
      Discovery (N=97) Replication (N=305) 
Gene 
Chr. Variant Position * Location Model P 
Minor allele HR 
95%CI P 
Minor allele HR 
95%CI 
ABCC1 16 rs212081 16225971 Intronic 
Recessive 
2.59x10
-4
 T 6.62 2.40-18.3 0.46 T 1.19 0.75-1.90 
SLCO6A1 5 rs981988 101819981 Intronic Recessive 1.52x10
-3
 G 54.2 4.59-639 0.11 G 0.20 0.03-1.41 
GSTP1 11 rs7927381 
67346743 4.3kb upstream 
Recessive 1.52x10
-3
 T 54.2 4.59-639 0.28 T 3.06 0.39-23.8 
ABCB1 7 rs7787082 87157051 Intronic Additive 1.91x10
-3
 A 0.29 0.13-0.64 0.90 A 1.00 0.71-1.42 
ABCC3 17 rs12451302 48751164 Intronic Recessive 2.62x10
-3
 G 5.16 1.77-15.0 0.29 G 0.80 0.52-1.22 
CYP2C9 10 
rs4918758 96697252 2kb upstream Recessive 2.98x10
-3
 C 5.11 1.74-15.0 0.09 C 1.55 0.93-2.59 
ABCC3 17 rs3785912 48756937 Intronic Recessive 4.06x10
-3
 A 5.99 1.77-20.3 0.25 A 0.70 0.38-1.29 
ABCC1 16 rs3888565 16183045 Intronic Additive 4.69x10
-3
 A 0.28 0.12-0.68 0.25 A 0.83 0.59-1.15 
CYP3A5 7 rs28365067 99272310 Intronic Additive 5.84x10
-3
 T 4.42 1.54-12.7 0.89  T 1.04 0.62-1.74 
ABCC1 16 rs35621 16168608 Intronic Additive 7.27x10
-3
 T 0.21 0.07-0.66 0.97 T 0.99 0.68-1.46 
ABCB1 7 rs2214102 87229501 5´ UTR Recessive 8.15x10
-3
 A 28.4 2.38-339 - - - 
ABCC1 16 rs16967755 16199255 Intronic Additive 0.01 G 0.31 0.13-0.76 0.64 G 1.07 0.80-1.45 
ABCC6 16 rs16967488 16252696 Intronic Dominant 0.01 C 2.80 1.24-6.35 0.73 C 1.07 0.74-1.53 
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ALDH1A1 9 rs348481 75514436 1.1kb downstream Recessive 0.01 C 8.03 1.53-42.0 0.99 C 0.99 0.31-3.15 
ABCC2 10 rs717620 101542578 5´ UTR Recessive 0.02 A 15.8 1.72-146 0.91 A 0.93 0.23-3.77 
ABCC1 16 rs35626 16170615 Intronic Additive 0.02 T 0.41 0.20-0.85 0.90 T 0.98 0.74-1.30 
CYP2C9 10 rs11597626 96604273 Intronic Dominant 0.02 G 0.37 0.17-0.84 0.89 G 1.03 0.71-1.48 
CYP2C9 10 rs12251688 96693727 4.6kb upstream Dominant 0.02 T 0.38 0.17-0.84 0.83 T 1.04 0.72-1.49 
CYP3A4 7 rs4646437 99365083 Intronic Dominant 0.02 T 3.06 1.20-7.79 0.43 T 1.19 0.77-1.83 
ABCC6 16 rs7190447 16289126 Intronic Recessive 0.02 C 14.30 1.53-134 2.44x10
-3
 C 9.28 2.20-39.2 
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 Supplementary Table S5. Analysis of associations between SNPs and OS (continued) 
      Discovery (N=97) Replication (N=305) 
Gene 
Chr. Variant Position * Location Model P 
Minor allele HR 
95%CI P 
Minor allele HR 
95%CI 
ABCC1 16 rs12922404 16060994 Intronic Dominant 0.02 T 2.61 1.16-5.89 0.17 T 1.29 0.89-1.88 
ABCB1 7 rs2235048 87138511 Intronic Recessive 0.02 C 2.88 1.16-7.12 0.46 C 0.85 0.55-1.31 
ABCB1 7 rs17064 87133470 3´ UTR Additive 0.02 T 4.08 1.22-13.7 0.96 T 0.99 0.60-1.61 
ABCC6 16 rs2238469 16283071 Intronic Recessive 0.03 A 4.36 1.17-16.3 0.15 A 0.23 0.03-1.73 
ABCC3 17 rs8079432 48749883 Intronic Additive 0.03 G 2.77 1.11-6.91 0.68 G 0.91 0.57-1.45 
ABCC4 13 rs9590220 95906694 Intronic Additive 0.03 T 0.38 0.16-0.91 0.13 T 1.28 0.93-1.75 
ABCB1 7 rs10264990 87202615 Intronic Recessive 0.03 C 3.21 1.11-9.26 0.10 C 1.54 0.92-2.59 
GSTP1 11 rs614080 67347287 3.8kb upstream Recessive 0.03 G 2.56 1.09-6.04 0.52 G 0.85 0.52-1.39 
ABCC1 16 rs212087 16230290 Intronic Recessive 0.03 T 0.34 0.13-0.91 0.10 T 1.46 0.93-2.30 
ABCB1 7 rs4148737 87171152 Intronic Recessive 0.03 G 2.96 1.08-8.10 0.03 G 1.60 1.05-2.44 
ABCG2 4 rs2725264 89026109 Intronic Additive 0.04 G 2.60 1.06-6.36 0.41 G 0.83 0.53-1.29 
CYP1B1 2 rs4646429 38306935 3.6kb upstream Additive 0.04 A 0.44 0.20-0.95 0.95 A 0.99 0.73-1.34 
CYP2C8 10 rs11188147 96793820 2.7kb downstream Recessive 0.04 T 2.49 1.06-5.87 0.03 T 1.77 1.06-2.96 
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MPO 17 rs7208693 56357818 Missense Additive 0.04 A 2.17 1.04-4.51 0.76 A 0.93 0.54-1.47 
ABCC1 16 rs4148354 16174506 Intronic Dominant 0.04 G 0.42 0.19-0.96 0.87 G 1.07  0.69-1.57 
CYP2C8 10 rs1934956 96828160 Intronic Recessive 0.04 T 4.95 1.06-23.2 0.47 T 1.44 0.53-3.96 
CYP2A6 19 
rs8192729 41350996 Intronic Additive 0.05 A 2.99 1.02-8.75 0.92 A 1.03 0.62-1.69 
ABCC1 16 rs2299670 16220858 Intronic Additive 0.05 G 0.51 0.26-0.99 0.69 G 1.06 0.79-1.43 
SOD1 21 rs2070424 33039320 Intronic Additive 0.05 G 3.22 1.02-10.2 0.06 G 1.54 0.98-2.41 
LPO 17 rs8178407 56344656 Intronic Dominant 0.05 G 2.61 1.01-6.77 0.77 G 0.95 0.66-1.37 
ABCC1 16 rs11075295 16177687 Intronic Recessive 0.05 G 9.14 1.02-82.1 0.96 G 0.98 0.36-2.65 
ABCB1 7 rs13237132 87191669 Intronic Additive 0.05 G 1.80 1.00-3.22 0.20 G 1.19 0.91-1.54 
ABCC4 13 rs9590211 95892414 Intronic Dominant 0.05 A 2.14 1.00-4.57 0.71 A 0.93 0.63-1.37 
Associations between SNPs and OS in ES patients were assessed by the Cox regression analyses, adjusted for age and metastasis at diagnosis and recurrence. Only SNP associations with P < 0.05 in the discovery 
cohort were considered in the replication cohort. Three models of inheritance were evaluated. HRs are per copy of the specified minor allele. Variants shown in bold were those associated with overall survival 
in both cohorts at P<0.05. * Chromosome positions are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19). Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphisms; OS, 
overall survival; HR, hazard ratio; CI, confidence interval. 
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Supplementary Table S6. Analysis of functional annotations of rs7190447, rs4148737 and rs11188147 and correlated variants (r2≥0.8)  
  Correlated variant LD (r2) 
Enhancer 
histone marks 
DNase Proteins bound Motifs changed 
rs7190447 - - - HA-sp CTCF GATA, Pou3f2 
rs7206048 rs7190447 0.96 K562 GM12892 MAFK Egr-1,GATA 
rs6498619 rs7190447 1 K562 - - Pax-5 
rs8044613 rs7190447 1 - - - Evi-1,Pou2f2 
rs11862259 rs7190447 1 - - - Mef2, NF-AT1 
rs7184822 rs7190447 0.98 - - - 22 altered motifs 
rs7186376 rs7190447 1 - - - 
ERalpha-a, HNF4, 
TLX1, NFIC 
rs7187235 rs7190447 1 - - - AP-1 
rs7186601 rs7190447 1 - - - 
BDP1_disc2, GCNF, 
Nr2f2, p300_known1 
rs7192303 rs7190447 1 HSMM 
PanIsletD, AG09309, 
AG10803, HA-h, HA-
sp, HGF, HIPEpiC, 
HNPCEpiC, HPdLF, 
HVMF 
CTCF, SMC3, ZNF143, 
RAD21, 
FOXA1,FOXA2, 
GATA3 
INSM1 
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rs7199104 rs7190447 1 - - - Foxa,Foxj2, Osf2 
rs4148737 - - GM12878 GM12865,HA-h,HAc - EBF, ERalpha-a, Hic1 
rs35572298 rs4148737 0.84 - - - 8 altered motifs 
rs35280822 rs4148737 0.89 - - - Homez,Lhx3 
rs12154941 rs4148737 0.91 - - - AP-1,Zfx 
rs4148736 rs4148737 1 - - - GR,Nanog 
rs6961419 rs4148737 1 - 
HConF,HFF-
Myc,NHDF-neo 
- - 
rs6961882 rs4148737 1 - - - 6 altered motifs 
rs4148735 rs4148737 1 GM12878 Melano - GR, p300 
rs1922242 rs4148737 1 - - - 5 altered motifs 
Continue on next page 
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Supplementary Table S6. Analysis of functional annotations of rs7190447, rs4148737 and rs11188147 and correlated variants (r2≥0.8) (continued) 
Variant Correlated variant LD (r2) 
Enhancer 
histone marks 
DNase Proteins bound Motifs changed 
rs2091766 rs4148737 0.88 - - - 8 altered motifs 
rs11188147 - - - - - - 
rs1578436 rs11188147 1 - - - 9 altered motifs 
rs7073968 rs11188147 1 - - - HNF4, NF-I 
rs10882517 rs11188147 1 - - - Foxa, GZF1, Pou1f1 
rs11188149 rs11188147 0.99 - - - Pax-4 
rs947173 rs11188147 0.99 - - - BCL, BDP1, NRSF 
rs1891070 rs11188147 0.99 - - - Foxp1, Hdx 
rs11572133 rs11188147 0.99 - - - NRSF, Sin3Ak-20 
rs12773510 rs11188147 0.99 - - - 11 altered motifs 
rs199539470 rs11188147 0.95 - - - 10 altered motifs 
rs58385086 rs11188147 0.99 - - - 11 altered motifs 
rs11188156 rs11188147 0.98 - - - DMRT3,Gfi1b 
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rs10882521 rs11188147 0.93 - - - 4 altered motifs 
rs9702453 rs11188147 0.83 - - - HNF4, Pdx1 
rs145809484 rs11188147 0.90 - - - GCM, Gcm1 
rs143042734 rs11188147 0.88 - - - 5 altered motifs 
rs13313110 rs11188147 0.98 - - - Gfi1,Hsf,TATA 
rs3752988 rs11188147 0.99 - - - Ik-2,Mef2 
rs10882525 rs11188147 0.99 - - - 4 altered motifs 
The replicated variants associated with overall survival (in bold) and SNVs in strong (r
2
>0.8) linkage disequilibrium (LD) with the replicated variants were analyzed using HaploReg to explore if 
they affected chromatin states or altered regulatory motifs or binding sites. AG09309, adult toe fibroblast cells; AG10803, abdominal skin fibroblast cells; GM12865, lymphoblastoid cells; 
GM12878, lymphoblastoid cells; GM12892, lymphoblastoid cells; HAc, human cerebellar astrocytic cells; HA-h, human hippocampal astrocytic cells; HA-sp, human spinal cord astrocytic cells; 
HConF, conjunctival fibroblast cells; HFF-Myc, foreskin fibroblast cells expressing canine cMyc; HGF, gingival fibroblasts cells; HIPEpiC, iris pigment epithelial cells; HNPCEpiC, non-pigment 
ciliary epithelial cells; HPdLF, periodontal ligament fibroblasts cells; HSMM, skeletal muscle myoblast cells; HVMF, villous mesenchymal fibroblast cells; K562, erythrocytic leukemia cells; 
Melano, human epidermal melanocyte cells; NHDF-neo,neonatal dermal fibroblast cells; PanIsletD, dedifferentiated human pancreatic islets 
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